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Summary 
RNA helicases are essential in all steps of RNA maturation, beginning with transcription and ending with 
RNA decay. They catalyze the separation of nucleic acid double strands and thereby facilitate structural 
remodeling. Their cellular importance is reflected in severe diseases caused by RNA helicase 
dysregulation. The largest group of RNA helicases is confined by the so called DEAD-box helicases of 
superfamily 2, characterized by the signature sequence D-E-A-D. DEAD-box helicases share a 
structurally conserved core of two RecA-like domains that carry signature motifs involved in ATP-
binding, ATP-hydrolysis, RNA-binding and RNA-remodeling. An exceptional member of the DEAD-box 
protein family is the human RNA helicase DDX1 (DEAD-box helicase 1). In contrast to all other family 
members, DDX1 harbors a SPRY domain insertion in between the signature motifs of the helicase core.  
DDX1 is involved in a plethora of different RNA maturation processes and has been associated with 
tumor progression. Moreover due to its versatile function in RNA processing, it is hijacked by viruses for 
their replication. This medical relevance makes DDX1 a potential target for the development of 
pharmaceutics; however, such an approach would require mechanistic insights into DDX1 function.  
This thesis therefore aimed at the structural and functional characterization of DDX1. The structure of 
the SPRY domain was determined to near atomic resolution. This structure showed two layers of 
concave shaped, anti-parallel β-sheets that stack onto each other. A comparison with structures of 
previously described SPRY domains revealed that the general fold is conserved, but the loops that 
mediate the interaction with partner proteins in other SPRY structures show distinct conformations and 
sequences in human DDX1-SPRY. A patch of positive surface charge is found in proximity of these 
interaction loops that is conserved within DDX1 SPRY domains and may replace the canonical protein-
protein interaction surface. Based on its orientation in a homology model of DDX1, the SPRY domain 
possibly also enlarges the RNA binding site of the helicase core. The structural analysis is complemented 
by a detailed biochemical and biophysical characterization of DDX1 including the SPRY domain. 
Equilibrium titrations and transient kinetics with fluorescent nucleotide analogs were used to determine 
ATP- and ADP-binding affinities. The binding of ADP is unexpectedly tight and ADP-affinity is one of the 
tightest observed for DEAD-box proteins. DDX1 binds ADP tighter by a factor of almost 1000, when 
compared to its ATP-affinity; the latter is in the range of what has been reported for other helicases. 
Thus, the enzyme would be arrested in an inactive ADP-bound conformation under physiological 
conditions. These observations suggest that a nucleotide exchange factor – as described for the DEAD-
box protein DDX19 – is necessary to resolve this ADP-stalling dilemma. Furthermore, the affinity for RNA 
and the influence of RNA on ATP/ADP binding was determined. Analysis of the data revealed synergistic 
effects of RNA and ATP binding, which were also reflected in RNA stimulated ATP hydrolysis. These 
observations concluded in a working model for DDX1, in which both, RNA and ATP per se have the 
ability to induce a conformational change to an “active” state of the helicase. 
    Summary 
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In conclusion this thesis provides the first structural information on DDX1 and by presenting the SPRY 
domain structure, it gives insights into the unique protein-protein interaction domain insertion. The 
biochemical data provide mechanistic details, show an unsual tight ADP binding and cooperativity in 
ATP and RNA binding, and allowed developing a model for DDX1 substrate binding.   
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Zusammenfassung 
RNA Helikasen spielen eine entscheidende Role im gesammten Lebenszyklus eines RNA Moleküls, 
beginnend bei der Transkription bis hin zum schlußendlichen Abbau. Sie katalysieren das Aufschmelzen 
eines Nukleinsäure-Doppelstranges und helfen damit 3-dimensionale Strukturen aufzubrechen und neu 
zu formen. Ihre wichtige zelluläre Bedeutung zeigt sich in schweren Krankheitserscheinungen, die mit 
der Fehlregulation von RNA Helikasen verknüpft sind. Die sogenannten DEAD-box Helikasen der 
Superfamilie 2, die sich über ihre charakteristische Aminosäure-Signatur D-E-A-D definieren, stellen die 
größte Gruppe von RNA Helikasen dar. Sie alle teilen sich einen strukturell konservierten Kern, 
bestehend aus zwei Domänen, die beide dem Protein RecA ähnlich sind und die charakteristische 
Motife beinhalten, die in die ATP-Bindung, ATP-Hydrolyse, RNA-Bindung und RNA-Umformung 
involviert sind. Die menschliche RNA Helikase DDX1 (steht für DEAD-box Helikase 1) stellt ein 
außergewöhnliches Mitglied der DEAD-box Familie dar. Im Gegensatz zu allen anderen 
Familienmitgliedern wird die konservierte Grundstruktur in DDX1 durch eine SPRY Domäne 
unterbrochen, die sich mitten zwischen den charakteristischen Helikase Motifen befindet. DDX1 ist an 
einer Vielzahl unterschiedlicher RNA Reifungsprozesse beteiligt und wird auch mit der Entwicklung von 
Tumoren in Verbindung gebracht. Die funktionelle Vielseitigkeit in der RNA Prozessierung bringt zudem 
mit sich, dass Viren DDX1 für ihre Vermehrung zweckentfremden. Aufgrund der medizinischen 
Bedeutung, ist DDX1 ein mögliches Ziel für die Entwicklung von Pharmazeutika, allerdings würde eine 
solche Entwicklung grundlegende mechanistische Kenntnisse über die Funktion von DDX1 
vorraussetzen.  
Die Zielsetzung dieser Arbeit war daher eine stukturelle und funktionelle Charakterisierung von DDX1. 
Die Struktur der SPRY Domäne wurde bis zur nah-atomaren Auflösung bestimmt. Diese Struktur zeigte 
zwei Schichten von konkav geformten, anti-parallelen β-Faltblättern, die aufeinander gestapelt sind. Im 
Vergleich mit Strukturen von bereits bekannten SPRY Domänen scheint zwar die generelle Struktur 
erhalten zu sein, aber es fällt auf, dass die Peptid-Ketten, die in anderen SPRY Domänen den Kontakt zu 
Partner Proteinen herstellen, deutlich unterschiedliche Konformationen und Sequenzen in der SPRY 
Domäne von DDX1 zeigen. Ein Bereich mit positiver Oberflächenladung findet sich in der Nähe dieser 
Peptid-Ketten, der innerhalb der SPRY Domänen von verschiedenen DDX1 Homologen aus 
unterschiedlichen Organismen konserviert ist und eventuell die kanonische Oberfläche ersetzt, die 
klassischerweise für Protein-Protein Interaktion von SPRY Domänen zuständig ist. Basierend auf der 
Orientierung der SPRY Domäne in einem Homologie-Modell von DDX1, könnte sie eventuell auch die 
RNA Bindungsstelle des Helikase Grundgerüstes erweitern. Die strukturellen Ergebnisse dieser Arbeit 
werden von einer detaillierten biochemischen und biophysikalischen Charakterisierung der kompletten 
DDX1 Helikase (inklusive der SPRY Domäne) komplettiert. Mit Hilfe von Gleichgewichtstitrationen und 
transienten Kinetik Messungen mit fluoreszenten Nukleotid-Analoga konnten ATP- und ADP 
Affinitätskonstanten bestimmt werden. Die Bindung von ADP war unerwartet fest und die ADP Affinität 
    Zusammenfassung 
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gehört zu den festesten, die je für DEAD-box Proteine gemessen wurden. ADP bindet fast 1000fach 
fester als ATP, wobei die Affinität für ATP im Bereich dessen ist, was auch für andere Helikasen berichtet 
wurde. Die hohe Affinität zu ADP würde dafür sorgen, dass das Enzym unter physiologischen 
Bedingungen in einem inaktiven ADP-gebundenen Zustand stecken bleibt. Dies wiederum suggeriert, 
dass ein Nukleotid-Austausch-Faktor – wie bereits für das DEAD-box Protein DDX19 beschrieben – 
vonnöten ist um diese Blockierung durch ADP zu beseitigen. Desweiteren wurden die Affinität für RNA 
und der Einfluß von RNA auf die Bindung von ATP/ADP bestimmt. Die Ergebnisse zeigten synergistische 
Effekte zwischen der Bindung von RNA und ATP, welche auch bei der Messung der RNA stimulierten 
ATP Hydrolyse zur Tage treten. Auf der Basis dieser Effekte wurde ein Arbeitsmodell für DDX1 
entworfen, in welchem sowohl RNA also auch ATP an sich die Eigenschaft haben eine 
Konformationsänderung zu einem aktiven Zustand der Helikase herbeizuführen.  
Zusammenfassend lässt sich sagen, dass diese Arbeit mit der Struktur der SPRY Domäne die ersten 
strukturellen Informationen über DDX1 liefert und Einblicke in die einzigartige Protein-Protein 
Interaktions-Domänen Insertation gibt. Die biochemischen Daten liefern mechanistische Details, zeigen 
eine ungewöhlich starke ADP Bindung und synergistische Effekte in der Bindung von ATP und RNA, und 
erlauben es ein Model für die Substrat-Bindung an DDX1 zu entwickeln. 
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1.Introduction 
1.1 DNA- and RNA helicases 
 
Helicases are ubiquitous enzymes, initially defined by their property to use the energy obtained by 
nucleoside triphosphate (NTP) hydrolysis to catalyze the separation of nucleic acid double strands[1] and 
thus, are the central nucleic acid remodeler in the cell[2, 3]. Due to the universal need of nucleic acid 
structure conversion, helicases are essential in almost every process that involves DNA or RNA. A classic 
example for the importance of helicases in the cell is DNA replication, where they unwind long stretches 
of DNA in a very processive manner, which is typical for canonical helicases[4, 5].   
Helicases are categorized into six superfamilies (SFs), based on biochemical activities and based on 
characteristic, conserved helicase sequence motifs[6, 7]. SF1 and SF2 are monomeric (or occasionally 
dimeric) nucleic acid dependent NTPases, whereas SF3, 5 and 6 form hexameric toroids with nucleotide 
binding sites at the interface between their protomers[7]. All helicase SFs share the striktly conserved P-
loop motif I (Walker A) and motif II (Walker B) – essential for NTP binding and hydrolysis[8, 9], but the 
number and sequence of additional helicase motifs varies[7]. Helicase SF1 and SF2 that constitute the 
largest group of helicases harbor seven characteristic helicase motifs that show sequence similarities 
between both SFs[10-12] (Figure 1.1). 
 
 
Figure 1.1 Helicase superfamilies 1 and 2, domain organization and conserved motifs. The basic helicase structure and 
position of conserved motifs is indicated for exemplary helicase families[13]. Out of the conserved motifs seven are found in both, 
SF1 and SF2 helicases (namely motifs I, Ia, II, III, IV, V, VI)[6]. Conserved motifs are numbered with roman letters, except for the 
glutamine-containing motif Q[14]. Please note that motif V of DEAD-box helicases can be further subdivided into motifs V, Va and 
Vb. Grey areas indicated additional domains.  
 
 
SFs 1 and 2 consist of DNA- and RNA-helicases and also enzymes that can process both nucleic acids[12] 
(Table 1.1). They share a common core structure of two tandemly arranged globular α/β-domains that 
    Introduction 
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both resemble the fold of the RecA recombination protein (Figure 1.2); however, they do not show 
sequence similarity to RecA[15]. Despite their structural similarity, the two globular RecA-like α/β-
domains that form the SF1 and 2 helicase core have very different sequences and RecA-like domain 2 
lacks an ATP-binding site[16]. 
In contrast to SF1 of helicases that contains many processive, translocating helicases[7], SF2 is larger and 
functionally more diverse and has been further divided into 10 subfamilies based on sequence 
homology[12] (suppl. Figure 7.5.1). SF2 members have different nucleotide (nt) preferences and 
unwinding polarities (Table 1.1). Reported protein activities  in vitro range from translocation coupled 
to unwinding, translocation without unwinding, unwinding without translocation or neither 
translocation nor unwinding at all[1].  
 
Table 1.1 Enzymatic properties of individual SF1 and SF2 helicase families 
 n.a. means not available (adapted from Fairman-Williams, 2010)[12] 
 
 No. of proteins Nucleic acid preference NTP 
utilization 
Unwinding polarity 
 
Homo 
sapiens 
Saccharomy
ces cerevisiae 
Escherichia 
coli DNA RNA  3’ -> 5’ 5’ -> 3’ 
DEAD-box 37 26 5 -  ATP   
DEAH/RHA 15 7 2   ATP,GTP,CTP,
T/UTP 
  
NS3/NPH-
II (viral) 
- - -   ATP,GTP,CTP,
T/UTP 
 - 
Ski2-like 7 5 2   ATP  - 
RIG-I-like 5 1 -   ATP  - 
RecQ-like 5 2 1  - ATP  - 
RecG-like - - 3  - ATP n.a. n.a. 
SWI/SNF 28 16 1  - ATP n.a. n.a. 
T1R - - 3  - ATP  - 
Rad3/XPD 5 2 2  - ATP  - 
Rep, PcrA, 
UvrD 
2 2 4  - ATP  - 
Pif1-like 2 2 2  - ATP -  
Upf1-like 11 5 2   ATP -  
 
1.2 DEAD-box helicases 
 
The biggest subfamily within helicase SF2 is composed of the so-called DEAD-box proteins. The name is 
derived from the sequence of the conserved Walker B motif (helicase motif II) Asp-Glu-Ala-Asp[17]. DEAD-
box proteins show specificity for RNA substrates and exclusively hydrolyze ATP[12] (Table 1.1). They play 
key roles in RNA maturation processes[18], where a plethora of functions has been ascribed to different 
family members[19]. These diverse functions seem to be specific for each family member and go beyond 
simple RNA unwinding[20]. So far, 37 proteins of the DEAD-box subfamily have been described in Homo 
sapiens, 26 proteins in Saccharomyces cerevisiae and five proteins in Escherichia coli[12] (Table 1.1). The 
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first identified DEAD-box helicase was the translation initiation factor eIF4A that consists solely of the 
minimal helicase sequence and serves as the prototypical DEAD-box protein[17, 21]. 
DEAD-box helicases share a highly conserved core (Figure 1.2) with an RNA- and an ATP-binding site, 
both sites being distributed between the two RecA-like domains[22]. 
 
 
 
Figure 1.2 General topology of DEAD-box proteins. DEAD-box proteins consist of two tandemly arranged RecA-like domains 
like other SF1/2 helicases, but harbor distinct signature motifs. The two RecA-like domains are highly similar to each other, but 
only RecA-like domain 1 harbors an ATP-binding site. The conserved signature motifs at their respective positions are highlighted. 
The color code is according to the designated function (yellow = ATP binding and hydrolysis, red = RNA binding, purple = 
mediate communication between ATP- and RNA-binding site). Also see Figure 1.3 for details on the conserved motifs. 
 
In many cases DEAD-box proteins have been found to be part of large multimeric protein complexes – 
well studied examples include eIF4AIII, which is part of the exon junction complex (EJC)[23, 24] and yeast 
Dbp5 (human DDX19), which is recruited to the nuclear pore complex (NPC)[25]. 
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1.2.1 Conserved motifs of the DEAD-box helicase core 
In addition to the seven helicase motifs shared between helicase SF1 and SF2 – motifs I, Ia, II, III, IV, V, 
VI[6] (see Figure 1.1) – the two globular RecA-like domains of DEAD-box proteins (Figure 1.2) harbor 
further family specific signature motifs. These include motifs Q, Ib, Ic, IVa, Va, V resulting in an overall 
number of at least 13 conserved sequences[19] (Figure 1.3 a). Seven of the conserved motifs are located 
on the N-terminal-, six motifs on the C-terminal RecA-like domain.  
The motifs can be separated into three groups, according to their function in ATP binding/hydrolysis 
(depicted in yellow in Figure 1.3), RNA binding (depicted in red in Figure 1.3) or in mediating 
communication between the ATP and RNA binding site (depicted in purple in Figure 1.3) [18].  
 
ATP binding and hydrolysis is mediated by motifs Q, I and II that belong to RecA-like domain 1 and 
motif VI that belongs to RecA-like domain 2[26, 27]. The Q-motif contains a conserved glutamine that 
coordinates the adenine base moiety and thereby confers ATP specificity[14] (Figure 1.3). Typically a 
conserved phenylalanine of the Q-motif additionally stacks with the adenine base moiety[28]. Next in the 
primary structure is the highly conserved P-loop motif I=Walker A motif with the sequence G-S/T-G-K-T, 
which is DEAD-box family specific[17] and in contrast to the classical P-loop motif G/A-X-X-X-X-G-K-S/T[10]. 
The Walker A motif interacts with the phosphate groups of ATP/ADP and coordinates the Mg2+ ion in 
the ATP binding site[29]. More specifically, the ε-amino group of the Walker A lysine interacts with the β-
phosphate group and the hydroxyl-group of the serine coordinates the Mg2+ ion octahedrally[15] (Figure 
1.3 b and c). Helicase motif II=Walker B motif corresponds to the conserved D-E-A-D sequence and is 
essential for ATP hydrolysis[30]. The first aspartate residue coordinates the Mg2+ ion with its carboxyl-
group and the glutamate residue acts as the catalytic base and activates a water molecule for 
nucleophilic attack on the γ-phosphate group[19] (Figure 1.3 c). Finally, motif VI of RecA-like domain 2 
provides two arginine fingers that coordinate the phosphate groups of bound ATP and it also interacts 
with the nucleobase[31]. It thereby complements the ATPase site that otherwise only consists of residues 
from RecA-like domain 1 (Figure 1.3 b). 
 
RNA binding is mediated by motifs Ia, Ib and Ic that cluster at the surface of RecA-like domain 1 and 
constitute the first part of an RNA binding site[31] (Figure 1.3 b). RecA-like domain 2 harbors conserved 
motifs IV, IVa, V and Vb, which constitute the second part of the RNA binding site (Figure 1.3 b). 
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Figure 1.3 DEAD-box helicase core and conserved motifs. A, A schematic representation of the helicase core with the location 
of the conserved motifs is shown. Helicase motifs are colored according to their function (yellow = ATP binding and hydrolysis, 
red = RNA binding, purple = mediating communication between ATP- and RNA-binding site). B, Ribbon representation of the 
structure of the helicase core of eIF4AIII[24] (PDB entry 2J0S) is shown with the conserved motifs colored according to A, ATP and 
RNA represented as stick-models. C, A schematic representation of the interactions of ATP with the conserved motifs in the ATP 
binding site is shown[15, 19].  
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Communication between the ATP and RNA binding site is mediated by motifs III and Va[32]. Motif III of 
RecA-like domain 1 forms an extended network of hydrogen-bond interactions and is essential for RNA 
unwinding activity[30]. It senses bound ATP and signals to the RNA binding site[13]. In RecA-like domain 2, 
motif Va recognizes the ribose moiety of bound nucleotides and is also involved in coordination 
between ATP hydrolysis and RNA binding[12].  
 
 
1.2.2 Conformational transitions of the DEAD-box helicase domains 
For a long time only apo or ADP bound structures of DEAD-box proteins have been available[13, 32]. These 
structures show that the two RecA-like domains of the DEAD-box helicase core are connected by a short 
flexible linker[33]. The relative orientation of the two RecA-like helicase domains varies significantly 
between different DEAD-box protein apo structures, indicating large domain flexibility[34]. ADP binding 
does not seem to have an influence on domain orientation[26, 29].  
Back in 2006 a breakthrough in the field came with the first structure of a DEAD-box helicase bound to a 
single-stranded RNA (ssRNA) and a non-hydrolyzable ATP analog[31]. Since then several similar substrate-
bound complexes of different DEAD-box proteins have been reported[23-25, 28, 35]. Interestingly, all ssRNA-
NTP-helicase complexes show a virtually identical orientation of the two RecA-like domains with respect 
to each other, the so-called “closed”-state. In contrast, an “open”-state is represented by the apo form, 
where the relative domain orientations are not exactly defined[34]. Thus, two distinct states of DEAD-box 
helicases are structurally characterized[13]. In the absence of NTP and/or RNA substrate DEAD-box 
proteins are in an “open”-state with a flexible arrangement of the two RecA-like helicase domains, 
whereas they adopt a rigid “closed”-state upon binding of non-hydrolyzable ATP-analogues and RNA.  
Structures of the ternary DEAD-box protein, RNA, ATP complex have also helped to assign the 
functional contribution to individual helicase motifs in substrate binding[31]. In the “closed”-state, the 
two helicase domains come in close proximity and form a cleft, which establishes the functional ATPase 
site between the domains[31]. RNA molecules bind across the surface of both RecA-like domains 
opposite of the ATP-binding cleft (Figure 1.3). They are bound by the conserved helicase motifs that 
contact five nucleotides of the RNA[34]. Interactions exclusively rely on the RNA sugar phosphate 
backbone, thereby confering the low sequence specificity of DEAD-box helicases[34]. Despite this 
sequence promiscuity, DEAD-box protein - oligonucleotide interactions are highly RNA specific, which is 
mediated by interactions with the 2’-hydroxy-group of the sugar moiety[24].  
 
The most important observation from structures of DEAD-box helicase in the “closed”-state was a 
characteristic bend of the bound single-stranded RNA (ssRNA)[31] (Figure 1.4). This distorted 
conformation of the RNA is caused by steric constraints imposed by RecA-like domain 1[32]. The 
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observed RNA conformation would interfere with the Watson-Crick base pairing of double-stranded 
RNA (dsRNA), suggesting that tethering and subsequent bending of RNA by DEAD-box proteins leads to 
melting of the double-stranded region and finally to strand separation[31].  
 
 
 
Figure 1.4 DEAD-box protein dsRNA binding and unwinding by bending. On the left panel, a ribbon representation of the 
structure of the isolated RecA-like domain 2 (including a C-terminal extension domain) of the yeast DEAD box helicase Mss116p 
bound to dsRNA is shown[36]. RecA-like domain 1 is not resolved in this structure and indicated by a green blob. On the right panel, 
a ribbon representation of the structure of the entire helicase core (RecA-like domains 1, 2 and the C-terminal extension) of 
Mss116p bound to ssRNA is shown[35]. It has been suggested, that upon formation of the “closed”-state of the helicase both RecA-
like domains come together and the second RNA strand is displaced, i.e. the dsRNA is melted, induced by sterical constraints via 
strand-bending[32]. Motif Va interacts with double-stranded substrate in the “open”-state, but probably alters its position in the 
“closed”-state to help form the ATP-binding site[36]. PDB codes are as follows: Mss116p RecA-like domain 2 and C-terminal 
extension with dsRNA (4DB2[36]); Mss116p helicase core and C-terminal extension with ssRNA/AppNHp (3I5X[35]). 
 
The hypothesis of an “unwinding by bending” mechanism of DEAD-box proteins was further 
substantiated by a recent study that showed that dsRNA and ATP bind independently to RecA-like 
domain 2(Figure 1.4, left side) and RecA-like domain 1, respectively, in the “open”-state[36]. As 
suggested before[32], upon closure of RecA-like domains 1 and 2 (formation of the “closed”-state), parts 
of the bound strand are bent, i.e. the A-form conformation is destabilized, which leads to displacement 
of the second strand by the steric constraints that disturb the Watson-Crick base pairing[36] (Figure 1.4, 
right side). Interestingly, ssRNA forms additional contacts with RecA-like domain 1 after strand melting, 
which provides further energy for domain closure and the unwinding reaction[37]. Comparison of a 
structure of the isolated RecA-like domain 2 bound to dsRNA and the structure of complete helicase 
core (RecA-like domains 1 and 2) bound to ssRNA also shows significant structural changes in motif Va 
(Figure 1.4). It has been suggested that motif Va initially contributes to duplex RNA binding and 
rearranges to help form the ATPase active site in the “closed”-state[36]. 
 
So far, no structure of a binary complex of a DEAD-box protein bound to ATP or bound to RNA has been 
determined. For the SF1 helicase Upf1 though (which is not a DEAD-box protein), structures of a binary 
protein-nucleotide complex show a conformational change and a domain closure in the AppNHp 
bound state when compared to the ADP bound state (both in the absence of RNA)[38]. 
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1.2.3 Auxiliary domains of DEAD-box helicases 
In addition to the conserved helicase core many DEAD-box proteins harbor auxiliary domains that 
contribute to their specific functions. In contrast to other helicase-families these domains are generally 
not inserted in the two RecA-like domains, but form N- and C-terminal extensions[12]. Those extensions 
function as protein-protein or protein-RNA interaction platforms[19]. A protein-RNA interaction platform 
has for instance been observed in the structure of the C-terminal extension domain of Bacillus subtilis 
YxinN, which shows the fold of an RNA recognition motif (RRM)[39]. The C-terminal extension of Thermus 
thermophilus HerA protein contains both a protein-protein dimerization domain and an RRM[40-42] 
(Figure 1.5). Another example is the C-terminal domain of S. cerevisiae Mss116p that binds to the RNA, 
in addition to the helicase core and introduces a second bend in the RNA; thereby it contributes to the 
unwinding activity of the core[35] (Figure 1.4, right side).  
Protein-protein interactions have for instance been described for Drosophila melanogaster VASA, whose 
N-terminal extension interacts with GUSTAVUS (GUS) while its C-terminal extension interacts with 
OSKAR protein[43] and eIF5B[44]. 
 
 
Figure 1.5 C-terminal extension domains of T. thermophilus HerA adopted from Klostermeier et al.[40]. Similar as described in 
Rudolph and Klostermeier (2009)[41] and in Klostermeier and Rudolph (2009)[40], a model of the entire HerA helicase was 
assembled, based on individual structures. The structures of the T. thermophilus HerA protein N-terminal domain[45] (PDB entry 
2GXS) and of the C-terminal domain with the dimerization domain and the RNA binding domain=RRM[41] (PDB entry 3I32) were 
superposed on the structure of the closed state of D. melanogaster VASA in complex with AppNHp and ssRNA[31] (PDB entry 2DB3). 
Then the structure of the RRM in complex with ssRNA[42] (PDB entry 4I67) was superposed on the C-terminal domain. This model of 
the entire HerA helicase was constructed by using “secondary structure matching” in COOT[46]. The N-terminal domain of HerA 
was crystallized in complex with AMP without RNA[45], and the position of ssRNA is hypothetical and inferred from the VASA 
structure. Linkage of the separated crystal structures in the model of the entire protein is indicated by dashed purple lines. The C-
terminal domain of HerA contains both a dimerization domain and an RRM. The RRM can tether RNA substrates or can bind large 
RNA substrates that span both RecA-like domains and the RRM[42, 47]. 
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In addition to binding to substrates or interaction partners, auxiliary domains of DEAD-box helicases do 
also have regulatory functions, e.g. in H. sapiens DDX19, the N-terminus controls ATP hydrolysis by 
conditionally displacing a catalytical arginine finger[28]. Interestingly this N-terminus is locked in an non-
inhibiting conformation in the structure of DDX19 complexed with its interaction partner Nup214, 
reflecting modulation of DEAD-box activity by external factors[48]. Individual orientations of the auxiliary 
domains that have been determined so far, were all different with respect to the helicase core[19]. 
 
1.2.4 DEAD-box activities – local strand separation and ATP hydrolysis 
DEAD-box proteins use a different mechanism of substrate unwinding, when compared to all other RNA 
helicases[49] (Figure 1.6 a). They are unprocessive and do not show strict unwinding polarity[11]. Whereas 
classical helicases unwind RNA-duplexes by translocation on one of the strands, DEAD-box proteins 
employ an unwinding mode termed “local strand separation”[50-52] (Figure 1.6 b and Figure 1.8).  
 
 
 
Figure 1.6 Unwinding mechanism of translocating helicases differs from DEAD-box proteins. A, Classical translocating 
helicases unwind long stretches of duplex substrate with high processivity. They are tethered to their substrate by single-stranded 
overhangs and translocate with a defined polarity, thereby displacing the non-guidance strand. B, DEAD-box proteins can be 
tethered to their substrate by interacting factors (depicted in purple) or by certain structural elements. They unwind short 
duplexes in a non-processive manner and don’t necessarily require the energy of ATP hydrolysis. In contrast to classical helicases, 
they initiate the unwinding internally in the dsRNA[20]. 
 
DEAD-box proteins do not need a single-stranded overhang, but load on the double-stranded region 
and then open the strands just locally[52] – therefore the term “local strand separation” (Figure 1.6 b). 
Loading on the double-stranded region can be facilitated by ssRNAs that do not even have to be in 
spatial proximity to the dsRNA substrate[51]. Many family members are only capable of unwinding 
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duplex RNA with 14 or less base pairs, corresponding to less than two helical turns[19]. Increasing stability 
of the duplex substrate (via GC content) is proportional with decreasing unwinding efficiency[53-55]. The 
non-processive unwinding mechanism of DEAD-box helicases is well adapted for local remodeling 
processes in RNA and ribonucleoprotein (RNP) processing[13]. Unwinding of short double-strands 
prevents large scale dismantelling of complex RNA or RNP structures and is well suited for RNA 
duplexes, commonly formed in the cell that rarely exceed one helical turn[19]. The mechanism of “local 
strand separation” can be explained by the “unwinding by bending” hypothesis with the 
conformational changes between the “open”- and “closed”-state of the helicase[32]. The few base pairs of 
duplex that are separated by bending of one RNA strand and exclusion of the other strand by domain 
closure are sufficient to locally open the double strand, which leads to strand separation and unwinding 
only in short duplexes[36].  
 
 
Cycling between the “open”- and the “closed”-state is inseparably coupled to ATP hydrolysis[17]. DEAD-
box proteins hydrolyze ATP, though with catalytic rates that vary between 0.5 min-1 to 300 min-1 [56-58]. 
For many family members the intrinsic low ATPase-rate is stimulated significantly by ssRNA[59, 60]. The 
degree of stimulation of ATP hydrolysis by ssRNA ranges from less then ten-fold to several orders of 
magnitude for different proteins[37]. However, stimulation of ATP hydrolysis by ssRNA does not 
necessarily mean that a given protein is able to unwind duplex nucleic acids, since not for all proteins 
that showed an RNA stimulation an unwinding activity could be shown[12]. 
The ATPase cycle can be regulated by interactions with co-factors. For instance, the human eIF4A is 
locally activated in its ATPase activity by the scaffolding protein eIF4G that induces a half-open 
conformation of eIF4A and thereby accelerates phosphate release after ATP hydrolysis[55, 61, 62] (Figure 
1.7 a and b). In contrast, the natural tumor suppressor protein PDCD4 binds two eIF4A protomers and 
traps them in an inactive conformation, thereby inhibiting the enzymatic activity[63, 64] (Figure 1.7 c). 
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Figure 1.7 Regulation of the ATPase cycle of eIF4A by co-factors. Human eukaryotic initiation factor 4A (eIF4A) is modulated in 
its ATPase cycle by interacting factors.A, apo-structure of eIF4A[65] is depicted with the color code as in previous figures. B, The 
large scaffolding factor eIF4G binds both RecA-like domains and induces a half-open form[61] that promotes phosphate and RNA 
release[62]. C, The natural tumor suppressor protein “programmed cell death 4” (PDCD4) inhibits translation by binding to eIF4A[66]. 
Two protomers of eIF4A bind to one molecule PDCD4, which traps the DEAD-box protein in an inactive conformation and 
prevents its binding to eIF4G[63, 64]. PDB codes are as follows: (A) – apo eIF4A (1FUU), (B) – eIF4A/eIF4G-complex (2VSO), (C) –
 eIF4A/PDCD4-complex (2ZU6).  
 
 
 
Similar to eIF4A, ATP turnover by yeast Dbp5 (= human DDX19) is stimulated by the export factor 
Gle1[25]. Furthermore, a nucleotide exchange factor (NEF) plays a role in the Dbp5 regulation as the 
nucleoporin Nup159 (= human Nup214) acts as an ADP release factor (Figure 4.3.1) – this shows the 
presence of NEFs in RNA helicase regulation[67]. In contrast to the activation observed for Dbp5, the 
protein eIF4AIII in the exon junction complex is inhibited by the MAGOH-Y14 complex, which prevents 
release of the inorganic phosphate after hydrolysis and thereby keeps the helicase bound to the RNA[68]. 
 
Whereas conventional helicases processively translocate through their substrate and consume several 
ATP molecules for the complete melting[69, 70], DEAD-box proteins require only a single ATP molecule for 
stand separation[71]. However, their catalytic cycle is not necessarily always productive i.e. can lead to 
futile ATP hydrolysis without dsRNA strand separation[72]. Interestingly, ATP binding is required for 
strand separation (Figure 1.8– helicase cycle), whereas hydrolysis can be dispensable[73, 74]. Hydrolysis of 
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ATP is finally required to release the RNA from the DEAD-box protein, to complete substrate turnover 
and to reset the helicase for another unwinding cycle[57]. In general, ATP hydrolysis is fast and reversible, 
whereas the release of inorganic phosphate or ADP is the rate limiting step for the catalytic cycle[19, 57]. 
  
So far, detailed kinetic analysis of DEAD-box proteins is limited to E. coli DbpA and S. cerevisiae Mss116p 
and these studies were restricted to constructs of the helicase core, not containing large extensions or 
insertions[57, 58, 72]. Additional studies have characterized the ATPase cycle of Mus musculus eIF4A, E. coli 
Ded1p, Bacillus subtilis Yxin (a DbpA homologue) and Thermus thermophilus HerA[59, 75-77]. These studies 
show that ADP is often bound with higher affinity than ATP; sometimes up to one order of magnitude 
more tightly[34, 60]. In some situations cooperative effects of RNA and ATP binding have been observed[75], 
however, this is not generally true for all DEAD-box helicases. For instance in the case of DbpA, 
cooperativity is controversely discussed as it is in contrast to kinetic data[78-80]. 
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A combination of the observations on local strand separation and ATP hydrolysis finally concluded in a 
general model for the overall unwinding cycle of DEAD-box proteins[37] (Figure 1.8). The cycle starts 
with initial binding of RecA-like domain 2 to the ds substrate[36]. ATP binding to RecA-like domain 1 
induces the conformational transition to the “closed”-state in which dsRNA is separated locally and a 
functional ATPase site is formed[31] (Figure 1.8, step 2). Local melting of a few base pairs of the duplex 
can lead to opening of longer regions and finally to complete strand separation, resulting in the 
“closed”-state with bound ssRNA and ATP as observed in many crystal structures[23, 24] (Figure 1.8, step 
3). Importantly, after the unwinding, ATP is hydrolyzed (Figure 1.8, step 4), leading to a preference for 
the “open”-state in which Pi and ADP as well as RNA are released[60]. At this point, the helicase is reset for 
another cycle of duplex unwinding[1] (Figure 1.8, step 5). Importantly in the cellular environment 
DEAD-box associated factors can bind the ssRNA and thus, prevent an immediate reannealing[19].  
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Figure 1.8 Unwinding cycle of DEAD-box proteins. The cycle of unwinding by ‘local strand separation’ by DEAD-box proteins is 
depicted schematically. RecA-like domain 1 binds ATP and RecA-like domain 2 binds dsRNA substrate (step 1), which leads to 
domain closure. Both domains bind their respective substrate independently of each other[36]. Domain closure leads to melting of 
the Watson-Crick base pairing in the bound region due to sterical constraints and strand bending[31] (step 2). In a productive 
helicase cycle, the displaced RNA strand dissociates (step 3). ATP hydrolysis occurs after the unwinding event to reset the enzyme 
(step 4). Dissociation of the ATP hydrolysis products and the RNA finally resets the enzyme. 
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1.2.5 DEAD-box activities – more than just unwinding 
Besides the basic helicase function of separating nucleic acid double strands, DEAD-box proteins can 
exert a range of other biochemical activities. They can displace proteins from RNA in an ATP-dependent 
way, independent of duplex unwinding[81]. However, only proteins that interact with less than eight 
nucleotides have been reported to be displaced, most likely due to the non-processive nature of DEAD-
box proteins[82, 83].  
Another activity of DEAD-box proteins is RNA strand annealing, which, at first glance, seems to 
contradict the duplex unwinding activity (suppl. Figure 7.5.2). However, annealing has only been 
shown in vitro[84] and is not the reverse of the unwinding reaction since it is ATP independent[84-86]. For 
DDX21 ATP-independent RNA folding has been reported, which may also work via an annealing 
mechanism[87] (suppl. Figure 7.5.2 a). The annealing activity combined with unwinding activity allows 
for large scale conversion of RNA structures[88]. This is important for the chaperone-like function of 
DEAD-box proteins on certain RNA molecules[20, 89] (suppl. Figure 7.5.2 b). 
Furthermore, DEAD-box proteins can remain bound to RNA for prolonged periods of time, a function 
referred to as RNA clamping[68]. Such clamping has been reported for eIFAIII, which functions as an 
assembly platform for the exon junction complex (EJC)[23, 24, 68]. Similarily a clamping function has 
recently been reported for the yeast protein Mss116p that forms nucleotide-dependent, long-lived 
RNA-bound complexes[37, 90]. 
 
 
1.3 DDX1, a unique eukaryotic DEAD-box protein 
 
The human RNA helicase DDX1 – for DEAD-box protein 1 (originally called HuDBP-RB = human DEAD-
box protein amplified in Retinoblastoma cells) – is a 80 kDa DEAD-box protein localized both in the 
nucleus and in the cytoplasm, depending on cell-type[91]. What differentiates DDX1 from all other DEAD-
box helicases is the presence of a long SPRY-like domain insertion directly within the helicase core[92]. 
Besides for its unique domain composition, DDX1 is also interesting for its manifold involvement in RNA 
processing pathways in the cell (see section 1.3.3) and is of high medical relevance due to its role in 
tumor progression and HIV-1 replication[93, 94]. DDX1 is an essential protein, as knockout in D. 
melanogaster results in a lethal phenotype[95]. 
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1.3.1 The peculiar SPRY domain of DDX1 
DDX1 contains a long (constitutes almost 30% of the residues of the protein) insertion within RecA-like 
domain 1, which is located between conserved helicase motifs I and Ia in the polypeptide chain[92] 
(Figure 1.9). In contrast to an average 20-40 residues in other DEAD-box proteins, the insertion 
seperates the two motifs by around 240 residues in the primary sequence[96].  
 
 
 
Figure 1.9 The prominent SPRY insertion in DDX1. DDX1 is depicted schematically with the two canonical RecA-like domains, 
depicted in green (domain 1) and blue (domain 2) respectively. Additional segmentation at the ends marks N- and C-terminal 
extensions that are not part of the conserved helicase core. The SPRY domain is inserted prominently between conserved motifs I 
(=Walker A) and Ia. Additionally the position of motif II (=Walker B) is marked to show the spatial proximity to the SPRY domain. 
 
Sequence alignment indicated that the insertion corresponds to a so-called SPRY domain[92]. SPRY 
domains are modular insertion domains, which were originally identified as a sequence repeat in the 
dual-specificity kinase splA (=SP) and Ca2+-release channel ryanodine (=RY) receptors[97]. SPRY domains 
are highly conserved in their amino acid sequence[98]. A significant number of SPRY domain containing 
proteins harbor an N-terminal domain fusion with a protein domain termed PRY[99] (named after its 
association with SPRY domains). The fused PRYSPRY domains have a strong structural homology to the 
so called B30.2 domains, however, on the sequence level only the SPRY domains are conserved and the 
PRY domains are different[100]. It has therefore been proposed that PRYSPRY and B30.2 domains have 
derived from the same ancestral gene, but the first part of the gene has diversified greatly beyond the 
level of sequence similarity[100, 101]. This led to the recent renaming of PRYSPRY and B30.2 domains to the 
collective labeling as SPRY domains in general[98, 101]. 
SPRY domains are present in more than 150 human and ~80 murine proteins of different protein 
families that cover a wide range of functions[99]. They constitute protein-protein interaction modules, as 
could be shown by interaction studies[102-104]. Structural studies of SPRY domains of the mammalian 
SOCS box family of E3 ubiquitin ligases (SPSB) in complex with interacting regions of complex partners 
helped to identify the so-called surface A interaction site[101, 105]. Surface A is established by five extended 
loops[105, 106]. Initially, comparison of the structure of the orthologous drosophila protein GUSTAVUS in 
apo and in a peptide bound complex revealed that the five extended loops of surface A create a pre-
formed pocket [100, 101]. This was soon corroborated by structures of human SPSB proteins in apo or in 
different peptide bound complex forms[105] (Figure 1.10). Notably GUSTAVUS interacts tightly with the 
DEAD-box helicase VASA and the interacting peptide, used for structural studies was derived from this 
RNA helicase[44]. 
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Figure 1.10 Crystal structures of SPRY domains from SOCS box proteins.  Structures of human SPSB proteins in complex with 
short peptides, derived from their interactions partners are shown[105]. The structures reveal five extended loops that form an 
interaction surface, designated surface A[106]. Below the electrostatic surface is shown, that is conserved around the interaction 
site. PDB codes are as follows: (A) - hSPSB1/Par4 (2JK9), (B) - hSPSB1/VASA (3F2O), (C) - hSPSB2/VASA (3EMW).  
 
 
Recently, the structure of the SPRY domain of Ash2L, a regulating factor of Histone-methylation has 
been reported[107]. In Ash2L-SPRY a positively charged surface patch (located similarly as surface A) has 
been suggested to be the region mediating interaction with other components of the 
methyltransferase complex. This was substantiated by mutational analysis[107]. 
For the SPRY domain of DDX1 no information concerning a potential interaction surface is available so 
far. As DDX1 is commonly found in association with other proteins[108-110], the SPRY domain might be a 
platform for recruitment and interaction with those factors (Figure 1.11). Moreover the SPRY domain is 
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a unique feature of the DDX1 RNA-helicase and its functional relevance for the DEAD-box protein still 
awaits clarification. 
 
1.3.2 DDX1 in RNA maturation processes 
DDX1 is directly or indirectly (via interaction with other factors) involved in various aspects of RNA 
processing, as shown by several studies[109-114] (suppl. Table 7.6.1). Accumulating evidence specifically 
points towards a role in mRNA maturation as DDX1 is bound to cleavage stimulation factor (CstF-64)[112], 
interacts with heterogeneous nuclear ribonucleoprotein K (hnRNP K)[109] and binds poly(A) RNA[109]. 
Moreover it plays a role in mRNA transport [115] and was found in an RNP splicing complex[116]. Recently it 
was shown that DDX1 is also involved in AU-rich element mediated decay (AMD)[117]. In addition to 
mRNA maturation, further studies have reported roles of DDX1 in transcription regulation[110] and DNA 
repair[111]. Some of the studies on DDX1 could map the individual domains, essential for interaction with 
RNA processing factors (suppl. Figure 7.6.1). 
 
 
Most importantly, DDX1 is found in a multimeric complex in the nucleus and in mRNA transporting 
granules[115] (Figure 1.11). Together with the protein HSPC117 and three additional factors, DDX1 forms 
the HSPC117 complex[118], which acts as a tRNA ligase[114]. HSPC117 seems to be the major catalytic 
subunit in this pentameric complex. The three remaining components – Fam98, CGI-99 and 
Ashwin(=ASW) – of the complex have been identified in pulldown experiments from HEK 293 and HeLa 
cells[108, 113], but their functions have remained largely uncharacterized[119] (Figure 1.11). 
 
 
 
Figure 1.11 HSPC 117 complex components. The five different proteins that form the HSPC117 complex are depicted 
schematically and arranged in a potential complex, stabilized by DDX1. Size of the proteins is indicated by the number of amino 
acids below. For Fam98b two different isoforms exist, but the 330 amino acid long sequence has been defined as the canonical 
one. 
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Although addition of cruciform DNA duplexes that specifically bind to DDX1 inhibited interstrand 
ligation and tRNA maturation reactions[114], the functional role of the helicase activity of DDX1 in the 
HSPC117 complex catalyzed ligation process is unknown[119]. Interestingly, efficient depletion of DDX1 
did not compromise tRNA maturation as severely as depletion of HSPC117 did[114]. The intriguing 
question is how an RNA helicase activity could be important for the tRNA ligation reaction. It may 
partially unwind tRNA to facilitate ligation or simply tether the tRNA to the complex[119]. Depending on 
DDX1’s processivity it could clamp on the tRNA substrate and act as an assembly platform, thereby 
serving as a structural scaffold for the HSPC117 complex[19].  
 
 
 
 
1.3.3 DDX1’s medical relevance 
The first study describing DDX1 reported its overexpression in retinoblastoma cell lines[120]. Soon 
elevated expression levels were also detected in neuroblastoma cell lines[121]. Since then expression of 
DDX1 in several additional tumor tissues, from germ cell tumors[122] to rhabdomyosarcomas[123] and 
coamplification with the proto-oncogene MYCN[91, 121] has been reported (suppl. Table 7.6.2). In human 
breast cancer, elevated cytoplasmic DDX1 protein levels were associated with relapse and poor 
survival[124]. Due to this widespread expression in tumor tissue, DDX1 was recently proposed as a 
potential biomarker for cancer[125, 126]. 
 
In addition to its role in cancer progression, DDX1 is an important host factor for viral infection. This is 
most probably due to DDX1’s central function in RNA processing and therefore the viruses hijack this 
host protein[127, 128]. Replication of four different virus families – JC virus[129, 130], coronavirus[131], hepatitis C 
virus[132] and HIV-1[93, 133, 134] – depends on DDX1[128] (suppl. Table 7.6.3). Especially the involvement of 
DDX1 in the export of unspliced HIV-1 mRNAs via the Rev protein has been investigated extensively[127, 
135, 136] (suppl. Figure 7.22). 
Surprisingly despite its involvement as a host factor for viral replication, DDX1 was also reported to 
serve in the innate immune system as a sensor of viral dsRNA, which is bound directly to RecA-like 
domain 1[137]. The situation that DDX1 serves in viral defense, but is also hijacked by viruses for their 
replication sounds a bit paradox, however, this might reflect that DDX1 is a highly contested target in 
the ‘arms race’ between the host immune system and viruses[138].  
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1.4 Aims of this thesis 
 
Despite the “birth of the D-E-A-D box” more than 20 years ago[17] and a profound structural 
characterization of the canonical DEAD-box helicase core in recent years[31, 36], mechanistic and 
regulatory information is still limited. This situation is further complicated by the different individual 
activities of each family member that even seem to use different regulatory mechanisms[37]. Moreover, 
the structural information is limited to either one of the separated RecA-like domains[40, 45, 65] or the 
minimal helicase fold[31, 33]. Only few structures of auxilliary domains have been reported[35, 41]. These 
additional domains constitute N- or C-terminal extensions and are separated from the core RecA-like 
fold. Mechanistic studies, complementing the structures, are sparse and have often relied on short 
DEAD-box proteins of prokaryotic origin or from lower complexity organisms where molecular standard 
tools are available[57, 59]. 
The DEAD-box protein DDX1 harbors the SPRY domain in the helicase core in between the conserved 
helicase motifs, which suggests a profound structural and functional significance. Therefore, the first 
aim of this thesis was 
 
to obtain structural information on the SPRY domain, which is the unique feature of DDX1 
 
The 3-dimensional structure of the SPRY domain was determined at near-atomic resolution by using X-
ray crystallography. This approach was complicated by the need for protein crystals that diffract X-rays 
to high resolution, which required extensive construct optimization and screening. The SPRY structure 
revealed a compact β-sandwich fold with a conserved patch of positive charge that could serve as 
interaction platform. The architecture, conservation and functional implications of the SPRY domain are 
presented in the first results section of this thesis. 
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Out of the human DEAD-box helicases, DDX1 is the protein which has a special function in RNA 
maturation[95, 96, 109, 112] and due to its involvement in this fundamental process it also plays a role in 
cancer progression[94] and viral replication[93, 131, 132]. Mechanistic insights in this protein are therefore of 
general interest and could be used as a fundament for the design of inhibitors with putative medical 
relevance. Hence the second aim of this thesis was 
 
to investigate the functional characteristics of DDX1 and to additionally foster our 
understanding of DEAD-box helicases 
 
The helicase DDX1 protein was studied by a sophisticated combination of biochemical and biophysical 
approaches. Cooperative effects of ATP/ADP and RNA binding and enzymatic characteristics were 
investigated. This detailed analysis revealed unique mechanistic properties in comparison to related 
enzymes and allowed to develop a working model for DDX1. The functional characterization of DDX1 is 
presented in the second results section of this thesis. 
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2. Material and Methods 
 
2.1 Materials 
 
2.1.1 Chemicals 
The chemicals used in this study were acquired from the following companies:  
 
company compound 
BIOLOG (Bremen) mant-dADP, mantADP, mant-dATP, mantATP 
Bio & Sell (Nürnberg) agarose, dNTPs 
GERBU Biotechnik (Gaiberg) 
ampicillin, chloramphenicol, dithioerythritol (DTE), 
ethylenediaminotetraacetate (EDTA), glycerol, isopropyl β-D-
1-thiogalactopyranoside (IPTG), kanamycin, sodium-dodecyl-
sulfate (SDS) 
GibcoBRL (Karlsruhe) ethidium bromide solution, peptone, yeast extract 
Invitrogen (Karlsruhe) Topoisomerase kit 
Merck (Darmstadt) 
ammonium-sulfate, magnesium chloride, potassium 
dihydrogen phosphate, potassium hydrogen phosphate, 
potassium chloride, boric acid 
Promega (Mannheim) Pfu-turbo polymerase 
New England Biolabs (NEB, Ipswitch) 
restriction enzymes, dNTP mix, magnesium sulfate, Vent 
Polymerase, BSA 
Jena Bioscience (Jena) ATP, ADP, AppNHp, ATPγS 
Qiagen (Hilden) gel-extraction kit, PCR-purification kit, mini-prep kit 
Roche Diagnostics (Mannheim) 
alkaline phosphatase, nicotinamide adenine dinucleotide 
(NADH), phosphoenolpyruvate (PEP), pre-mixed lactate 
dehydrogenase (LDH) and pyruvate kinase (PK) from rabbit 
muscle (in aqueous glycerol), protease inhibitor tablets, lactate 
Roth (Karlsruhe) 
ammonium persulfate (APS), isopropanol, 
30% (w/v) Acryl amide : 0,8% (w/v) Bis-acryl amide stock 
solution (37.5:1) 
Serva (Heidelberg) Bromphenol blue, BSA, Coomassie Brilliant Blue R/G-250 
Expedeon (Harston, UK) InstantBlue protein stain 
Sigma/Fluka (Deisenhofen) 
acetic acid, phenylmethanesulfonylfluoride (PMSF), 
tetramethylethylenediamine  (TEMED), Thrombin, Trizma (Tris), 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),  
Sigma Aldrich (Steinheim) 
ß-mercaptoethanol (β-ME), p-nitrophenyl α-glucopyranoside, 
p-Aminobenzamidine dihydrochloride, ethanol, imidazole, 
tris(2‐carboxyethyl)phosphine (TCEP) 
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In the experiments double-distilled and de-ionized ELGA-water (purchased from VEOLIA water, Celle) 
was used for buffer- and sample preparation. 
 
2.1.2 Buffers 
buffer denomination composition 
Lysis buffer A 
50 mM Tris-HCl pH 8.0 
250 mM KCl 
10 mM β-ME 
Elution buffer A 
50 mM Tris-HCl pH 8.0 
200 mM KCl 
10 mM β-ME 
250 mM Imidazole 
buffer Ahep 
50 mM Tris-HCl pH 8.0 
5 mM MgCl2 
3 mM DTE 
buffer Bhep 
50 mM Tris-HCl pH 8.0 
5 mM MgCl2 
3 mM DTE 
1 M KCl 
buffer AmonoQ 
50 mM Tris-HCl pH 9.0 
5 mM MgCl2 
3 mM DTE 
buffer BmonoQ 
50 mM Tris-HCl pH 9.0 
5 mM MgCl2 
3 mM DTE 
1 M KCl 
buffer AmonoS 
50 mM MES-NaOH pH 5.5 
5 mM MgCl2 
3 mM DTE 
buffer BmonoS 
50 mM MES-NaOH pH 5.5 
5 mM MgCl2 
3 mM DTE 
1M KCl 
storage buffer 
10 mM HEPES-NaOH pH 8.0 
250 mM KCl 
5 mM MgCl2 
3 mM DTE 
EMSA reaction buffer 
50 mM Tris-HCl pH 8.0 
200 mM KCl 
10 mM MgCl2. 
oligonucleotide annealing buffer 
20 mM Tris-HCl pH 7.5 
200 mM K-Acetate 
0.1 mM EDTA 
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4 x unwinding buffer 
100 mM Tris-HCl pH 8.0 
400 mM KCl 
10 mM DTE 
RNA loading dye 
40 % (v/v) glycerol 
(50 mM EDTA pH 7.5) 
0.1 mg bromphenol blue 
2 x ATPase buffer 
50 mM Tris-HCl pH 8.0 
1 mM EDTA 
250 mM KCl 
0.5 mM NADH 
0.8 mM PEP 
2.8 units/ml PK 
4 units/ml LDH 
2 mM MgCl2 
titration buffer 
50 mM HEPES-NaOH pH 8.0 
5 mM MgCl2 
250 mM KCl 
5 x SDS-loading buffer 
50 mM Tris-HCl pH 7.0 
10% (w/v) SDS 
0.1% (w/v) bromphenol blue 
1% (v/v) β‐ ME 
14% (w/v) DTE 
10% (v/v) glycerol 
6 x DNA-loading buffer 
30% (v/v) glycerol 
0.25% (w/v) bromphenol blue 
0.25% (w/v) xylene cyanol FF 
SDS running buffer 
25 mM Tris‐HCl pH 8.0 
200 mM glycine 
0.1% (w/v) SDS 
running gel buffer 
1.5 M Tris‐HCl pH 8.8 
0.4% (w/v) SDS 
stacking gel buffer 
0.5 M Tris‐HCl pH 6.8 
0.8 % (w/v) SDS 
TB/competence buffer 
10 mM PIPES-HCl pH 6.7 
55 m M MnCl2 
15 mM CaCl2 
250 mM KCl 
7 % (v/v) DMSO 
TBE 
89 mM Tris‐HCl pH 8.0 
89 mM boric acid 
2 mM EDTA 
 
Most buffers and stock-solutions, if not containing DTE or β-ME were stored at 297 K for several days. 
Buffer stock solutions of BSA, MOPS, NADH and PEP were stored at 253 K. Chromatography-, lysis- and 
assay-buffers were prepared fresh for each experiment. 
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2.1.3 Software 
The following software was used during the study for data acquisition, handling, evaluation and 
experimental design: 
company software 
Adobe (München) Adobe CS 4.0, Adobe Illustrator, Acrobat 8.0 professional 
Biokin ltd. (Watertown, USA) Dynafit 4.05 
Bioinformatics.org (USA) PrimerX 
Barton, G.J. - Prot. engineering (1993) ALscript[139] 
Collaborative Computational Project 4 (Oxon, UK) CCP4 software suit 
DeLano Scientific LLC (USA) PyMOL 
dotPDN LLC (USA) paint.net v 3.36 
Epson (Meerbusch) Epson Scan 
Erithacus software (Horley, UK) GraFit 3.0 
European Bioinformatics Institute (Cambridge, GB) ClustalW 2.0.1, ClustalOmega 
GraphPad Software (San Diego, USA) Prism 5.01 
Jasco (Groß-Umstadt) Spectra manager 
Livingstone and Barton - CABIOS (1993) AMAS server[140] 
Microsoft (Unterschleißheim) office-suite professional 2003 
Sci-Ed (Cary, USA) Clone-manager 9.0 
Swiss Institute of Bioinformatics (CH) ExPASy proteomics server 
Wolfgang Kabsch (MPI for medical research) XDS, X-ray detector software 
zbio.net/Stormoff (Düsseldorf) six-frame translation 
  
Note that all simple sketch-like figures in this study were created with the software paint.net (Rick 
Brewster, dotPDN LLC, USA). Schematic figures were created with Adobe Illustrator (Adobe, München, 
Germany). 
All data representations were created with Prism 5.01 (GraphPad Software, San Diego, USA) or with 
GraFit 3.0 (Erithacus software, Sussex, UK). The fits shown were either created with Prism or GraFit. Fits 
created with Dynafit were plotted in Prism.  
Multiple sequence alignments were createad with either ClustalOmega or ClustalW from the European 
Bioinformatics Institute of the EMBL (EMBL-EBI, www.ebi.ac.uk/tools/msa). Secondary structure 
predictions were obtained with PSIPRED from the Bloomsbury Centre for Bioinformatics 
(bioinf.cs.ucl.ac.uk/psipred). Visualisation of sequence alignments was realized with the Linux software 
ALscript[139] and sequence conservation values were obtained with the AMAS-server[140]. 
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2.1.4 Crystallization screens 
The following screens were used for crystal screening in 96-well formate: 
company screen 
Qiagen (Germany) classics suite I and II 
Qiagen (Germany) Joint Consortium for Structural Genomics (JCSG) –  core suite 
Qiagen (Germany) PEG I and II suites 
Emerald (USA) Wizard I and II 
Hampton Research (USA) additive screen 
 
 
2.1.5 Growth media 
Bacteria were grown in lysogeny broth/Luria Bertani (LB) medium, supplemented with appropriate 
antibiotics. To obtain solid LB-agar plates, medium was supplemented with 15 g/l bacto-agar. All media 
and plates were prepared and autoclaved by the media kitchen of the Max Planck Institute for Medical 
Research (Heidelberg). 
LB medium 
10 g/l bacto-tryptone 
5 g/l bacto-yeast extract 
10 g/l NaCl 
(adjust pH with 10 M NaOH to 7.0) 
LB agar 
15 g/l bacto agar 
25 g/l standard-nutrient-broth 
 
Antibiotics were added to the media according to the resistance cassettes integrated into the 
chromosomes of the respective bacteria strains and according to the resistance marker on the plasmid 
DNA: 
vector antibiotic 
pET28a 50 μg/ml kanamycin 
pGEX-4T-1 100 μg/ml ampicillin 
pET22b 100 μg/ml ampicillin 
pET21d 100 μg/ml ampicillin 
pRIL 34 μg/ml chloramphenicol 
 
For selenomethionine labeling of target proteins, E. coli strain BL21-CodonPlus(DE3)-RIL cells were 
grown in minimal media supplemented with selenomethionine instead of methionine. The media were 
prepared according to Van Duyne et al., 1991[141].  
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2.1.6 Bacterial strains 
The E.coli strain DH5α was used for cloning of plasmid DNA, whereas the BL21-CodonPlus(DE3)-RIL cells 
were used for protein expression. For some expression trials also the strain K12 ER2508 was used, which 
is a derivative of RR1 that has been made lon-[142]. All cells were stored at 193 K in TB/competence-buffer. 
 
strain genotype source 
DH5α 
F- φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rk-, 
mk+) phoA supE44 thi-1 gyrA96 relA1 λ- 
Stratagene (Cedar Creek, TX, USA) [143] 
   
BL21-CodonPlus(DE3)- 
RIL 
ompT, hsdSB (rB-, mB-), gal(λcIts857,ind1,Sam7, nin5, lacUV5-
T7gene1), dcm(DE3) 
Invitrogen (USA) [144] 
   
K12 ER2508 
F- ara-14 leuB6 fhuA2 Δ(argF-lac)U169 lacY1 lon::miniTn10(TetR) 
glnV44 galK2 rpsL20(StrR) xyl-5 mtl-5 Δ(malB) zjc::Tn5(KanR) 
Δ(mcrC-mrr)HB101 
NEB (Ipswich, UK) [142, 145] 
  
 
 
 
2.2 Molecular biology 
 
2.2.1 Transformation protocol for chemically competent E. coli cells 
Chemically competent cells were prepared according to a protocol from Hanahan et al. [146] and were 
kindly provided by Maike Gebhardt, Christina Sendlmeier and Florence Jungblut (MPI for medical 
research). For plasmid tranformation 25 μl aliquots of respective E. coli cell suspension was thawed on 
ice and 1 μl plasmid DNA (10 – 50 ng/μl) was added carefully. Cells were incubated with the plasmid 
DNA for ~15 min on ice, „heat-shocked“ at 315 K for 20 sec and afterwards immediately placed on ice. 
After 3 min incubation on ice, 450 μl pre-warmed (310 K) LB medium was added to the cells and they 
were incubated at 310 K, shaking at 750 rpm in a thermomixer comfort (Eppendorf, Hamburg, Germany) 
for 1 h. Cells were harvested by centrifugation at 4500 rpm (2.400 x g) in a table-top-centrifuge 
(Heraeus® Biofuge®, Thermo-Scientific, Waltham, USA). Supernatant was discarded and cells were 
resuspended in 100 μl of fresh LB medium and plated on a pre-warmed LB-agar plate containing 
antibiotics according to the respective resistance cassette on the plasmid. Plates were incubated at 310 
K for 12 h or until single bacteria colonies were visible.   
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2.2.2 Amplification of DNA fragments using polymerase chain reaction (PCR) 
cDNA was used as a PCR-template to amplify genomic fragments corresponding to open-reading-
frames (ORFs). PCR primers were designed to contain restriction sites and ordered in the form of 
chemically synthesized oligonucleotides from MWG-eurofins (Ebersberg, Germany). Thermocycling was 
conducted following a three-step protocol[147] (see Thermocycling protocol below) in a TPersonal 
machine (Biometra, Göttingen, Germany). PCR reagents were purchased from New England Biolabs 
(NEB, Schwalbach, Germany) and parameters such as annealing temperature and elongation time were 
adapted to product length and primer properties. 
 
Reagent Concentration Volume 
10 x Thermopol buffer*  5 μl 
template cDNA ~ 50 ng/μl 0.5 μl 
dNTP’s 10 mM 5 μl 
Forward primer 0.1 mM 0.5 μl 
Reverse primer 0.1 mM 0.5 μl 
Formamid > 99.5 % 3.5 μl 
MgSO4 100 mM 0-2 μl 
Vent polymerase 2 U/μl 0.5 μl 
ddH2O > 99.9 % add to 50 μl 
* 200 mM Tris-HCl pH 8.8, 100 mM (NH4)SO4, 100 mM KCl, 20 mM MgSO4, 1 % (v/v) Triton X-100 
 
Thermocycling protocol 
Reaction step Temperature [K] Time [sec]  
Initial denaturation 365 120  
Melting 365 30  
Annealing 327 30 x 30 
Elongation 345 90  (60 per kb)  
Final elongation 345 600  
Storage 277 ∞  
 
PCR products were separated by agarose gel electrophoresis (see section 2.2.6). Separated DNA 
fragments were visualized by illuminating the gel with UV-light at 280 nm (excitation of intercalated 
dye), fragments were excised and DNA was purified by using a gel-extraction kit, following the 
manufacturer’s protocol (Qiagen, Hilden, Germany).   
 
2.2.3 Site directed mutagenesis 
Simple mutations (like e.g. single codon changes or amino acid substitutions) were introduced in 
plasmid templates by using site-directed mutagenesis (SDM) according to the QuikChange® protocol 
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(Stratagene, La Jolla, USA). Primers suitable for SDM reactions were designed with the online software 
PrimerX[148] and chemically synthesized by MWG-eurofins (Ebersberg, Germany). QuikChange® 
thermocycling was conducted in a TPersonal machine (Biometra, Göttingen, Germany).  
 
Reagent Concentration Volume 
10 x Pfu buffer*  5 μl 
template plasmid ~ 50 ng/μl 1 μl 
dNTP’s 10 mM 1 μl 
Forward primer 0.01 mM 1.25 μl 
Reverse primer 0.01 mM 1.25 μl 
Pfu Turbo polymerase 2 U/μl 1 μl 
ddH2O > 99.9 % add to 50 μl 
* 200 mM Tris-HCl pH 8.8, 100 mM (NH4)SO4, 100 mM KCl, 1 % (v/v) Triton X-100, 1 mg/ml BSA 
 
SDM QuikChange® thermocycling protocol 
Reaction step Temperature [K] Time [sec]  
Initial denaturation 368 30  
Melting 368 30  
Annealing 328 60 x 16 
Elongation 341 480  (60 per kb)  
Final elongation 341 600  
Storage 277 ∞  
 
After DNA amplification (by thermocycling), the reaction products were digested with DpnI (10 U) for 2 
h at 310 K to remove all parental (methylated) DNA. Then, the nicked PCR product was transformed into 
E. coli DH5α cells. Successful mutagenesis was verified by isolating plasmid DNA from single bacteria 
colonies and next-generation DNA sequencing (done by MWG-eurofins, Ebersberg, Germany).  
 
2.2.4 Preparation of plasmid DNA 
Plasmid DNA was prepared from single colonies of E. coli DH5α cells that grew on LB plates after 
transformation and plating. Single colonies were used to inoculate 5 ml LB culture, containing the 
appropriate antibiotics and cultures were grown at 310 K, shaking at 105 rpm for 14 h. Bacteria were 
harvested by centrifugation at 4.000 rpm (3.220 x g) in a 5810 R centrifuge (Eppendorf, Hamburg, 
Germany). Plasmid DNA was isolated from the cell pellet according to the QIAprep mini-prep protocol 
using the Spin Miniprep kit (Qiagen, Hilden, Germany). Final concentrations were determined 
spectroscopically by measuring absorption at a wavelength of 260 nm on a NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, USA).  
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2.2.5 Digest by restriction enzymes and ligation of nucleotide fragments 
Restriction endonucleases were used to digest PCR products and to generate sticky or blunt ends for 
ligation of nucleotide fragments in the multiple-cloning-site (MCS) of the respective target vector. 
Plasmid DNA was incubated with restriction enzymes (purchased from NEB, Schwalbach, Germany) for 2 
– 12 h at 310 K, depending on the respective endonuclease activity. After the restriction digest, samples 
were purified either via agarose-gel-electrophoresis (see section 2.2.6) or by using the PCR purification 
kit (Qiagen, Hilden, Germany), depending on fragment size.  
 
Reagent Concentration Volume 
10 x NEB buffer*  5 μl 
Bovine Serum Albumin (BSA)* 10 mg/μl 0.5 μl 
Restriction enzyme 1 10 – 20 U/μl 1 μl 
Restriction enzyme 2 10 – 20 U/μl 1 μl 
PCR product/plasmid DNA ~ 50 ng/μl 10 – 40 μl 
ddH2O > 99.9 % add to 50 μl 
* Depending on Restriction enzyme used, either NEB buffer 1,2,3 or 4 with or without BSA was used 
 
The resulting nucleotide fragments from the restriction reaction, i.e. digested vector and insert with 
compatible sticky ends, were ligated. Ligation was conducted according to the manufacturer’s protocol 
using the rapid DNA ligation kit (Fermentas, St. Leon-Rot, Germany). Correct concentrations of vector 
and insert for the ligation reaction (to achive a 1:3 ratio) were calculated using the ligation calculator of 
the university of Düsseldorf (insilico.uni-duesseldorf.de/Lig_Input).  
 
Reagent Concentration Volume 
5 x rapid ligation buffera  4 μl 
insertb 25 – 50 ng 5-14 μl 
vectorb 25 – 50 ng 5-14 μl 
T4 DNA ligase 10 U/μl 1 μl 
ddH2O > 99.9 % add to 20 μl 
a 400 mM Tris-HCl, 100 mM MgCl2, 100 mM dithiothreitol (DTT), 5 mM ATP  
b vector and insert concentrations were calculated individually to obtain a vector to insert ratio of 1:3 
 
Ligation reactions were incubated at 297 K for 10 min and then transformed in E. coli DH5α cells. 
 
2.2.6 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate nucleotide fragments, based on their electrophoretic 
mobility. To prepare gels 0.5 – 1.5 % (w/v) agarose (Bio & Sell, Feucht, Germany) was suspended in 1 x 
TBE buffer, heated to 368 K and poured in a plastic-tray before solidifying upon cooling down. Agarose 
gels were supplemented with 0.003 % (v/v) gel-red (Roth, Karlsruhe, Germany) to stain nucleotide 
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strands. Samples were supplemented with a loading-dye, to increase viscosity before loading. To 
estimate DNA size 1 μl of a NEB ruler, 1 kb DNA ladder (NEB, Schwalbach, Germany) was loaded. 
Electrophoresis was performed using a PowerPacTM High-Voltage power supply (Bio-Rad, Munich, 
Germany) at 100 V for 1-2 h. Separated DNA fragments were visualized by exciting intercalated dye at 
302 nm. Fragments were excised and DNA was purified by using the gel-extraction kit, following the 
manufacturer’s protocol (Qiagen, Hilden, Germany).   
 
2.2.7 Sequencing 
Successful cloning was verified by test digests only in situations, where restriction fragments helped to 
identify the presence of an insert or changed upon incorporation of a mutation. Constructs, which 
showed a correct restriction pattern in test digests or QuikChange® SDM products were further checked 
by sequencing. All sequencing reactions were performed by MWG-eurofins (Ebersberg, Germany) on 
ABI 3730XL sequencing machines (Life Technologies GmbH, Darmstadt, Germany) and evaluated by 
MWG-eurofins (Ebersberg, Germany). The material required for a typical sequencing reaction was 14 μl 
DNA sample of a concentration of 5 – 300 ng/μl mixed with 1 μl sequencing primer (stock 0.01 mM). 
Material for sequencing reactions was sent to MWG-eurofins (Ebersberg, Germany) via letter mail. 
 
 
 
Note that all cloning and sequencing primer are listed in the appendix  
(section 7.7). 
 
 
2.2.8 Cloning of the DDX1 ORF into pET28a 
The coding sequence of human DDX1 was amplified from cDNA (Accession: BC012739, clone ID: 
3835131) obtained from OpenBiosystems (Schwerte, Germany) by PCR and cloned into pET28a 
expression vector DNA (Novagen, Darmstadt, Germany). Briefly, a colony PCR was performed on 
bacteria containing the cDNA vector with the DDX1 ORF. Primers did contain restriction sites for cloning 
of the amplified DDX1-PCR fragment in the target vector. The forward primer (DDX1_NheI_fwd) was 
designed to contain a NheI-restriction-site upstream of the ORF and the reverse primer (DDX1_NotI_rev) 
was designed to contain a NotI-restriction-site downstream of the ORF. After DNA amplification, the PCR 
reaction was separated by agarose gel-electrophoresis and the band corresponding to the DDX1 DNA 
fragment (according to electrophoretic mobility) was excised and purified with a gel-extraction kit 
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(Qiagen, Hilden, Germany). The DDX1 PCR product DNA and the pET28a vector DNA were both digested 
with NheI- and NotI-restriction-endonucleases at 310 K for 12 h. After the digest, the linearized plasmid 
DNA and the DDX1 PCR product DNA were separated via agarose gel-electrophoresis, the 
corresponding bands were excised and the DNA was extracted from the gel slices via the gel-extraction 
kit (Qiagen, Hilden, Germany). The DDX1 PCR product DNA was ligated with the linearized pET28a 
vector DNA using the rapid DNA ligation kit (Fermentas, St. Leon-Rot, Germany). Ligation in pET28a 
resulted in a DDX1 construct (= pET28a(DDX1-WT)) harboring the sequence for a fused N-terminal hexa-
histidine tag (6xHis-Tag). The N-terminal 6xHis-Tag is fused to the DDX1 ORF via a Thrombin cleavage 
site.  
 
2.2.9 Cloning of the DDX1 ORF into pET22b 
To test for the effects of protein expression in the periplasm, the sequence encoding for DDX1 was 
subcloned into pET22b vector DNA. This vector carries an N-terminal pelB signal sequence for 
periplasmic protein localization[149]. The sequence, coding for the entire DDX1 ORF and the N-terminal 
6xHis-Tag, was cloned from pET28a(DDX1-WT) as NcoI – XhoI restriction fragment into pET22b vector 
DNA. Therefore, vector DNA from both, pET28a(DDX-WT) and pET22b was digested with NcoI- and XhoI-
restriction-endonucleases at 310 K for 2 h. Digestion products were separated via agarose gel-
electrophoresis, excised from the gel and purified via the gel-extraction kit (Qiagen, Hilden, Germany). 
The DDX1 digestion product was ligated with the linearized pET22b vector DNA using the rapid DNA 
ligation kit (Fermentas, St. Leon-Rot, Germany). Ligation resulted in a DDX1 construc (= pET22b(DDX1-
WT))t harboring the codon triplets for an N-terminal pelB signal sequence, followed by a 6xHis-Tag.  
 
2.2.10 Cloning of the DDX1 ORF into pGEX-4T-1 
To test for the effects of a GST-tag fusion on protein stability, DDX1 was subcloned into pGEX-4T-1 
vector DNA. This vector carries the sequence for an N-terminal GST-Tag to facilitate protein folding. SDM 
was used to introduce a BamHI-restriction-site upstream of the DDX1 ORF in pET28a (primers 
DDX1_genBamHI-pGEX_f and _r, for complete sequence see appendix section 7.4). The DDX1 ORF 
was cloned as a BamHI – NotI restriction fragment from pET28a vector DNA into pGEX-4T-1 vector DNA. 
Cloning and ligation were conducted as mentioned above resulting in pGEX-4T-1(DDX1-WT).  
 
2.2.11 Cloning of C-terminally truncated DDX1 variants in pET28a 
Several C-terminally truncated variants of DDX1 were constructed in vector pET28a, using 
pET28a(DDX1-WT) as a template. QuikChange® SDM was used to introduce double stop-codons 
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(sequence TGA TAA) at desired positions within the DDX1 ORF. Using the appropriate SDM-primers (see 
appendix section 7.4, SDM primer table) the following truncated DDX1-variants were constructed:  
pET28a(DDX1-432); pET28a(DDX1-610);  pET28a(DDX1-648); pET28a(DDX1-655); pET28a(DDX1-674); 
pET28a(DDX1-694); pET28a(DDX1-728) - the number denotes the position of the C-terminal truncation 
(also see table 3.1 in the results part). 
 
2.2.12 Cloning of DDX1ΔSPRY in pET28a 
The sequence, coding for the entire SPRY domain was removed from pET28a(DDX1-WT), resulting in 
construct pET28a(DDX1ΔSPRY). For this, endonuclease restriction sites were introduced upstream and 
downstream of the SPRY domain coding sequence via QuikChange® SDM. A BamHI-restriction-site was 
introduced after the codon triplett for lysine residue 69 and a second BamHI-restrction-site was 
introduced before the codon triplett for lysine residue 248 in pET28a(DDX1-WT) vector DNA. The DNA 
of the mutated construct was digested with BamHI-restriction-endonuclease, the reaction products 
were separated via agarose gel-electrophoresis and the vector DNA lacking the SPRY domain sequence 
was re-ligated. 
 
2.2.13 SDM to generate a Walker A Lysine mutant of DDX1 in pET28a 
The codon triplett for the essential Walker A lysine (GSGKT motif) at position 52 was mutated to alanine 
via QuikChange® SDM, resulting in construct pET28a(DDX1-K52A). To ensure correct mutation the 
plasmid was sequenced and the altered residue was additional verified by ESI-MS on the protein level 
(see below section 2.3.7), conducted by Melanie Müller and Marion Gradl.  
 
 
2.2.14 Cloning of the SPRY domain in pET28a 
In pET28a(DDX1-WT) a BamHI-restriction-site was introduced upstream (primers DX1SPRY_1gBamH-f 
and –r) and an XhoI-restriction-site downstream (primers DX1SPRY_2gBamH-f and –r, for complete 
sequence see appendix section 7.4) of the sequence, coding for the separated SPRY-domain (residues 
72-283 on amino acid level) via QuikChange® SDM. The mutated vector DNA was then digested with 
BamHI- and XhoI-restriction-endonucleases and the excised DNA encoding for the SPRY domain was 
ligated with pre-linearized pET28a vector DNA. The resulting construct was designated 
pET28a(SPRY_72-283). 
Additional N- and C-terminally truncated SPRY variants were generated using this construct as a 
template:  pET28a(SPRY_84-283); pET28a(SPRY_100-283); pET28a(SPRY_72-261); pET28a(SPRY_84-261); 
pET28a(SPRY_100-261) - constructs are summarized in table 2.1.  
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Table 2.1 Constructs of the DDX1-SPRY domain 
construct length (amino acids, 
referring to DDX1) 
vector Cloning strategy 
SPRY_72-283 Glu72 - Lys283 pET28a BamHI – XhoI restriction fragment from 
pET28a(DDX1) 
SPRY_84-283 Gly84 - Lys283 pET28a Removed N-terminal BamHI – BamHI restriction 
fragment from pET28a(SPRY_72-283) 
SPRY_100-283 Ser100 - Lys283 pET28a Removed N-terminal BamHI – BamHI restriction 
fragment from pET28a(SPRY_72-283) 
SPRY_72-261 Glu72 - Ala261 pET28a Introduced Stop-codon at the sequence coding for 
the C-terminus of pET28a(SPRY_72-283) 
SPRY_84-261 Gly84 - Ala261 pET28a Introduced Stop-codon at the sequence coding for 
the C-terminus of pET28a(SPRY_84-283) 
SPRY_100-261 Ser100 - Ala261 pET28a Introduced Stop-codon at the sequence coding for 
the C-terminus of pET28a(SPRY_100-283) 
 
The N-terminal truncated SPRY variants were obtained by introducing BamHI-restriction-sites upstream 
and downstream of the region to be removed by SDM. Constructs were digested with BamHI-
restriction-endonuclease and the vector DNA lacking the BamHI – BamHI restriction fragment was re-
ligated. C-terminal truncated SPRY variants were obtained by introducing Stop-codons via SDM. 
  
2.2.15 Cloning of subunits of the HSPC117 complex into pET28a 
The components of the HSPC117 complex were cloned either from cDNA or from other vector DNA into 
pET28a expression vector DNA (Novagen, Darmstadt, Germany). The coding sequence for the HSPC117 
proteins Fam98b and CGI-99 was available in the pFBDM vector DNA (cloned by Maike Gehardt) and 
was amplified via PCR, using the pFBDM vector DNA as a template. The coding sequence of both 
proteins was amplified with primers coding for a NheI-restriction-site upstream and an XhoI-restriction-
site downstream of the respective protein ORF. PCR products were then purified, digested with NheI- 
and XhoI-restriction-endonucleases and ligated with pre-linearized pET28a vector DNA, resulting in the 
expression constructs pET28a(Fam98b) and pET28a(CGI-99).  
The coding sequence for the protein ASW/C2ORF49 was amplified from cDNA (Accession: BC001310 
Clone ID: 3453623) obtained from OpenBiosystems (Schwerte, Germany) by PCR and cloned into 
pET28a expression vector DNA (Novagen, Darmstadt, Germany). The forward primer (ASW_NdeI_fwd2) 
was designed to contain a NdeI-restriction-site upstream of the ORF and the reverse primer 
(ASW_BamHI_rev1) was designed to contain a BamHI-restriction-site downstream of the ORF. After DNA 
amplification by thermocycling, the PCR product was digested with NdeI- and BamHI-restriction-
endonucleases and ligated with pre-linearized pET28a vector DNA to yield pET28a(ASW). 
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2.3 Protein biochemistry 
 
2.3.1 Recombinant protein expression 
Proteins were expressed in BL21-CodonPlus(DE3) RIL E. coli cells (Invitrogen, Carlsbad, USA) that were 
transformed with the respective expression plasmid DNA prior to cultivation. Baffled glass flasks with a 
total volume of 5 l (Schott AG, Mainz, Germany) were filled with 2 l of LB medium each, supplemented 
with selection antibiotics and inoculated with 5 – 25 ml (per 2 l) of an overnight bacteria pre-culture. 
Cells were grown at 310 K, shaking in a Multitron incubation shaking device (INFORS HT, Bottmingen, 
Switzerland) for 2-3 h until an OD600 ~ 0.8 was reached. Cultures were cooled down to 291 K and protein 
expression was induced by addition of 0.5 mM isopropyl-β-D-thiogalactosid (IPTG). Cultures were then 
incubated shaking at 291 K for ~ 14 h. Bacteria cells were harvested by centrifugation at 6.000 x g in a 
Sorvall Evolution RC 2925 centrifuge (Thermo Fisher, Waltham, USA) at 277 K for 20 min. Supernatant 
was discarded and cell pellets were dissolved in ~10 ml lysis buffer A (see section 2.1.2, buffer table) per 
2 l of input LB medium and either directly used for protein purification or shock frozen in liquid nitrogen 
and stored at 193 K.   
 
2.3.2 Analysis of protein expression and purity via SDS- and native PAGE 
All protein expression and purification steps were checked by discontinuous sodium-dodecyl-sulfate 
polyacrylamide gel-electrophoresis (SDS-PAGE)[150]. Gels containing 10 – 17 % (w/v) acrylamide 
(depending on desired resolution) were cast in the size 8.6 x 6.8 cm (mini-gels) using the Protean 4 
system (Bio-Rad, Munich, Germany).  
 
15 % running gel   
Component Volume  Supplier 
ddH2O 7.3 ml ELGA, Celle, Germany 
running-gel-buffer* 7.5 ml see buffer list, section 2.1.2 
30 % (w/v) acrylamide-,bisacrylamide (37.5:1) 15 ml Roth, Karlsruhe, Germany 
TEMED 25 μl Serva, Heidelberg, Germany 
added directly before casting to start 
polymerization reaction 
  
10% (w/v) APS 250 μl Merck, Darmstadt, Germany 
*running-gel-buffer was replaced by either 1xTBE or 40 mM CHES for native gels 
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To remove air-bubbles the running gel was overlaid with isopropanol. After polymerization of the 
running-gel, the isopropanol was removed and a stacking-gel (with different pH) was cast on top.  
stacking  gel   
Component Volume  Supplier 
ddH2O 8.9 ml ELGA, Celle, Germany 
stacking-gel-buffer 3.8 ml see buffer list, section 2.1.2 
30% (w/v) acrylamide-,bisacrylamide (37.5:1) 2.3 ml Roth, Karlsruhe, Germany 
Tetramethylethylenediamine (TEMED) 15 μl Serva, Heidelberg, Germany 
added directly before casting to start 
polymerization reaction 
  
10% (w/v) APS 150 μl Merck, Darmstadt, Germany 
 
A 15-well polycarbonate comb (Bio-Rad, Munich, Germany) was inserted into stacking gels before 
polymerization, resulting in wells of 3.35 mm width. Protein samples were denatured prior to gel-
loading, by addition of SDS-loading buffer and heating to 368 K for 5 min. Electrophoresis was 
performed with PowerPack 200 Voltage-supply (Bio-Rad, Munich, Germany) in SDS-PAGE running buffer 
at 40 mA per gel for ~ 40 min. Gels were stained using InstantBlue protein stain (Expedeon, Harston, 
UK). 
Helicase and gel-shift assays were done using native PAGE. Native PAGE was performed similar as 
described for SDS-PAGE, except acrylamide gels were prepared with either 1 x TBE pH 8.3 (for helicase 
assays) or 40 mM CHES-NaOH pH 10.0 (for gel-shift assays) instead of running-gel-buffer and no 
stacking gels were used. Furthermore, the 30% (w/v) acrylamide-,bisacrylamide (37.5:1) solution was 
exchanged for a 40% (w/v) acrylamide-,bisacrylamide (19:1). 
Samples were loaded on the gel in 8 % (v/v) glycerol (stained with 0.01 mg bromphenol blue per 100 μl) 
instead of SDS-loading buffer. For the gel-shift experiments, gels were run with 200 V per gel at 277 K 
for 60 min. For the helicase experiments, gels were run with 60 V per gel at 277 K for 40 min. 
Electrophoresis was performed in either 1 x TBE pH 8.3 (for helicase assays) or 40 mM CHES-NaOH 
pH 10.0 (for gel-shift assays), thermostated to 277 K.  
 
2.3.3 Cell lysis and clearification of lysate 
Cell pellets from 4 – 6 l E. coli culture in lysis buffer A (see section 2.1.2, buffer list), overexpressing the 
respective protein, were directly processed after protein expression or thawed from 193 K. Cell walls 
were disrupted by pulse-sonication (Branson Sonifier, Dietzenbach, Germany) at 277 K for 20 min. 
Lysate was cleared by ultracentrifugation at 125.000 x g in a L8-70M ultracentrifuge with a 45Ti rotor 
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(Beckman Coulter, Krefeld, Germany) at 277 K for 40 min. The cleared supernatant was used for 
purification of recombinant proteins. 
 
2.3.3 Purification of full-length and truncated DDX1 variants 
The same purification protocol was used for full-length DDX1, C-terminally truncated DDX1 constructs 
and other DDX1 mutagenesis variants. The cleared supernatant of bacteria lysate was loaded on a 1 ml 
Ni2+-NTA HiTrap column (GE Healthcare, Freiburg, Germany), pre-equilibrated with lysis buffer A using a 
peristaltic pump P-1 (GE Healthcare, Freiburg, Germany) at 277 K. The column was washed with three 
column volumes (CVs) of lysis buffer A and with one CV of lysis buffer A containing additionally 1 M KCl 
to remove nucleotides. Bound proteins were eluted in a linear gradient of 28 CVs (40 min gradient at 
0.7 ml/min) to elution buffer A, containing 250 mM imidazole using an ÄKTA purifier 10 (GE Healthcare, 
Freiburg, Germany). After elution from the 1ml Ni2+-NTA HiTrap column (GE Healthcare, Freiburg, 
Germany), homogeneous fractions of DDX1 were pooled and diluted in buffer Ahep. DDX1 was loaded on 
a 1 ml HiTrap heparin column (GE Healthcare, Freiburg, Germany), equilibrated with buffer Ahep using an 
ÄKTA purifier 10 at 277 K. Proteins were eluted in a linear gradient of 28 CVs to buffer Bhep containing 1 
M KCl. Elution fractions, containing protein were diluted in buffer AmonoQ and loaded on a MonoQ 10/100 
GL column (GE Healthcare, Freiburg, Germany) equilibrated with buffer AmonoQ. Bound proteins were 
eluted in a linear gradient of 28 CVs to buffer BmonoQ, containing 1 M KCl and protein fractions were 
concentrated using Amicon Ultra 10K centrifugal filter units (Milipore, Darmstadt, Germany) with a 
molecular weight cut-off (MWCO) of 10 kDa. Further purification was achieved by gel-filtration 
chromatography on a Superose 6© 10/300 GL column (GE Healthcare), equilibrated with storage buffer. 
Fractions containing pure DDX1 protein were pooled, concentrated in Amicon Ultra 10K filters and 
stored in ~ 20 mg/ml (200-300 μM) aliquots at 193 K.  
 
 column purification steps  
1.) Ni2+-NTA HiTrap column Binding of His-tagged proteins 
2.) HiTrap heparin column Retention of ATP binding proteins, removal of nucleotides 
3.) MonoQ 10/100 GL column Anion-exchange to retain negatively charged proteins 
4.) Superose 6 10/300 GL column Polishing by size-exclusion chromatography 
 
Protein purity during all steps was verified by 15 % (w/v) SDS-PAGE. Purified DDX1 protein constructs 
were confirmed to run as a single protein band corresponding to their respective electrophoretic 
mobility. Protein identity was further verified in experiments conducted by Melanie Müller and Marion 
Gradl using mass spectrometry (see section 2.3.7). 
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2.3.4 Purification of the SPRY domain of DDX1 
The protocol for the purification of the separate SPRY domain was slightly modified from the DDX1 
purification protocol. Cleared supernatant of bacteria lysate was loaded on a 1 ml Ni2+-NTA HiTrap 
column (GE Healthcare, Freiburg, Germany), pre-equilibrated with lysis buffer A, using a peristaltic 
pump P-1 (GE Healthcare, Freiburg, Germany) at 277 K. The column was washed with three column 
volumes (CVs) of lysis buffer A and with one CV of lysis buffer A containing additionally 1 M KCl to 
remove column-bound impurities. Bound proteins were eluted in a linear gradient of 28 CVs to elution 
buffer A, containing 250 mM imidazole using an ÄKTA purifier 10 (GE Healthcare, Freiburg, Germany). 
Protein containing fractions were pooled and either digested with 200 U thrombin (Sigma-Aldrich, 
Steinheim, Germany) at 277 K overnight (added 4 mM CaCl2 to the buffer for the digest) to remove the 
N-terminal 6xHis-Tag or directly diluted in buffer Ahep and loaded on a 1 ml HiTrap heparin column (GE 
Healthcare, Freiburg, Germany), equilibrated with buffer Ahep using an ÄKTA purifier 10 at 277 K. In case 
of loading the thrombin-digested protein on the heparin column, a HiTrap Benzamidine column (GE 
Healthcare, Freiburg, Germany) was connected ahead, to remove thrombin during the heparin column 
loading process. Digested or undigested proteins were eluted in a linear gradient of 28 CVs to buffer 
Bhep. Protein containing fractions were diluted in buffer AmonoS and loaded on a MonoS 5/50 GL column 
(GE Healthcare, Freiburg, Germany), equilibrated in buffer AmonoS. Again bound proteins were eluted in a 
linear gradient of 28 CVs to buffer BmonoS and protein fractions were concentrated using Amicon Ultra 10 
KDa MWCO (10 K) filters (Millipore, Darmstadt, Germany). Further purification was achieved by gel-
filtration chromatography on a Superdex S75 10/300 GL column (GE Healthcare, Freiburg, Germany), 
equilibrated in storage buffer. Fractions containing pure SPRY protein were pooled, concentrated in 
Amicon Ultra 10K filters and stored in ~ 20 mg/ml (700-800 μM) aliquots at 193 K for crystallization. All 
purification steps were verified by 15 % (w/v) SDS-PAGE, purified SPRY protein was confirmed to run as a 
single band with a electrophoretic mobility similar to a 28 kDa particle and identity was further 
controlled in MALDI-MS experiments conducted by Melanie Müller and Marion Gradl (see section 
2.3.7). 
Selenomethionine-substituted protein was expressed according to Van Duyne,1993[151] (see section 
2.1.5) and protein purification was performed essentially as described for native protein, except that 
DTE concentration in the buffers Ahep, AmonoS and storage buffer was increased from 3 mM to 5 mM.  
 
2.3.5 Purification of HSPC117 complex components 
Besides DDX1 three other protein components of the pentameric HSPC117 complex were expressed, 
the proteins Fam98b, CGI-99 and ASW.  
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The cleared supernatant of Fam98b or CGI-99 expressing bacteria lysate was loaded on 1 ml of Co2+-
Talon beads (Clontech, Saint-Germain-en-Laye, France), pre-equilibrated with lysis buffer A using a 
peristaltic pump P-1 (GE Healthcare, Freiburg, Germany) at 277 K. After loading, beads were washed 
with three CVs of lysis buffer A and proteins were eluted in a linear gradient of 28 CVs to lysis buffer A 
containing additional 120 mM Imidazole. Protein Fam98b could not be found in the eluate fractions and 
purification was ceased at that point; however, soluble protein material of CGI-99 was detected. CGI-99 
protein containing fractions were diluted in buffer AmonoQ and loaded on a MonoQ 10/100 GL column (GE 
Healthcare, Freiburg, Germany), equilibrated with buffer AmonoQ. Bound proteins were eluted in a linear 
gradient of 28 CVs to buffer BmonoQ and CGI-99 protein containing fractions were concentrated using 
Amicon Ultra 10K centrifugal filter units (Milipore, Darmstadt, Germany) with a MWCO of 10 kDa. Finally, 
the proteins were polished by gel-filtration chromatography on a Superdex S75 10/300 GL column (GE 
Healthcare, Freiburg, Germany), equilibrated in storage buffer. Fractions containing pure CGI-99 protein 
were pooled, concentrated in Amicon Ultra 10K filters and stored in ~ 10 mg/ml (300-400 μM) aliquots 
at 193 K. 
The cleared supernatant of ASW expressing bacteria lysate was loaded on a 1 ml Ni2+-NTA HiTrap 
column (GE Healthcare, Freiburg, Germany) pre-equilibrated with lysis buffer A using a peristaltic pump 
P-1 (GE Healthcare, Freiburg, Germany) at 277 K. The column was washed with three CVs of lysis buffer A 
and with one CV of lysis buffer A containing additionally 1 M KCl to remove column-bound impurities. 
Bound proteins were eluted in a linear gradient of 28 CVs to elution buffer A, using an ÄKTA purifier 10 
(GE Healthcare, Freiburg, Germany). ASW protein containing fractions were pooled, diluted in buffer 
Ahep and loaded on a HiTrap 1 ml heparin column (GE Healthcare, Freiburg, Germany), equilibrated with 
buffer Ahep using an ÄKTA purifier 10 at 277 K. Bound ASW protein was eluted in a linear gradient of 28 
CVs to buffer Bhep and protein containing fractions were concentrated using Amicon Ultra 10 KDa 
MWCO filters (Millipore, Darmstadt, Germany). The concentrated protein sample was loaded on a 
Superdex S75 10/300 GL column (GE Healthcare, Freiburg, Germany), equilibrated in storage buffer. 
Fractions containing pure ASW protein were pooled, concentrated in Amicon Ultra 10K filters and 
stored in ~ 30 mg/ml (300-400 μM) aliquots at 193 K. 
 
2.3.6 Co-purification and pulldown studies 
To test for interactions between the individual subunits of the HSPC117 complex, co-expression and co-
purification studies were performed. In co-expression experiments, cell pellets of DDX1, CGI-99 and 
Fam98b expressing bacteria (pellet from 2 l LB medium per construct) were combined and cell walls 
were disrupted by pulse-sonication (Branson Sonifier, Dietzenbach, Germany) at 277 K for 20 min. The 
combined lysate was cleared by ultracentrifugation at 125.000 x g in a L8-70M ultracentrifuge with a 
45Ti rotor (Beckman Coulter, Krefeld, Germany) at 277 K for 40 min. The cleared supernatant, putatively 
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containing the three recombinant proteins, was loaded on a 1 ml Ni2+-NTA HiTrap column (GE 
Healthcare, Freiburg, Germany) pre-equilibrated with lysis buffer A using a peristaltic pump P-1 (GE 
Healthcare, Freiburg, Germany) at 277 K. The column was washed with three CVs of lysis buffer A and 
with one CV of lysis buffer A containing additionally 1 M KCl to remove column-bound impurities. 
Bound proteins were eluted in a linear gradient of 28 CVs to elution buffer A, using an ÄKTA purifier 10 
(GE Healthcare, Freiburg, Germany). Proteins not forming a complex were further purified by individual 
protocols as described above.  
 
A pulldown experiment was performed with the proteins ASW and DDX1. 
The cleared supernatant of ASW expressing bacteria lysate was loaded on a 1 ml Ni2+-NTA HiTrap 
column (GE Healthcare, Freiburg, Germany) pre-equilibrated with lysis buffer A using a peristaltic pump 
P-1 (GE Healthcare, Freiburg, Germany) at 277 K. The column was washed with three CVs of lysis buffer A 
and with one CV of lysis buffer A containing additionally 1 M KCl to remove column-bound impurities. 
Bound proteins were eluted in a linear gradient of 28 CVs to elution buffer A, using an ÄKTA purifier 10 
(GE Healthcare, Freiburg, Germany). ASW protein containing fractions were pooled, diluted in ~ 10 ml of 
lysis buffer A (supplemented with 4 mM CaCl2) and digested with 200 U thrombin (Sigma-Aldrich, 
Steinheim, Germany) at 277 K overnight to remove the N-terminal 6xHis-Tag. The thrombin-digested 
ASW protein was concentrated to ~ 2 ml in Amicon Ultra 10 KDa MWCO filters (Millipore, Darmstadt, 
Germany) and then diluted in 20 ml lysis buffer A, to decrease the concentration of perturbing 
imidazole in the sample. ASW protein sample was loaded via a 50 ml superloopTM (GE Healthcare, 
Freiburg, Germany) on a 1 ml Ni2+-NTA HiTrap column (GE Healthcare, Freiburg, Germany) pre-
equilibrated with lysis buffer A, with an upstream HiTrap Benzamidine column (GE Healthcare, Freiburg, 
Germany) using a peristaltic pump P-1 (GE Healthcare, Freiburg, Germany) at 277 K. The Ni2+-NTA HiTrap 
column was washed with three column volumes (CVs) of lysis buffer A. The flow-through and the wash 
were collected that should contain only the 6xHis-Tag free ASW protein sample.  
The cleared supernatant of DDX1 expressing bacteria lysate was loaded on a 1 ml Ni2+-NTA HiTrap 
column (GE Healthcare, Freiburg, Germany) pre-equilibrated with lysis buffer A using a peristaltic pump 
P-1 (GE Healthcare, Freiburg, Germany) at 277 K. The column was washed with three CVs of lysis buffer A 
and then 6xHis-Tag free ASW protein sample was loaded on the same column. Bound proteins, 
putatively forming a complex, were eluted in a linear gradient of 28 CVs to elution buffer A using an 
ÄKTA purifier 10 (GE Healthcare, Freiburg, Germany). 
 
 
Materials and Methods 
 41
2.3.7 Determination of protein concentration 
The concentration of all protein samples was determined spectroscopically by measuring the 
absorbance at a wavelength of 280 nm in a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies, Wilmington, USA). At this wavelength, the aromatic amino acids tyrosine and tryptophan 
as well as cystein determine the overall absorbance[152, 153]. Based on amino acid composition individual 
extinction coefficients (ε) per construct were calculated using the online tool ProtParam[154]. Protein 
concentrations were determined according to the law of Lambert-Beer: 
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IA   [Equation 1] 
In this equation I0 denotes the intensity of the incoming light, I1 the intensity of the transmitted light, 
ε280 the respective extinction coefficient at 280 nm, A280 the protein absorbance at 280 nm and d 
denotes the pathlength of the cuvette in cm.  
 
 
 
2.3.8 Mass spectrometry 
All Mass spectrometric analysis was done by either Melanie Müller (M. M.) or Marion Gradl (M. G.). 
Sample handling and sample preparation for the measurements were performed according to 
Wulfmeyer and colleagues (2012)[155] by M.M. and M.G..  
Electrospray-ionisation (ESI) measurements were performed by M. M. and M. G. using desalted samples. 
Samples were analyzed in a Bruker maXis hybrid quadropole/atmospheric pressure ionization 
orthogonal accelerated time of flight (TOF) mass spectrometer, equipped with a reflectron and an 
Apollo II ESI source (Bruker Daltoniks, Billerica, USA). Data were collected with the standard Bruker 
micrOTOF control version 3.0 SR1 compass 1.3 SR2 software and analyzed with the data analysis version 
4.0 SP3 ESI compass 1.3 software. Instrument calibration was conducted with the appropriate 
components (m/z 118‐1222) of the ESI‐L standard (Agilent Technologies, Waldbronn, Germany) and 
optimized for m/z range of ca. 100‐1000. Concentrations of the samples were adjusted to a final 
concentration of 10‐60 μM in 50 % acetonitrile, 49.9 % water and 0.1 % formic acid. Using a syringe 
pump (KD Scientific, Holliston, USA) samples were injected into the mass spectrometer at a flow rate of 
3 μl/min. Samples were analyzed in both positive and negative polarity in MS and MS/MS modes. 
MS/MS was performed with low energy collision-induced dissociation (CID), using various collision 
energies ranging from 5 to 50 V. 
Peptide mass fingerprinting (PMF) was performed by M. M. and M. G. by trypsin digestion of proteins 
“in‐gel” and then applying standard procedures on the obtained peptides[155]. Matrix-assisted laser 
desorption/ionisation (MALDI)‐TOF with a Shimadzu Axima Performance mass spectrometer 
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(Shimadzu/Kratos Analytical, Duisburg, Germany) in reflectron mode was used to analyze the peptides 
and the same instrument was used to confirm identities of select peptides by sequencing with high 
energy CID MS/MS. The Mascot PMF or Mascot MS/MS search software (Matrix Science, London, UK) 
with a hybrid taxonomy which includes all E. coli proteins and the specific proteins of interest in the 
BMM department was used to identify the proteins. Also see Mutschler 2011[156]. 
 
2.3.9 Domain mapping by limited proteolysis experiments 
Limited proteolysis experiments were conducted by digesting protein samples with commercially 
available proteases (Sigma-Aldrich, Taufkirchen, Germany). 25 μl protein sample in storage buffer with a 
concentration of 70 μM was supplemented with 4 mM CaCl2 and either 2.5 μg trypsin, chymotrypsin or 
thermolysin were added (0.1 g/l final protease concentration). Digests were incubated at 310 K and 
quenched at defined time-points by freezing 2 μl aliquots in liquid nitrogen. Digestion products were 
separated via SDS-PAGE and defined proteins bands were excised from the gel and analyzed by MALDI-
MS. 
 
 
2.3.10 Electrophoretic mobility shift assay 
Electrophoretic mobility shift assays (EMSAs) were used to test binding of DDX1 to different RNA 
species. Binding to a 10mer polyA, a 10mer polyU and a 13mer RNA of random sequence was tested by 
using 3’-Carboxyfluorescein (FAM) labeled variants of the RNAs. RNA species with the FAM label at the 
5’-end were also tested, but did not differ in binding when compared with the 3’-labeled variant, so that 
experiments were restricted to the following RNA species: 
10mer polyA RNA 5’-AAAAAAAAAA-3’-FAM 
10mer polyU RNA 5’-UUUUUUUUUU-3’-FAM 
13mer RNA of random sequence 
(according to Jankowsky and Fairman, 2008)[157] 
5’-AGCACCGUAAAGA-3’-FAM 
20mer RNA 5’-GCGAGACAGUGUGACUUUGG-3’-FAM 
all RNAs were purchased from biomers.net GmbH (Ulm)  
 
For the binding reactions, 0.5 μM RNA was incubated with 0.5 to 50 μM protein at 293 K in 20 μl EMSA 
reaction buffer (see section 2.1.2) for 20 min. Reactions were quenched by cooling them to 277 K and 
8 % (v/v) of glycerol were added. Reactions were separated by native PAGE on a 5 %/15 % step-gradient 
acrylamide-gel (see section 2.3.2). Shifted RNA was visualized by excitation of the the FAM label at 
302 nm on a UV-scanner. Subsequently, proteins were stained using InstantBlue. 
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2.3.11 Helicase assay 
A gel-based helicase assay was used to test for an unwinding activity of DDX1. For this assay double-
stranded substrate was prepared by annealing either short, fluorescently labeled DNA oligonucleotides 
with RNA or labeled RNA with RNA oligonucleotides. All substrate strands – unlabeled or fluorescently 
labeled with either fluorescein (Fl) or carboxyfluorescein (FAM) – were ordered as chemically 
synthesized oligonucleotides from biomers.net (Ulm, Germany).  
DNA – 41mer 
(according to Li et al., 2008)[111] 
5’-GAATACAAGCTTGCATGCCTGCAGGTCGACTCTAGAGGATC-3’-Fl 
RNA – 29mer 
(according to Li et al., 2008)[94] 
5’-GAUCCUCUAGAGUCGACCUGCAGGCAUGC-3’ 
 
DNA – 13mer 
(according to Jankowsky and Fairman, 
2008)[157] 
5’-AGC ACC GTA AAG A-3’-Fl 
 
RNA – 38mer 
(according to Jankowsky and Fairman, 
2008)[157] 
5’- UCUUUACGGUGCUUAAAACAAAACAAAACAAAACAAAA-3’ 
 
RNA – 13mer 
(according to Jankowsky and Fairman, 
2008)[157] 
5’-AGCACCGUAAAGA-3’-FAM 
all oligonucleotides  were purchased 
from biomers.net GmbH (Ulm) 
oligos were labeled either with Fluorescein (=Fl) or Carboxyfluorescein (=FAM) at their 
termini 
 
Annealing reactions were conducted in 25 μl annealing buffer (see section 2.1.2) with 100 μM unlabeled 
and 50 μm labeled oligonucleotide, to ensure that all labeled RNA is incorporated in a duplex. 
Annealing reactions were heated to 368 K for 2 min and then incubated at RT for 2 h. For the actual 
unwinding experiment 1.25 μM duplex substrate was incubated with 10 – 20 μM DDX1 and 10 mM 
MgCl2 (which was replaced by 10 mM EDTA in control reactions) in a total volume of 20 μl unwinding 
buffer (see section 2.1.2). Optional 10 mM of ATP, AppNHp, ATPγS or ADP (Jena Bioscience, Jena, 
Germany) were added. Reactions were incubated at 310 K for 30 min and then quenched by cooling to 
277 K and addition of 5 μl RNA loading dye. Unwound substrate strands were then separated by native 
PAGE on a 15 % (w/v) native gel prepared in 1xTBE buffer pH 8.3 (see section 2.3.2). Separated 
fluorescently labeled oligonucleotide strands were visualized by excitation of the Fl or FAM label at 
302 nm using a UV-scanner. Subsequently, proteins were stained using InstantBlue. 
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2.4 Biophysical Methods 
 
2.4.1 Circular dichroism spectroscopy 
Circular dichroism (CD) spectroscopy was used to estimate the secondary structure composition of 
protein constructs and their thermal stability. All measurements were performed with 5 μM protein 
sample in storage buffer (see section 2.1.2) in a Jasco J-810 CD spectropolarimeter (Jasco Corp., Groß-
Umstadt, Germany). Spectra of the protein samples were recorded from 180 nm to 260 nm in a quartz-
glass cuvette (0.1 cm path length, Hellma, Müllheim, Germany) in a total volume of 200 μl storage 
buffer. A buffer baseline was recorded for all measurements, to correct for absorption of HEPES in the 
storage buffer (see section 2.1.2). The signal output from the instrument in [mdegs] was converted into 
mean residue ellipticity (θMRE), by first calculating the mean residue weight (MRW): 
   1.  residuesofno
weightmolecularMRW  [Equation 2] 
and then calculating the θMRE according to  
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with d = path length of the cuvette in [mm] and C = protein concentration in [mg/ml] 
For thermal denaturation curves, the cuvette was heated from 293 K to 368 K with a heating rate of 
ΔT/Δt = 1 K/min and unfolding of protein secondary structure was followed by recording light-
polarisation at 222 nm. Melting curves were fitted to a two-state-unfolding equation according to 
Consalvi and colleagues[158, 159]:  
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where aN and aD are the baseline intercepts of the native (N) and denatured (D) state, bN and bD the 
corresponding slopes of the baselines, ΔH the enthalpy at the transition midpoint, T the current 
temperature, Tm the melting temperature and R the gas constant.  
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2.4.2 Static light scattering 
The oligomeric state of the protein was assessed via static light scattering (SLS). For static light 
scattering 50 μM of DDX1 protein in 40 μl storage buffer was injected on a Superdex 200 10/300 GL 
column (Pharmacia, Freiburg, Germany) using a Waters FPLC system (Waters Corp., Milford, USA). The 
Superdex 200 column was connected to a Wyatt Dawn Heleos II multi-angle-light-scattering (MALS) 
detector (Wyatt Technology, Dernbach, Germany), detecting scattered light from 18 angles. Refractive 
index and light scattering data were used to calculate the radius of gyration and the corresponding 
molecular weight with the help of the Astra Software (Wyatt Technology, Dernbach, Germany). 
 
2.4.3 Dynamic light scattering 
For dynamic light scattering (DLS) 25 μM of DDX1 protein in a total volume of 60 μL storage buffer were 
measured in a Viscotek 802 (Malvern Instruments, Mannheim, Germany), which records scattered light 
at 90° angle. Before each measurement the sample was centrifuged at maximal speed in a table-top-
centrifuge (Heraeus® Biofuge®, Thermo-Scientific, Waltham, MA, USA). 30 light fluctuation curves with 
four second measurement time each were recorded. All traces with constant intensity were averaged to 
fit a combined auto-correlation function. From the auto-correlation function the hydrodynamic radius 
was extracted and used to calculate the molecular weight assuming a globular protein shape. All DLS 
data analysis was performed using the OmniSIZE Software (Malvern Instruments, Mannheim, Germany).  
 
2.4.4 Steady-state ATPase assay 
Steady-state ATP hydrolysis was measured using a coupled photometric assay[160, 161]. The rate of 
hydrolysis of ATP by DDX1 is measured directly by a conversion cascade that uses the produced ADP. In 
this coupled assay ADP is converted to ATP by pyruvate-kinase (PK), thereby converting 
phosphoenolpyruvate (PEP) to pyruvate (PYR). Produced PYR is further utilized by lactate-
dehydrogenase (LDH) which converts it to lactate (LAC) and oxidizes NADH to NAD+. Thereby, the 
decrease of NADH absorbance at 340 nm can be used to directly quantify the molar amount of 
produced ADP. Reactions (100 μl) were measured at 298 K in a Jasco V-650 spectrophotometer (Jasco 
Corp., Groß-Umstadt, Germany).  
For the reactions 2 x ATPase buffer (see section 2.1.2) was supplemented with a mixture of 4 U/ml LDH / 
2.8 U/ml PK (Roche, Mannheim, Germany), 15 mM KCl and 1 mM ATP. Reaction was started by addition 
of 5 mM MgCl2 and was incubated until a stable baseline was reached, indicative of a complete 
conversion of traces of ADP contaminations into ATP. For the start of the reaction protein and substrate 
were added and rates of ADP generation (assumed to equal the ATP hydrolysis rate) were measured.  
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The initial reaction rates were determined as  
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with ν = intial reaction rate, εNADH = extinction coefficient of NADH at 340 nm (6220 M-1 cm-1), d = path 
length of cuvette, c = protein concentration, ΔAbs340 = decrease in absorbance at 340 nm, Δt = time 
interval. 
The rate for ΔAbs340/Δt was determined from a linear fit to the steady state decrease in absorbance 
using the Spectra-Viewer software (Jasco Corp., Groß-Umstadt, Germany). 
 
To determine the Michaelis-Menten parameters, 1 μM DDX1 was incubated with varying amounts of 
either ATP-MgCl2 or a 20mer RNA (5’-GCGAGACAGUGUGACUUUGG-3’) in ATPase buffer. The ATP-
concentration dependence of the ATPase rate and stimulation of hydrolysis by RNA titration were 
analyzed with the hyperbolic form of the Michaelis-Menten-equation.  
 
mKS
S
 max  [Equation 6] 
with S = substrate concentration, νmax = maximal apparent reaction velocity, Km = apparent Michaelis-
Menten constant. 
 
Measurements with the Walker A lysine-mutant of DDX1 (K52A) were performed at varying ATP-MgCl2 
and protein concentrations in the presence or absence of stimulating RNA. 
 
2.4.5 Fluorescence equilibrium titrations 
Binding affinities for nucleotides were determined by fluorescence equilibrium titration, using N-
methylanthraniloyl(mant)-labeled nucleotide analogues. Mant-ADP and mant-dADP were purchased 
from BIOLOG (Bremen, Germany). Fluorescence spectra of isolated and protein bound mant-nucleotides 
in titration buffer (see section 2.1.2) were recorded on a Jasco FP-8500 spectrofluorometer (Jasco Corp., 
Groß-Umstadt, Germany) thermostated to 298 K using a peltier-element. 50 nM up to 500 nM mant-
nucleotide in 150 μl titration buffer (depending on measurement) were titrated with DDX1 in a range of 
10 nM to 5 μM. For competition experiments with unlabeled nucleotides, the concentration of mant-
nucleotide (200 nM or 500 nM) and protein (1 μM) were kept constant, and 0.1 μM to 120 μM ADP-MgCl2 
or 5 μM to 5 mM ATP- MgCl2 were titrated. 
Fluorophores were excited at 356 nm and spectra were recorded from 370 nm to 520 nm with 5 nm slid-
width of excitation and emission light. The fluorescence of equilibrated solutions at 488 nm emission in 
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dependence of protein concentration was used to plot binding curves. Titration data of protein binding 
to mant-nucleotides were fitted to a quadratic binding equation[162, 163]:  
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where F0 is the baseline, Fmax the amplitude of signal change, B0 is the total concentration of mant-
nucleotide that was constant during the measurement (B0 = B+AB), X is the concentration of 
component A (=DDX1-protein) that is varied and Kd is the dissociation constant for the complex AB of 
mant-nucleotide and DDX1. 
 
Data, recorded during competition experiments, where mant-nucleotide-DDX1 complex was incubated 
with excess of unlabeled nucleotides were fitted to a cubic binding equation[164, 165] with [AC] as the 
concentration of the complex of protein with unlabeled nucleotide : 
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where [C0] is the total concentration of unlabeled nucleotide, [B0] the total concentration of mant-
nucleotide and [A0] the total concentration of protein. The general solution of a cubic equation (see 
Press et al. 1989[166]) gives three solutions, out of which only one is meaningful[164] and was selected 
manually. 
The Kd,AB for the protein mant-nucleotide complex was used as a constant as previously determined 
from the binding titrations. Data fitting was performed either with GraFit 5.0 (Erithacus Software, Horley, 
UK) or Prism 5.0 (GraphPad Software, San Diego, USA). All titrations involving ATP were performed in 
the presence of 2 mM PEP and 4U/ml PK (Roche, Mannheim, Germany) as an ATP regeneration system.  
The influence of RNA on binding parameters was tested by conducting the titrations in the presence of 
28 μM RNA. Note that the protein-stock used for titrations was incubated and saturated with excess 
amounts of RNA (2 mM) prior to measurements. Three different RNAs were tested for their influence on 
binding parameters, a 10mer polyA RNA, a 13mer RNA of random sequence and a 20mer RNA (see table 
in section 2.3.8 - EMSA). All RNAs were purchased from biomers.net GmbH (Ulm, Germany). 
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2.4.6 Stopped-flow measurements 
Transient kinetic measurements were used to check the reliability of the equilibrium titrations. Data 
were recorded on a BioLogic SFM-400 stopped-flow instrument (BioLogic Science instruments, 
Grenoble, France), thermostated to 298 K. Mant-fluorescence was excited at 356 nm and detected with 
a 420 nm cut-off filter (420FG03-25, LOT Oriel Group, Darmstadt, Germany). Traces were recorded in 
triplicates and averaged. For binding experiments 0.5 μM DDX1 in titration buffer was rapidly mixed 
with 2.5 to 7.5 μM mant-nucleotides in a measurement chamber, consisting of a FC-15 (1.5 x 1.5 mm) 
quartz cuvette (BioLogic, Claix, France) and traces were fitted to the sum of two exponential functions. 
The first rate constant that made for the majority of the amplitude did scale linearly with nucleotide 
concentration. The on-rates for nucleotide binding were obtained from the slope of a plot of those first 
rate constants. Off-rates for nucleotide binding were obtained by chase experiments. Therefore, 0.5 μM 
mant-nucleotide were pre-incubated with 0.5 μM DDX1 in titration buffer (see section 2.1.2) and then 
displaced by rapid mixing with either 250 or 500 μM ADP. Traces were fitted to a single exponential 
function that did contain the rate constant for the mant-nucleotide off-rate. The dissociation constant Kd 
was calculated from the ratio of off- to on-rate. Experiments were performed with both mant-ADP and 
mant-dADP.  
Recorded stopped-flow traces were initially analysed analytically assuming pseudo-first order 
conditions. For the titration of the proteins with fluorescent nucleotides, the nucleotide was assumed to 
be in large excess and therefore its concentration unaltered during the binding reaction. 
  
][]['][][][ 1111 PmantkPkPmantkPmantkdt
dPmant        [Equation 10] 
This differential equation can be solved by an exponential function: 
 tkkeAmpPmant   )'( 11][       [Equation 11] 
In order to obtain positive amplitudes data traces were fitted to the sum of exponential functions in the 
form  
 offseteAmpsignal tk   )1(       [Equation 12] 
Fitting of the data traces to exponential functions was done with GraphPad Prism 5.01 (GraphPad 
Software, San Diego, USA).  
 
 
2.4.7 RNA affinity accessed by equilibrium titrations 
RNA affinities of DDX1 were determined by exploitation of the cooperativity in ATP and RNA binding 
and using mant-nucleotide equilibrium titrations as described before (see section 2.4.5). Mant-dADP 
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(0.2 μM) was incubated with DDX1 (1 μM) in titration buffer for complex-formation and subsequently 
this complex was partially displaced upon addition of either 50, 100, 200 or 400 μM ATP-MgCl2 in 
individual experiments. In the actual experiment, RNA was titrated to the complex and binding was 
followed by fluorescence decrease, induced by RNA dependent ATP binding. Again an ATP 
regeneration system was included in all measurements. The RNA-dependent mant-displacement curves 
at different ATP concentrations were fitted globally by numeric iteration using DynaFit (Petr Kuzmic), 
using a minimal binding scheme as reaction mechanism for modeling (see appendix 7.6 for DynaFit 
script file). All previously determined equilibrium titration data were included in the fit.  
 
 
2.5 Crystallographic methods 
2.5.1 Protein crystallization 
Crystallization experiments were performed as sitting-drop vapour diffusion setup using commercially 
available crystallization-screens (Qiagen, Hilden, Germany) at 293 K. Experiments were set-up in 96-well 
XTL low profile plates (Greiner Bio-One, Frickenhausen, Germany) by mixing 100 nl protein sample at 20 
mg/ml with 100 nl reservoir solution using a mosquito robotic system (TTP Labtech, Hertfordshire, UK). 
X-ray diffracting crystals were obtained with the constructs of the SPRY domain (see table 2.2).  
 
Table 2.2 SPRY domain crystal-forming constructs 
Details on the crystallization conditions are given; a “+”-symbol in the last column, means linbro-optimization was performed 
 
construct final concentration in 
crystallization experiment 
condition time of crystal 
growth 
Linbro-optimization 
SPRY_72-283 21 mg/ml 40 % (v/v) PEG 600, 0.1 M tri-
Sodium-citrate pH 5.5 
3 days + 
SPRY_72-
283ΔTag 
25 mg/ml 35% (v/v) PEG 600, 0.1 M tri-
Sodium-citrate pH 5.5 
6 days + 
SPRY_84-261 19 mg/ml 30% (w/v) PEG 3000, 0.1 M 
CHES pH 9.5 
2 days - 
SPRY_84-261 
(SeMet) 
24 mg/ml 30% (w/v) PEG 3000, 0.1 M 
CHES pH 9.5 
2 days + 
 
Initial crystal-formation with the SPRY_72-283 protein was observed after three days in a reservoir 
solution consisting of 40 % (v/v) polyethylene glycol (PEG) 600, 0.1 M tri-Sodium-citrate pH 5.5. This 
condition was refined by hanging-drop vapour diffusion using 24-well Linbro plates (Greiner Bio-One, 
Frickenhausen, Germany), mixing 1 μl protein solution with 1 μl of reservoir solution. Small crystals, 
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which were obtained after three days, were crushed and used to streak-seed into fresh protein/reservoir 
drops.  
Crystals of protein SPRY_84-216 were obtained in various conditions using the JCSG Core Suite (Qiagen, 
Hilden, Germany). Largest and best diffracting crystals grew in 30% (w/v) PEG 3000, 0.1 M CHES pH 9.5. 
Crystals of protein SPRY_84-216 with Selenomethionine incorporated were obtained under the same 
conditions. 
Protein SPRY_72-283 lacking the N-terminal hexahistidine Tag (SPRY_72-283ΔTag) showed crystal 
formation in a 96-well screen with a reservoir solution containing 35% (v/v) PEG 600, 0.1 M tri-Sodium-
citrate pH 5.5. The 6xHis-Tag had been cleaved-off proteolytically by thrombin, removing the sequence 
MGSSHHHHHHSSGLVPR from the N-terminus. Spheroid crystals appeared after three days and grew as 
single crystals with typical dimensions of 140 x 90 x 40 μm within six days. For the ease of crystal 
handling, the experiment was reproduced in a hanging-drop vapour diffusion set-up using 24-well 
Linbro plates (Greiner Bio-One, Frickenhausen, Germany). In each well 1 μl of protein solution was 
overlaid with 1 μl of reservoir solution on a coverslide and incubated hanging, equilibrated against a 
total volume of 700 μl reservoir/precipitant solution. The same buffer composition as in the original hit 
condition in the 96-well plate was used and Linbro plates were incubated at 297 K for three days.  
 
2.5.2 Crystal harvesting and cryoprotection 
For data collection, single crystals were harvested into a cryoloop. To harvest the SPRY crystals from 
Linbro plates 0.2 mm loops, equipped with a 20 μm nylon thread were used. For cryoprotection of 
crystals from protein constructs SPRY_72-283 and SPRY_72-283ΔTag the mother solution was used 
directly, whereas for the SPRY_84-216 protein 20 % (v/v) glycerol were added to the mother solution. 
Crystals were transferred with the cryoloop two times into 3 μl of cryoprotectant solution and incubated 
briefly during each step. Subsequently they were flash-cooled in liquid nitrogen.  
 
2.5.3 Data collection and processing 
Diffraction data were collected at synchrotron beamline X10SA (PXII) at the Swiss Light Source (SLS) of 
the Paul-Scherrer-Institute in Villigen, Switzerland. Collection was done in a joint venture between 
Scientist from Heidelberg and Dortmund, which formed a “data-collection” team. Data were collected at 
100 K in a rotation setup on a Pilatus 6M detector (Dectris, Baden, Switzerland). 
Prior to synchrotron measurements, crystals were tested for their diffraction quality in-house. A Rigaku 
MicroMax 007 HF (Rigaku, Kemsing, UK) microfocus rotating anode (40 kV/30 mA), equipped with 
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VariMax HF focussing mirrors (Confocal Max-Flux® CMF optics, Rigaku, Kemsing, UK) and a Mar345 
imaging plate (MarResearch, Norderstedt, Germany) were used. Cooling to 100 K was provided by a 
nitrogen cryostream (Oxford Cryosystems, Long Hanborough, UK).   
All data sets were processed with the XDS software package[167, Kabsch, 2010 #244]. Diffraction data were 
indexed and integrated with XDS and then scaled and merged using XSCALE[167]. Finally, XDSCONVERT 
was used to convert files into the appropriate format compatible with the programs of the CCP4 
suite[168], for phasing, model building and refinement. To test for model bias, 5 % of the reflections were 
randomly picked and omitted during refinement and used for calculation of an Rfree value.  
Rmeas, calculated by XDS was used as an indicator of data consistency. Rmeas corresponds to Rmerge, 
corrected by the redundancy, according to [169]  
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with n as the redundancy/multiplicity, <Ihkl> as the mean intensity of symmetry-equivalent reflections 
and i as a numerator (i.e. giving the sum over all symmetry-equivalent reflections). 
Resolution bins, where the Rmeas [equation 13] were better than 50 % and the <I/δ(I)> was better than 7 
were considered to be reliable. 
 
2.5.4 Phasing by molecular replacement 
Molecular replacement (MR) was used of to obtain initial phases for the SPRY crystals of the protein 
construct SPRY_72-283ΔTag. MR was performed using PHASER[170]. The SPRY domain of Ash2L (PDB 
entry 3TOJ[107]), deposited in the protein data bank (PDB), with a sequence identity of 23.8 % was used as 
a search model, but alternative conformations and water molecules were removed. The search was 
carried out using a resolution cut-off at 2.5 Å.  With the determined unit cell of the crystal symmetry as 
obtained by XDS[171], the Matthews coefficient[172] of the crystal was calculated, according to 
 
ZXweightmolecular
cellunitofvolume

 [Equation 14] 
where Z is the number of AUs in the unit cell and X is the number of molecules in the AU. 
The number of molecules per AU was estimated from the Matthews coefficient, by comparison of X 
values with empirical observed ones[173] and used to constrain the MR search. Based on the Z-score of 
the rotation- and translation functions, possible solutions were evaluated. 
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2.5.5 Structure determination and refinement 
Initial phases  from MR were refined using the CCP4 interface[168, 174], by a rigid-body refinement using 
REFMAC[175]. A model of the SPRY domain was built manually using Coot [46]. This model was improved by 
iterative cycles of refinement with REFMAC using TLS[176] and manual improvement in Coot, leading to 
the final model. Manual model building in Coot was guided by secondary structure prediction[177] and 
residues that belong to secondary structure elements were placed first, due to easier allocation. 
Residues that were initially hard to place were first build as alanine residues. 
To guide refinement, the R-factor (Rwork)[178] as calculated by REFMAC, was used as an indicator for the 
model quality.  
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Model building was aimed towards minimizing the Rwork to obtain a good agreement between the 
model and the measured data. Waters were picked manually by selecting peaks above 3 σ in the Fo-Fc 
difference map in correct hydrogen bonding distance. To differentiate between Na+ and water the 
coordination sphere was considered (water – tetrahedral, Na+ – octahedral). The Rfree value, calculated 
during refinement from the excluded reflections, was reported[179]. The Rfree value was calculated as 
described in equation 15. To antagonize model bias, the gap between Rwork and Rfree was minimized. The 
Model was considered to be sufficiently build at the point, when convergence between Rwork and Rfree i.e. 
a stable R-factor was reached. 
The stereochemistry of the model for intermediate and final structures was evaluated using the 
subroutines implemented in Coot (rotamers, Ramachandran-plot…)[46]. Furthermore, MOLPROBITY[180] 
and PROCHECK[181] were used to assess the model quality. All structural representations were generated 
using PyMOL[182] with subsequent raytracing. Electrostatic surface potentials were calculated with the 
PyMOL plug-in APBS[183]. 
 
 
2.5.6 Homology modelling 
The structural model of the entire human DDX1 helicase was assembled based on homology modeling 
of the helicase core using SWISS-MODEL[184]. The structure of a DEAD box RNA helicase from the 
hyperthermophile Methanococcus jannaschii (PDB entry 1HV8)[33] that shares 21.6 % sequence similarity 
to DDX1 was used as a template to model RecA-like domains 1 and 2. Both protein sequences were 
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aligned and the alignment in FASTA-formatting was used as input parameter. The algorithm of SWISS-
MODEL[184] initially mutates each residue in the template structure to the corresponding residue in the 
target protein to be modeled. Subsequently the geometry is optimized by energy minimization. In this 
way a homology model of the DDX1 helicase core without the SPRY domain was obtained. 
This homology model was superposed on a structure of human DDX3X (PDB entry 2I4I)[185]. The SPRY 
domain was placed in the homology model according to the position of residues 250-260 of DDX3X 
with the help of Coot[46]. Finally the model[152, 160] was illustrated with PyMOL[182]. 
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3. Results 
 
3.1 Generation of a stable, recombinant protein constructs 
 
This chapter describes the purification of recombinant protein material of Homo sapiens DDX1, suitable 
for structural, biophysical and biochemical studies. The sequence, coding for full-length protein was 
cloned from cDNA and this protein could be expressed in E. coli cells, but upon cell lysis several protein 
fragments were detected. Extensive construct optimization guided by biochemical and bioinformatic 
analysis led to the design of C-terminal truncated DDX1 variants that were stable and could be purified 
to high homogeneity. In addition, individual domains of DDX1 were cloned and purified. Constructs of 
the SPRY domain were prepared for structural studies. Several different SPRY constructs were generated 
to facilitate crystallization experiments later on. Moreover, further components of the HSPC117 complex 
(besides DDX1) were cloned and purified.  
 
3.1.1 Characterization of DDX1 by bioinformatic tools 
Initially, the DDX1 protein was analyzed in silico by bioinformatic tools to guide experimental design. 
Human DDX1[120] has a three domain architecture (introduction Figure 1.10) consisting of 740 amino 
acids with a molecular weight of 82.4 kDa according to the verified UniProt reference sequence (ID 
Q92499). A BLAST search revealed general conservation of DDX1 amongst mammalian orthologs[186]. No 
homolog of DDX1 was found in Saccharomyces cerevisiae and the closest relative in yeast, the helicase 
Dbp2p, shows only 18.7 % sequence identity (suppl. Figure 7.1.2, SIAS server, Pedro Reche[187]). The 
amino acid sequences of DDX1 orthologs of representative eukaryotic model organisms were analyzed 
in a multiple sequence alignment by Clustal Omega and a high conservation was found(Figure 
3.1.1)[188]. The sequence identity between H. sapiens and Caenorhabditis elegans, the most distal 
homolog identified among these organisms, is 46.7 %. All helicase signature motifs are highly 
conserved between the model organisms (Figure 3.1.1), but in C. elegans the characteristic DEAD 
sequence of motif II[10] was found to be DEID. However, this third residue of motif II has been reported 
not to be strictly required for ATP hydrolysis in other DEAD-box proteins[15, 16]. Nevertheless, for the 
human export factor UAP56 it was shown, that a polymorphism of this residue can influence the 
stabilization of motif III (SAT)[26]. In the DDX1 polypeptide chain, the first conserved helicase motif Q is 
preceded only by few amino acids at the N-terminus. In contrast, at the C-terminus a long stretch of ~ 
130 amino acids follows the last conserved helicase motif VI[92]. This suggests that DDX1 contains a C-
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terminal extension to the helicase core, which is further supported by comparison with other DEAD-box 
proteins[189], which revealed that the canonical helicase core ends at ~ residue 670. 
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Figure 3.1.1 Sequence alignment of DDX1 orthologs from eukaryotic model organisms. DDX1 from H. sapiens is aligned with 
DDX1 orthologs from eukaryotic model organisms (no direct DDX1 homolog was found in yeast; X. laevis=Xenopus laevis) and the 
degree of sequence conservation is indicated by color coding. Secondary structure as predicted for human DDX1 with PSIPRED[177] 
is indicated above the sequence and colored according to domain allocation. For the SPRY domain information on the location of 
β-strands is inferred from the crystal structure. RecA-like domain 1 is colored in green, the SPRY domain is colored in blue and 
RecA-like domain 2 is colored in red. Conserved helicase sequence motifs (as explained in figure 1.3) are marked by blue 
bordering. Domain boundaries of C-terminally truncated constructs used in DDX1 expression trials are indicated by dashed lines 
with residue numbering.  
 
The results of a secondary structure prediction of human DDX1 with PSIPRED[177] revealed that residues 
that are predicted to form helices and strands agree well with the fold of homologous DEAD-box 
proteins (also see suppl. Figure 7.1.1). The sequences of the predicted secondary structure elements, 
especially β-strands and α-helices, are mostly conserved across species, and only some loop regions 
show sequence variation. Additional sequence variation is found at the N- and C-terminus of the SPRY 
domain (see section on SPRY structure for details). Small differences in polypeptide chain length are 
detected in the C. elegans protein when compared to the human ortholog. Regions in the SPRY domain, 
in the loop proceeding motif II and in the linker between both RecA-like domains are longer in C. 
elegans DDX1 (Figure 3.1.1). Conversely the loop between motif IV and motif IVa is considerably shorter 
in C. elegans and Drosophila melanogaster DDX1 orthologs. Moreover, in D. melanogaster DDX1 the C-
terminal tail that shows low sequence conservation is shorter by eight residues when compared to the 
human protein. 
 
3.1.2 Expression and purification of recombinant DDX1 
The coding sequence for human DDX1 was cloned from cDNA into a pET28a bacterial expression vector 
that encodes for an N-terminal 6xHis-Tag (see materials and methods, section 2.2.9). Upon 
expression in E. coli, the protein was found in the soluble fraction of the cell lysate. It was purified via 
Ni2+-NTA affinity chromatography followed by another affinity chromatography step on a heparin 
column. Four prominent protein bands were observed on a SDS-gel of the heparin elution fractions 
(Figure 3.1.2). Bands were excised from the gel and their identity was determined via MALDI-MS PMF. 
The proteins, migrating in a band at around ~ 80 kDa did correspond to full-length DDX1 (calculated 
mass 82.4 kDa), the other bands, however, proofed to be DDX1 fragments (Figure 3.1.2). The presence 
of protein fragments could have different causes, for instance it could result from translation abortion or 
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full-length protein might be proteolytically unstable and rapidly (partially) degraded by endogenous 
proteases of E.coli. 
 
 
 
Figure 3.1.2 DDX1 WT is soluble upon bacterial expression, but shows degradation. Full-length DDX1 (amino acids 1-740) 
from H. sapiens was purified by Ni2+- and heparin-affinity chromatography. Elution fractions from a heparin column run were 
separated on a 15% (w/v) SDS-gel and stained with Coomassie InstantBlue®. A band corresponding to full-length DDX1 is seen at 
~80 kDa, but three additional bands are seen below, which may be indicative for abortive translation or degradation of the 
protein. Indeed, species running below the DDX1 full-length band did correspond to DDX1 fragments. Identity of all bands was 
checked via MALDI-MS.  
 
Different strategies were used to prevent potential protein degradation. Protease inhibitor was added 
to the lysis buffer and the 6xHis-Tag was moved from the N- to the C-terminus. The protein was 
expressed in the periplasm using pET22b shuttling vector[135] and it was also expressed in different 
protease deficient E. coli strains[190] (see section 2.1.6). However, these attempts were not successful and 
the protein material was unsuitable for further in vitro studies of DDX1.   
 
Analysis of the MALDI-MS PMF results showed that the observed protein fragments were prevalently 
truncated at the C-terminus. These fragments remained stable throughout the purification, which 
indicates that C-terminally truncated variants of human DDX1 may be less prone to proteolytic 
degradation when compared to the full-length protein. Based on this finding and guided by secondary 
structure prediction several C-terminally truncated protein constructs were designed (small excerpt in 
Table 3.1).  
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Table 3.1 Truncated DDX1 constructs 
Different C-terminally truncated DDX1 constructs are shown and their respective solubility, stability and ATPase activity 
(measured in a coupled assay) is indicated by “+” or “-“ (yes or no). The hydrodynamic radius and the molecular weight as 
determined via DLS are shown on the right. 
 
construct length solubility stability ATPase activity 
hydrodynamic radius and mol. 
weight (according to DLS) 
DDX1 full-length 1-740 + - n.a. n.a. 
DDX1-728 1-728 + + + 
3.96 nm/85.8 kDa 
(see section 3.3.1) 
DDX1-694 1-694 + + + 4.32 nm/105.2 kDa 
DDX1-674 1-674 + + + 4.48 nm/114.5 kDa 
DDX1-655 1-655 + + - 4.14 nm/95.2 kDa 
DDX1-648 1-648 + + - 3.93 nm/84.2 kDa 
DDX1-610 1-610 + + - 3.95 nm/85.1 kDa 
 
Only a small number of N-terminal truncated species were identified in the MALDI-MS PMF analysis of 
the DDX1 fragments. They mostly lacked the entire N-terminal region of the polypeptide chain up until 
the SPRY domain. N-terminal truncated species were considered to be non-functional, since they lack 
the catalytically important Q- and Walker A motifs. 
 
All C-terminally truncated protein constructs that were soluble and stable, could be purified by an 
identical protocol and showed similar oligomerization properties (Table 3.1). However, the three most 
severly truncated constructs were found to be ATP hydrolysis deficient (only assessed qualitatively, see 
section 2.4.4). The longest, but still stable C-terminally truncated construct ended at residue 728, which 
is located at the C-terminus of the last predicted helix (Figure 3.1.1). Protein DDX1-728 that only lacks 
12 residues when compared to full-length DDX1 could be purified to high homogeneity (Figure 3.1.3). 
 
 
 
    Results 
60 
 
 
Figure 3.1.3 Purification of construct DDX1-728 by size exclusion chromatography. A construct of human DDX1 that was C-
terminally truncated by only 12 amino acids could be expressed as a stable fragment in E. coli and purified to high homogeneity.  
A, Chromatogram from a gel-filtration/size-exclusion run on a Superose S6 column© (see material and methods) is shown. The 
absorbance at 280 nm is indicated by a blue line, absorbance at 260 nm with a red line, respectively. Fractions 1-7 were pooled 
and analysed are indicated below. B, 15 % (w/v) SDS-PAGE with the indicated elution fractions showed a single protein band after 
staining with Coomassie InstantBlue®.  
 
The majority of recombinant DDX1-728 protein eluted from the Superose S6 column© at a volume, 
corresponding to monomeric species (Figure 3.1.3). Only a low amount of protein eluted prior to the 
main peak and these supposably aggregated fractions were discarded. Since DDX1-728 protein was 
used for all biochemical and biophysical studies on on human DDX1, “DDX1” always refers to construct 
DDX1-728 in the rest of the manuscript, unless explicitly stated. 
 
 
3.1.3 Expression of the SPRY domain of DDX1 
To identify stable domains within DDX1, limited proteolysis experiments were performed. The results of 
these experiments should guide the design of constructs that were used for crystallization experiments. 
Recombinant DDX1 protein (construct DDX-694) was digested with trypsin, chymotrypsin, thermolysin 
and proteinase K (see material and methods, section 2.3.8). Reactions were quenched at defined time 
points, reaction products were separated by 15 % (w/v) SDS-PAGE (Figure 3.1.4 a and suppl. Figures 
7.3.7 and 7.3.8) and protein bands were excised from the gel and their identity was determined by 
MALDI-MS PMF. 
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Figure 3.1.4 Limited proteolysis of DDX1 to identify stable domains.  A, Construct DDX1-694 was digested with trypsin 
protease for the indicated time points (in min) or at 277 K over night (= o/n). Degradation bands were excised from the gel and 
identified via MALDI-MS PMF. Domain boundaries as derived from the detected peptides are indicated on the right side with ΔN 
and ΔC denoting N- and C-terminal truncations, respectively. Interestingly, most fragments were truncated directly at the 
boundaries of the SPRY domain. Fragment DDX1ΔN79 lacks all amino acids N-terminal to the SPRY domain. Fragments 
DDX1ΔN289 and DDX1ΔN318 lack the N-terminus and the SPRY domain. Fragment DDX1ΔN422 lacks RecA-like domain 1. 
Fragment DDX1ΔC296 lacks all amino acids downstream of the SPRY domain. Note that the protein construct used for the 
experiment, DDX1-694, is already C-terminally truncated. B, Domain boundaries as identified by MALDI-MS PMF are indicated on a 
representation of DDX1-694. Note that domain boundaries only correspond to the peptides that were detected and do not 
necessarily represent the actual protein fragments.  
 
Interestingly, most proteolysis fragments did correspond to truncations directly at the boundaries of the 
SPRY domain (Figure 3.1.4 b). Fragment DDX1ΔN79 was cleaved directly at the beginning of the SPRY 
domain, whereas fragments DDX1ΔN289, DDX1ΔN318 and DDX1ΔC296 were cleaved at the end of the SPRY 
domain. These results showed that the SPRY domain per se is a stable fragment. Furthermore, when the 
products of a 24 h digest of DDX1-728 with trypsin were loaded on a Ni2+-NTA affinity column, 
fragments corresponding to the SPRY domain were found in the flow-through, whereas RecA-like 
domains 1 and 2 were retained (suppl. Figure 7.3.8). This shows that the SPRY domain does neither 
interact with the Ni2+-NTA matrix nor with the RecA-like domain fragments (that bind to the column 
even without a 6xHis-Tag), at least not under the given conditions. 
Since the SPRY domain was proven to be highly protease resistant, constructs for its expression were 
designed. Domain boundaries were inferred from the MALDI-MS PMF results and refined based on 
sequence alignment of the entire sequence of human DDX1 with other helicases (also see Figure 
3.2.12). Initially, the entire region that corresponds to the DDX1 specific insertion (amino acids 72 to 
283) was cloned and used for expression (suppl. Figure 7.1.3). Secondary structure prediction by 
PSIPRED[177] for the SPRY domain suggested that N- and C-terminal residues do not adopt a defined 
structure. At closer inspection of the sequence alignment (Figure 3.1.1) these N- and C-terminal regions 
may constitute linker regions that connect the SPRY domain with the helicase core. This fits well with 
the previous results from limited proteolysis on DDX1-694 (Figure 3.1.4) that showed several cleavage 
sites in the putative linker regions, indicative of flexibility. Separate limited proteolysis experiments on 
the SPRY domain protein were performed (suppl. Figure 7.1.4) and based on the results, additional 
SPRY domain constructs with N- and C-terminal truncations were designed. All truncated SPRY domain 
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constructs are summarized in Table 2.1 (section 2.2.14, materials and methods). Constructs were tested 
for expression and protein solubility. Constructs that were stable and homogeneous in solution were 
used in crystallization screening (see section 3.2.1). 
 
 
 
3.1.4 Expression of components of the HSPC117 complex and pull-down experiments 
with DDX1 
 
CGI-99 and Fam98b 
The HSPC117 tRNA ligation complex is a five component system[114, 118] (see Introduction, Figure 1.10). 
The two complex components CGI-99 and Fam98b[108] were cloned with an N-terminal 6xHis-tag and 
expressed in E. coli (see material and methods, Section 2.3.5). Cell lysates of both constructs were 
pooled together with DDX1-728 expressing E. coli lysate and purified via Ni2+-NTA affinity 
chromatography.  
 
 
 
Figure 3.1.5 HisTrap run with HPSPC117 complex components. Proteins CGI-99, DDX1-728 and Fam98b were expressed in 
E.coli with an N-terminal 6xHis-tag. Bacteria cells before induction (b.i.) and after induction (a.i.) of the respective construct are 
shown.  Bacteria lysates were pooled together and loaded on a HisTrap (Ni2+-NTA affinity) column. Elution fractions of an 
Imidazole gradient are shown. 
 
A significant overexpression of CGI-99 and Fam98b was observed on SDS-PAGE (Figure 3.1.5). 
However, only CGI-99 could be found in the eluate fractions. The majority of CGI-99 did elute later than 
DDX1, thus the proteins do most likely not form a stable complex under the purification conditions. CGI-
99 could be further purified to high homogeneity using anion-exchange and gel-filtration 
chromatography. Upon concentrating above ~2 mg/ml (= 75 μM) it precipitated and thus, was 
unsuitable for crystallization experiments.  
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ASW 
The fourth HSPC117 complex component, the protein ASW[119] was cloned and expressed in E. coli with 
an N-terminal 6xHis-tag (see material and methods). The protein was found in the soluble fraction and 
could be purified to good homogeneity. Upon concentrating above ~5 mg/ml (= 195 μM), it did start to 
precipitate. In a gel-filtration chromatography run, most protein was found in the void-volume of the 
column, indicative of aggregation. To investigate the interaction of ASW with DDX1, the 6xHis-tag was 
cleaved off by thrombin digestion, undigested protein was removed via re-chromatography, and ASW 
protein was loaded on a His-trap column, onto which DDX1-728 was immobilized (Figure 3.1.6).  
 
 
 
Figure 3.1.6 HisTrap run with DDX1-728 and ASW. A HisTrap (Ni2+-NTA affinity) column was pre-loaded with DDX1-728. ASW 
protein (not containing a His-tag) was loaded on the column with immobilized DDX1 and proteins were eluted by an Imidazole 
gradient. 
 
The majority of ASW protein was found in the flow-through. Only small amounts of ASW did co-elute 
with DDX1-728 in the first few fractions (Figure 3.1.6), which can probably be attributed to unspecific 
binding to the column matrix. Thus, under the conditions of the experiment, ASW and DDX1 do not 
form a stable complex.  
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3.1.5 Summary of the recombinant protein expression 
The results of this section demonstrated that it is possible to recombinantly express human DDX1 in 
E. coli cells. However, determining the identity of protein fragments obtained from full-length DDX1 by 
MALDI-MS PMF revealed several C-terminally truncated species. Based on these observations, protein 
constructs with similar C-terminal truncations were designed. Dependent on the extent of the 
truncation, some protein constructs were ATPase deficient, but did otherwise not differ in their 
biophysical properties and could be purified by an identical protocol. Interestingly, despite the 
presence of harshly truncated proteins in the full-length DDX1 preparation, truncation by 12 residues at 
the C-terminus was sufficient to yield the stable protein construct DDX1-728. 
Limited proteolysis experiments were performed to detect domain boundaries within DDX1 and the 
SPRY domain was identified as a protease resistant fragment. Since secondary structure prediction and 
the determined cleavage sites indicated unstructured termini, different truncated variants of this SPRY 
domain construct were designed. 
The protein constructs, described in this section form the basis for experimental characterization of 
DDX1, described in paragraphs 3.2 and 3.3. 
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3.2 Structural studies 
 
This chapter describes the structural studies on DDX1 that were performed using X-ray crystallography. 
Proteins of the SPRY domain of DDX1 were used in crystallization experiments, which resulted in 
crystals under a few conditions. Several rounds of optimization were required that finally led to the 
formation of well diffracting crystals. A number of different crystal forms were obtained when proteins 
of different SPRY domain constructs were screened. Proteins of a construct that was lacking the 6xHis-
tag yielded crystals that diffracted up to 2 Å resolution. Diffraction data were phased by MR and a three 
dimensional structure of the SPRY domain was determined at near atomic resolution. In the structure 
the SPRY domain adopts the β-sandwich fold of a modular insertion domain, typical for SPRY domains. 
Most importantly, the structural details were used to investigate a putative function of the SPRY domain 
as a protein-protein or RNA-interaction platform. The potential residues on the protein surface, that 
could be involved in such a function were identified. Crystallization experiments were also performed 
using the entire DDX1 helicase, but the protein was recalcitrant to crystallize, even in the presence of 
ATP-analogs and RNA. Finally, based on the conserved helicase core structure and the SPRY domain 
structure, a homology model of DDX1 was constructed. 
 
Structure of the SPRY domain 
 
3.2.1 Screening for well-diffracting SPRY crystals 
The SPRY domain is the exclusive structural feature that distinguishes DDX1 from the canonical helicase 
structure[92], which has been determined for other DEAD-box proteins[30, 34, 62]. To gain insight in this 
unique domain insertion, recombinant protein material of the separated domain was produced for 
structural studies. Several soluble SPRY protein constructs that differ in the length of the N- and C-
termini were obtained (Table 3.2). Proteins were tested for their suitability for crystallization 
experiments by characterizing their thermal stability in CD-unfolding and sample homogeneity via DLS 
measurements (Figure 3.2.1).  
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Figure 3.2.1 Stability and homogeneity of SPRY crystallization construct. The biophysical characterization of SPRY domain 
constructs is shown exemplarily for construct ‘SPRY_72-283’ that was used to solve the molecular structure. A, CD melting curve of 
SPRY_72-283 monitored at 222 nm and fitted to a two-state-unfolding process yields a Tm of 326.9 +/- 0.26 K. This melting 
temparature indicates a stable protein sample. CD values are in mean residue ellipticity = MRE. B, Data from DLS measurement 
with SPRY_72-283. The combined autocorrelation function (grey circles) is shown on the lower x-axis and a fit to this data is 
depicted as a black line. The upper x-axis shows the distribution of the hydrodynamic radii by relative mass (amplitude of each bar 
indicates the percentage of the total mass of the sample) as obtained from the fit. The fit did yield a peak in the mass-distribution 
of hydrodynamic radii at 2.89 nm (corresponding to a molecular weight of 40.8 kDa) and a peak width of 18.0 % RSD, which 
indicates a high degree of sample homogeneity. 
 
These SPRY domain proteins were subjected to sparse-matrix screening experiments in 96-well sitting 
drop-format (JCSG core suite, Qiagen) and a few conditions were found in which growth of small 
protein crystals was observed. Larger crystals were obtained by fine screening with increasing protein- 
and reservoir volumes (in a 24-well format) and by streak-seeding into freshly prepared hanging-drop 
setups. 
 
Table 3.2 Different SPRY protein constructs used to determine the structure of the SPRY domain 
The solubility of the proteins and their tendency to form crystals is indicated by “+” or “-“ (yes or no). For measured protein 
crystals, space group, unit cell parameters and lower diffraction limit are given. “n.a.” means not applicable, “ΔTag” means the 
6xHis-Tag was removed by thrombin digestion. 
 
construct solubility crystals space group unit cell parameters best-diffraction 
(in Å) 
SPRY_72-283 + + P212121 a = 43.73, b = 75.64, c = 122.73, 
α = β = γ = 90° 
4.0 
SPRY_72-283ΔTag + + P212121 a = 45.06, b = 76.14, c = 122.66, 
α = β = γ = 90° 
2.0 
SPRY_84-283 + - n.a. n.a. n.a. 
SPRY_100-283 - n.a. n.a. n.a. n.a. 
SPRY_72-261 + - n.a. n.a. n.a. 
SPRY_84-261 + + P1 a = 35.47, b = 99.28, c = 136.36, 
α = 102.56°, β = 97.62° γ = 98.33° 
2.7 
SPRY_84-261 
(SeMet) 
+ + P21 a = 37.14, b = 133.80, c = 35.96, 
α = γ = 90°, β = 118.26° 
3.4 
SPRY_100-261 - n.a. n.a. n.a. n.a. 
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Largest crystals grew from construct SPRY_84-261 in 30 % (w/v) PEG 3000, 0.1 M CHES-NaOH pH 9.5 
(Figure 3.2.2 a) and diffraction data were collected at the beamline X10SA (PXII) at the SLS in Villigen, 
Switzerland (see section 2.5.3). Crystals diffracted to 2.7 Å resolution and the symmetry belonged to the 
space-group P1. The Matthews coefficient[172] of 2.34 Å3/Da suggested ten molecules per asymmetric 
unit. Due to the high number of expected molecules per asymmetric unit, it was impossible to obtain 
phases by molecular replacement. In order to get experimental phases, selenomethionine-labeled 
protein was expressed in E. coli. ESI-MS measurements confirmed that all seven methionines were 
substituted by selenomethionine (Se-Met). The Se-Met labeled SPRY_84-261 protein showed rapid 
formation of crystals under the same conditions as for the native SPRY_84-261 protein construct (Figure 
3.2.2 b). Crystals diffracted to a resolution of 3.4 Å, however, the symmetry belonged to space-group 
P21. Due to low anomalous signal, phasing of diffraction data of the single anomalous dispersion 
experiment was not successful.  
 
 
 
Figure 3.2.2 Different crystal forms obtained with SPRY constructs. Protein constructs of the SPRY domain crystallized in four 
different crystal forms, each form diffracting to a different resolution. A, crystals of construct SPRY_84-261 that grew in 30 % (w/v) 
PEG 3000, 0.1 M CHES pH 9.5. B, crystals of Se-Met version of SPRY_84-261 that grew in almost the same condition as the native 
protein, 30 % (w/v) PEG 3000, 0.1 M CHES pH 9.8. C, crystals of construct SPRY_72-283 that grew in 40 % (v/v) PEG 600, 0.1 M tri-Na-
citrate pH 5.5. D, crystals of SPRY_72-283ΔTag (thrombin treated) that grew in 35 % (v/v) PEG 600, 0.1 M tri-Na-citrate pH 5.3.  
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Crystals that grew from the longest SPRY protein construct, SPRY_72-283 (Figure 3.2.2 c), were small 
and did diffract only to ~ 4.0 Å, but when the N-terminal 6xHis-Tag was removed (SPRY_72-283ΔTag), 
crystals of significantly improved diffraction quality were obtained (Figure 3.2.2 d). Most probably the 
unstructured and flexible 6xHis-Tag does not participate in crystal packing and its charge may hinder 
crystal growth. 
 
3.2.2 Phasing and refinement of the SPRY structure 
Crystals of construct SPRY_72-283ΔTag were used for structure determination of the SPRY domain. 
Spheroid crystals appeared after 3 days in 35 % (v/v) PEG 600, 0.1 M tri-Sodium-citrate pH 5.5 and grew 
as single crystals with typical dimensions of 140 x 90 x 40 μm3 within five to six days at 297 K (Figure 
3.2.2 d). For data collection, single crystals were harvested and soaked in reservoir solution for cryo-
protection to prevent ice formation during flash-cooling in liquid nitrogen. Diffraction data were 
collected at the X10SA (PXII) beamline at the SLS in Villigen (Switzerland). Space group, unit cell 
parameters, and statistics of data collection are given in Table 3.3. Symmetry of the crystals of SPRY_72-
283ΔTag belonged to the orthorhombic crystal system and the space group was P212121. Diffraction 
data were processed with the XDS package[171]. Phases were obtained by molecular replacement (MR) 
with the software PHASER[170]. By using the BLAST service of the PDB website (rcsb.org) with the 
sequence of the DDX1-SPRY domain, the SPRY domain of human Ash2L[107] (PDB entry 3TOJ) with 23.8 % 
sequence identity was identified as the best search model. The automated molecular replacement 
mode of PHASER was used to search for two molecules within the asymmetric unit of the SPRY_72-
283ΔTag crystals as indicated by a Matthews coefficient[172] of 2.01 Å3/Da with a theoretical solvent 
content of 38.9 %. The search was carried out on data between 47 and 2.5 Å resolution. Based on the Z-
score of the rotation- and translation function two solutions were found, but one of them was 
eliminated due to six clashes in the packing function. The final solution had a Z-score of 4.84 in the 
rotation function, a Z-score of 4.89 in the translation function and a log likelihood gain of 319 after final 
refinement. Phases were extended by a fourier-transform to the 2.0 Å resolution of the full dataset. 
Using the MR phases an electron density map was calculated and the model was built manually in 
Coot[46] with subsequent improvement in REFMAC[175] using restrained maximum likelihood refinement 
including TLS[176] refinement. Iterative cycles of refinement in REFMAC and model building in Coot led to 
a final model with an R-factor of 20.1 % and an R-free of 24.6 %. All refinement statistics are summarized 
in Table 3.3. Two molecules of SPRY (chains A and B) were found per asymmetric unit (Figure 3.2.3) 
with a solvent content of 34.5 %.  
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Table 3.3 Statistics of data collection and refinement (molecular replacement). 
Values in parentheses are for the highest resolution shell. 
 
PDB code n.a. 
X-ray source beamline X10SA 
Wavelength (Å) 1.06998 
Space group P212121 
Unit-cell parameters (Å,°) a = 45.06, b = 76.14, c = 122.66,  
α = β = γ = 90° 
Observed reflections 367 329 (48 403) 
Unique reflections 28 891 (3 815) 
Resolution range (Å) 50-2.0 (2.1-2.0) 
Redundancy 12.71   (12.69) 
<I/σ(I)> 23.63 (6.52) 
Completeness (%) 98.6 (97.6) 
Rmeas†(%) 7.9 (58.6) 
Refinement statistics  
   Resolution (Å) 47.78-2.0 
   No. of reflections (used in refinement) 27 446 
   No. of reflections (used for calculation of Rfree) 1 445 
   Rwork/Rfree‡ (%) 20.09/ 24.19 
   No. of non-H atoms 3154 
     Protein    3002 
     Water-molecules    152 
   Average B factors (Å2) 31.05 
     Protein (chain A/B)    30.59/31.13 
     Water-molecules    34.70 
   R.m.s. deviations from ideal geometry  
     Bond lengths (Å) 0.010 
     Bond angles (°) 1.300 
   Ramachandran plot  
     Most favoured regions 90.6 % 
     Additional allowed regions 9.1 % 
     Generously allowed 0.3 % 
     Disallowed regions 0.0 % 
 
† Rmeas = Σhkl [n/(n − 1)]1/2 Σi |<Ihkl> − Ihkl,i| / ΣhklΣi Ihkl,i, where <Ihkl> is the mean intensity of symmetry-equivalent reflections and n is 
the redundancy. 
‡ Rwork= hkl Fobs – Fcalc/ hkl Fobs (working set, no  cut-off applied), Rfree is the R value calculated for 5% of the data set not 
included in the refinement. 
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3.2.3 Overall structure of the SPRY domain 
The structure of the complete SPRY domain of DDX1 was determined at a resolution of 2.0 Å (Figure 
3.2.3). This thesis thereby presents the first structural detail of the human RNA helicase DDX1. The 
protein construct used in the crystallization experiment consisted of a polypeptide chain from residue 
72 to 283 (212 residues), however, a clear electron density was only present for residues 86-275 of 
chain A and 86-279 of chain B. The first fourteen residues at the N-terminus (aa 72-85) and the last five 
residues at the C-terminus (aa 279-283) could not be modeled. They might be disorderd in the crystal or 
might have been cleaved off during the course of the crystallization experiment.  
The two models of the polypeptide chain differ in four residues at the C-terminus that are clearly 
present in chain B (depicted in green in Figure 3.2.3), but could not unambiguously be modeled in 
chain A, due to poorly defined electron density. These last four residues at the C-terminus (aa 276-279) 
form an additional β-strand (β16) and are held in place in chain B by an intramolecular interaction with 
strand β1, which stabilizes their conformation (Figure 3.2.3 b). This may be an artifact of crystal 
packing, since from sequence alignment these residues are not expected to be associated with the SPRY 
domain and in chain A the loop leading over to β16 (which here of course is not present) points away 
from the SPRY core (and strand β1). Chains A and B were superposed using secondary structure 
matching (SSM) in Coot[46] and show a core RMSD of 0.246 Å. Since this result demonstrates that chain A 
and B are almost identical, but for chain B more residues could be modeled, the following figures and 
discussion will focus on this chain. 
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Figure 3.2.3 Topology diagram and structure of the DDX1-SPRY domain. A, a topology diagram of the SPRY domain is shown. 
The β-strands that form β-sheet 1 are depicted in blue (and labeled in white), the β-strands that form β-sheet 2 are depicted in red 
(and labeled in blue), the β-strands that form β-sheet 3 are depicted in green. B, the two copies of the SPRY domain in the 
asymmetric unit, chain A (depicted in yellow) and chain B (depicted in green) were superposed by secondary structure matching 
(SSM) in COOT and are shown in ribbon representation. They superpose with an RMSD of 0.246 Å and differ in four residues at the 
C-terminus that are present in chain B, but could not unambiguously be modeled in chain A. C, a ribbon representation of the β-
sandwich fold of the SPRY domain is shown. β-sheet 1 is depicted in blue, β-sheet 2 in red and β-sheet 3 in green. Loop D is 
highlighted in purple. The different strands and N- and C-termini are labeled.  
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The SPRY domain adopts a compact β-sandwich conformation. In contrast to other SPRY domains, that 
usually harbor α-helical regions at the N- and C-terminus[107], all secondary structure elements are β-
strands. The overall β-sandwich fold is slightly distorted, forming a bowl-like platform. Two layers of 
concave shaped β-sheets stack together, in the following referred to β-sheet 1 and 2 (Figure 3.2.3 c). A 
third, much smaller β-sheet 3 forms a lid on the β-sandwich interspace. β-sheet 1 is composed of eight 
strands (β1, β4, β7, β8, β9, β10, β13 and β16; blue in Figure 3.2.2), β-sheet 2 is composed of six strands 
(β2, β3, β6, β11, β12 and β14; red in Figure 3.2.2) and β-sheet 3 only consists of two strands (β5 and β15; 
green in Figure 3.2.2). All β-strands that form the β-sandwich core fold are arranged in antiparallel 
configuration. Only strands β4/β5 and β15/β16 are oriented in a parallel direction (Figure 3.2.3 c). Short 
loops are connecting the β-strands on one edge of the β-sandwich, whereas on the other edge of the β-
sandwich, where the β-sheet 3 lid is located, the loops are far more extended. Those extended loops 
include the long loop between β-strands β7 and β8, designated loop D (purple in Figure 3.2.3 c), 
which adopts a conserved conformation in other SPRY structures[107]. This loop lies in the bowl-like 
curvature of β-sheet 1. The conformation of loop D is locked by a salt bridge between Arg146 and 
Asp157 (2.7 Å) (Figure 3.2.4 b). Loop D does cover a hydrophobic patch on the concave side of the β-
sandwich. An equivilant loop is found on the other, convex side of the β-sandwich (suppl. Figure 
7.1.5). This loop connects β-strands β14 and β15 and also covers a hydrophobic patch on the β-sheet 
surface (but here on β-sheet 2). In the SPRY structure N- and C-termini are in spatial proximity, which is 
in line with a role as a modular insertion domain.  
 
3.2.4 Interface between the two β-sheet layers 
The SPRY domain adopts a compact β-sandwich fold. Salt bridges, hydrogen bonds and hydrophobic 
contacts contribute to the interaction at the interface of the two β-sheets and to conformational 
rigidity. Hydrogen bonds are formed between the oxygen atom of the side chain phenol of Tyr135 and 
the main chain amide of Gly148 (3.4 Å, suppl. Figure 7.1.6 a) as well as between side chain amide of 
Lys173 and the main chain carbonyl of Ala215 (2.6 Å, suppl. Figure 7.1.6 b), which stabilize the 
sandwich-fold. A salt bridge is formed between Glu184 and Lys207 (3.5 Å) and this ionic interaction 
locks the loop connecting β10 and β11 at the outer end of the domain, most distant from the termini 
(Figure 3.2.4 c).   
Residues Cys139 and Cys145 can potentially form a disulfide-bond, which would bring β-strands β6 and 
β7 closer together, which are about 8.6 Å apart (Cα to Cα) in the structure (Figure 3.2.4 d). Formation of 
a disulfide-bond would also influence the conformation of the loop connecting both strands, which is 
one of the potential interaction loops (see below). The distance between the sulfur atoms of Cys139 and 
Cys145 is 4.3 Å (Figure 3.2.4 d). The protein was expressed under reducing conditions and thus, the 
potential disulfide-bond can not form. 
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Figure 3.2.4 Side chain interactions within the SPRY structure. A, an overview of the SPRY domain structure is shown with 
windows that indicate the zoom area in the upcoming panels. B, close-up of loop D that lies in a bowl-like curvature and is 
stabilized by a salt bridge between Arg146 and Asp157. C, a salt bridge between Glu184 and Lys207 stabilizes the loop 
connecting β10 and β11. D, potential disulfide-bridge between Cys139 and Cys145. Residues are labeled in black and the loops 
that are stabilized in magenta. Color code for sheet 1, 2 and 3 and labeling of the β-strands are as in figure 3.2.3. 
 
 
In addition to the ionic interactions, the β-sandwich fold is supported by an intramolecular hydrophobic 
core formed by the strands from β-sheet 1 with the opposite strands of β-sheet 2. Hydrophobic 
interactions involve residues from strands β2, β5, β6, β7, β8, β11, β12, β13 and β14 that stack together 
through Van der Waals contacts (Figure 3.2.5).  
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Figure 3.2.5 Hydrophobic core in the SPRY domain. The β-sandwich fold of the SPRY domain is stabilized by interaction of 
hydrophobic residues from the two β-sheets. Both sheets encompass an intramolecular hydrophobic core. Hydrophobic residues 
are depicted as stick models, labeled and colored in grey. β-sheet 1 is depicted in blue, β-sheet 2 in red and β-sheet 3 in green.  
The SPRY domain is rotated by 90° compared to figure 3.2.3 to better visualize the hydrophobic core. 
 
 
 
 
3.2.5 Comparison of DDX1-SPRY to the structures of other SPRY domains 
Since the first report of a NMR structure of the SPRY domain from murine SOCS box protein-2 in 
2006[191], several crystal structures of mammalian SPRY domains have been determined. To detect and 
characterize particular features of the DDX1-SPRY domain, its structure was used for a structure-based 
sequence alignment with the other SPRY domain structures by the DALI web-server[192]. Several hits with 
high Z-score were obtained, showing that the same overall domain architecture is found in all SPRY 
structures. Amongst the best hits were the SPRY domains of human SPSB proteins 1, 2, 4[105], the SPSB 
orthologue protein GUSTAVUS from D. melanogaster[101] and human trithorax protein Ash2L[107]. With a 
Z-Score of 25.8 and an overall root mean squared deviation (rmsd) of 1.6 Å for the alignment of 170 
residues, Ash2L-SPRY (PDB entry 3TOJ[107]) showed the highest structural similarity, despite bearing only 
23.8 % sequence identity. The high structural similarity justifies the intial utilization of Ash2L-SPRY as a 
search model for MR in retrospect. It also proves that the BLAST routine of the PDB website is well suited 
Results 
 75
to identify MR targets. The DALI superposition of DDX1-SPRY with the structure of the SPRY domain of 
Ash2L (Figure 3.2.6 a) was investigated in detail to characterize similarities and differences. 
Furthermore, the DALI superposition of DDX1-SPRY with the structure of the SPRY domain of 
GUSTAVUS in complex with 20-residue VASA peptide (PDB entry 2IHS[101], Figure 3.2.6 b) was 
investigated to compare the peptide interaction region. This peptide complexed structure of 
GUSTAVUS-SPRY showed similarity with a Z-score of 18.3 and 2.0 Å r.m.s. deviation for alignment of 152 
residues (24 % sequence identity). 
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Figure 3.2.6 Comparison of the DDX1-SPRY domain with other SPRY domains. A, the SPRY domain of human DDX1 (depicted 
in green) was superposed with the SPRY domain of the protein Ash2L[107] (depicted in red, PDB entry 3TOJ). Regions that show 
most significant structural differences are indicated by more intense color shading. Interaction loops that differ in length and the 
long 44-residue loop, lacking in the Ash2L structure, are encircled. The loop D (as discussed in section 3.2.3) is marked. B, a 
superposition with the SPRY domain of the D. melanogaster protein GUSTAVUS[101] (depicted in yellow, PDB entry 2IHS) is shown. 
Color code and markings are as in A. The 20-residue VASA peptide is depicted in a stick representation (in blue). The region 
encompassing residues 169 to 174 is not resolved in the GUSTAVUS crystal structure. C, superposition as in A, but here the tadpole 
like extension of Ash2L-SPRY is highlighted that is not present in the DDX1-SPRY structure. C is rotated by 180° compared to A. D, 
superposition as in B, but here the N-terminus of GUSTAVUS-SPRY and the C-terminus of DDX1-SPRY are highlighted that both 
cover a hydrophobic patch on β-sheet 2. D is rotated by 150° compared to B. 
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SPRY domains have been reported to interact with other proteins via a common interaction surface A[100, 
101, 105]. Interestingly, largest differences between DDX1-SPRY, Ash2L-SPRY and GUSTAVUS-SPRY are 
found in the loops that form surface A with r.m.s. deviations between 2.8 to 3.6 Å (Figure 3.2.6 a and b, 
grey circles). The loop connecting β3 and β4 is extended in DDX1-SPRY, when compared with Ash2L-
SPRY and slightly tilted in comparison to GUSTAVUS-SPRY. The loop between β6 and β7 is shorter and 
retracted in contrast to both Ash2L-SPRY and GUSTAVUS-SPRY. Furthermore, the loop, connecting β13 
and β14 is shorter in DDX1-SPRY in comparison to GUSTAVUS-SPRY. In GUSTAVUS-SPRY conserved 
loop D contributes to the interaction surface with the VASA peptide[101]. In DDX1-SPRY, however, loop D 
is shorter (by seven residues), far less extended and not part of surface A. Furthermore, a four residue β-
strand (depicted in purple in Figure 3.2.6 b) seems to be an exclusive feature of loop D in GUSTAVUS-
SPRY. In Ash2L-SPRY loop D is also shorter (when compared to GUSTAVUS-SPRY), but displays 
conformational differences in comparison to DDX1-SPRY. 
In addition to the loops of surface A, further structural differences were detected when the DDX1 SPRY 
domain was compared to both other SPRY domain structures. Ash2L-SPRY contains a large 44-residue 
loop that connects β11 and β12, which was removed from the crystallization construct. The yeast Ash2L 
homolog Bre2 even contains two large loops, a 40 residue loop between β6 and β7 and a 120 residue 
loop between β11 and β12. In contrast to Ash2L and Bre2 human DDX1-SPRY lacks this extended loop. 
The corresponding loop between β11 and β12 is short and well resolved in the electron density (Figure 
3.2.6 a). The largest loop in DDX1-SPRY is 23 residues between β14 and β15 at the C-terminus. In Ash2L-
SPRY N- and C-terminus come together and form an additional β-sheet, which adds a tail to the 
compact SPRY domain core and generates an overall tadpole like structure[107] (Figure 3.2.6 c). In 
contrast, this convergence of N- and C-terminus is not observed in the DDX1-SPRY structure, where the 
C-terminus folds back on the SPRY core structure. Interestingly, GUSTAVUS-SPRY contains two helices at 
the N-terminus that show extensive hydrophobic interactions with β-sheet 2 and stabilize its 
curvature[100] (Figure 3.2.6 d). In contrast, in the SPRY domain of human DDX1 these interactions are 
taken over by the long loop in the C-terminal region that extends from β14 and crosses over strands β6, 
β11 and β12. Also in contrast to GUSTAVUS-SPRY, strand β4 is shorter and interrupted. After a short loop 
region, it continues into strand β5 that forms the separated β-sheet 3 (together with β15), which is not 
present in GUSTAVUS-SPRY. 
 
To further investigate differences in peptide recognition motifs between the SPRY domain structures, 
which were identified in the DALI search, the sequences of the best hits were aligned and conservation 
values were mapped on the DDX1-SPRY surface (Figure 3.2.7). 
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Figure 3.2.7 Conservation of peptide interaction residues amongst SPRY domain structures. The SPRY domain of human 
DDX1 is compared with other SPRY domains for which structures in complex with short peptides of the interaction partners are 
available[101, 105, 107]. A, the SPRY domain of human DDX1 is aligned with SPRY domains that show high structural similarity (as 
identified by a DALI[192] search). All proteins are of human origin, except for GUSTAVUS, which is a D. melanogaster protein. The 
degree of sequence conservation is indicated by color coding. Secondary structure is indicated above the sequence and β-strands 
are colored according to sheet 1 (=blue), sheet 2 (=red) and sheet 3 (=green). Loop D is indicated in purple. Residues of interaction 
loops that form surface A as identified in other SPRY structures[101] are indicated by grey circles. Residues that form a conserved 
positively charged surface patch in DDX1 homologs from different species (see below) are marked by triangles. B, the sequence 
conservation values are mapped on the surface of DDX1-SPRY. The short 20-residue VASA peptide from the structure of the 
GUSTAVUS SPRY domain[101] (PDB entry 2IHS) is superposed on the DDX1-SPRY surface. View is rotated by 60° compared to figure 
3.2.6 b to better visualize the binding surface.  
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Noticeably, additionally to the conformational differences, least sequence conservation between Ash2L-
SPRY and DDX1-SPRY is found in the loops connecting the strands β1 - β2, β3 - β4, β6 - β7 and β13 – 
β14, that form surface A (Figure 3.2.7 a). Investigation of the VASA peptide interaction in the complex 
structures revealed that only one of the residues (Val84 in GUSTAVUS/Val116 in DDX1) in the loops of 
surface A that mediate peptide-contact in GUSTAVUS-SPRY is conserved in DDX1-SPRY (Figure 3.2.7 b). 
Asn68, Arg81, Thr115 and Tyr133 (Ala101, Ser113, Gly143, Asp157 in DDX1) that form essential contacts 
to the SPRY interaction partner, not only in GUSTAVUS-SPRY[101], but also in the SPRY domains of human 
SOCS box proteins[105] are not found in DDX1-SPRY (Figure 3.2.7 a). 
 
Overall the comparison of the DDX1-SPRY domain with the other SPRY domain structures, revealed 
profound conformational and compositional differences in the loop regions that mediate the contact 
with interaction partners in all other peptide complexed SPRY structures. Furthermore, the residues of 
the DDX1 specific extended surface A (see below) are not conserved amongst different mammalian 
SPRY domains (Figure 3.2.7 a). 
 
3.2.6 The SPRY domain is a conserved interaction platform 
To further characterize the role of the SPRY domain within DDX1, a sequence alignment of DDX1 
orthologs of representative eukaryotic model organisms from primates to insects was used to map 
conservation values on the SPRY ribbon structure (Figure 3.2.8). Residues in the hydrophobic core that 
stabilize the β-sandwich fold were found to be either conserved or substituted with similar hydrophobic 
residues (grey diamonds in Figure 3.2.8 a). All β-strands are conserved, except for strand β15 of sheet 3 
that shows a variation between hydrophobic and charged residues in different species. Residues of 
strand β5 that forms β-sheet 3 together with β15 are, however, conserved. Interestingly, strands β1, β4, 
β7, β8 and β9 of β-sheet 1 are virtually identical in all DDX1 orthologs, whereas the strands of β-sheet 2, 
mostly β2, β12 and β14 are less conserved (also see suppl. Figure 7.1.7). However, hydrophobic 
residues that contribute to conformational stability of the core are still preserved in less conserved 
strands. These residues include Ile104 of strand β2, Val203 and Phe205 of strand β12 and Leu238 of 
strand β14 (Figure 3.2.8 a). Least sequence conservation is found at the N- and C-termini of the SPRY 
domain. The termini correspond to the regions that connect the compact SPRY domain to the DDX1 
helicase core, which again is well conserved across species (compare Figure 3.1.1). 
Interestingly, the D. melanogaster and C. elegans DDX1 SPRY domains show differences in the 
polypeptide length and the loop connecting β5 to β6 is elongated by one residue in both species. The 
C. elegans protein displays additional length differences in the loop between β12 and β13 that is 
extended by two residues as well as in the loop between β14 and β15 that is extended by one residue. 
However, the loops that contain differences in the number of residues show low sequence conservation 
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in the adjacent regions of the polypeptide chain and are part of the so called surface B (see Figure 3.2.8 
b) for which no interactions have been described yet[100]. 
 
 
Figure 3.2.8 Conservation of the SPRY domain amongst DDX1 from higher eukaryotes.. A, The SPRY domain of human DDX1 
is aligned with SPRY domains of DDX1 homologs from model organisms and the degree of sequence conservation is indicated by 
color coding. Secondary structure is indicated above the sequence and β-strands are colored according to β-sheet 1 (=blue), β-
sheet 2 (=red) and β-sheet 3 (=green). Residues of the hydrophobic core that stabilize the domain fold are indicated by grey 
diamonds. Residues of interaction loops as identified in other SPRY structures[101] are indicated by grey circles. Residues that form 
a conserved positively charged surface patch are marked by black triangles (see below). Domain boundaries of the crystal 
structure (residues 86-279) are indicated in grey and domain boundaries of the crystallization construct are indicated in brown 
(residues 72-283). B, ribbon representation of the structure of the human DDX1-SPRY domain, colored according to sequence 
conservation. Surfaces A and B, formed by the loops that connect the β-strands are indicated by grey shading.  
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The residues that form the canonical interaction surface A in peptide complexed structures of other 
SPRY domains were found to be not conserved in the SPRY domain of DDX1 (see section 3.2.5 above). 
To find the potential location of a protein-protein interaction surface in DDX1-SPRY the sequence 
conservation on the protein surface was examined (Figure 3.2.9). A highly conserved patch could be 
identified that only partially overlaps with the location of surface A in other SPRY domains. In DDX1, this 
conserved patch is much more extended than in other SPRY domains and is mainly formed by the loop 
between β3 and β4, the upper parts of β13 and β7, the loop between β8 and β9 and the middle portion 
of β14 (Figure 3.2.9 a).  
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Figure 3.2.9 Extended surface A, a conserved positively charged patch on the surface of the SPRY domain. A, Sequence 
conservation (as obtained from sequence alignment -> see figure 3.2.8) is mapped on the surface of the DDX1-SPRY domain. The 
structure is oriented as in figure 3.2.6 and figure 3.2.8. The surface is partially transparent to show the peptide backbone. A large 
conserved patch is seen. This conserved surface is formed by the loop between β3 and β4, the upper parts of β13 and β7, the loop 
between β8 and β9 and the middle portion of β14.  B, the same surface sequence conservation is shown, but the molecule is 
rotated by 180° around the y-axis compared to A. C, the electrostatic surface potential, calculated using APBS[183] is shown. The 
dielectric constant of the solvent was set to 80 kT/e. The contouring of the surface goes from +7 kT/e in blue to -7 kT/e in red. D, 
same surface potential as in C, but the molecule is rotated by 180° around the y-axis compared to C. 
 
 
For mammalian SPRY domains it has been shown that mostly electrostatic interactions are established 
with protein partners bound to surface A[105]. The electrostatic surface potential of the DDX1-SPRY 
domain shows two elongated, positively charged patches that could serve as potential interaction 
regions. One of the positively charged surfaces is formed by residues of strands β7, β13 and the loop 
connecting β3 and β4 (Figure 3.2.9 c). Interestingly, this region is also conserved, suggesting that it 
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may mediate the interaction with other protein factors or with RNA. To differentiate this conserved 
positively charged region from the canonical interaction surface A, it will be referred to as extended 
surface A. 
The second positively charged surface patch is found at the N-terminus (Figure 3.2.9 d). It is most likely 
buried in the linker connecting the SPRY domain with the DDX1 helicase core and thus, probably not 
accessible for protein interactions. Furthermore, this charged region is not conserved (Figure 3.2.9 b). 
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Structure of DDX1 
 
3.2.7 Crystallization trials with full-length protein 
A number of structures of the canonical DEAD-box helicase core have been reported in recent years[31, 33, 
36], making the SPRY domain the only novel structural feature of DDX1. Nevertheless, to obtain the 
complete picture and to determine the arrangement of the SPRY domain within the canonical core fold, 
crystallization experiments with full-length DDX1 were conducted. Crystallization trials using the apo-
protein and co-crystallization with non-hydrolyzable ATP-analogs such as ATPγS and AppNHp were not 
successfull (see appendix section 7.3.3). 
Most structures of DEAD-box proteins were determined in complex with RNA[37] (PDB entries 2DB3, 
2HYI, 2J0S, 3I5X). In these structures RNA stabilizes the helicase core by binding across the two helicase 
domains, bridging them and bringing them close together[23, 24, 31, 35], ensuring a rigid scaffold required 
for crystallization. Co-crystallization experiments with different DDX1 constructs and different RNA 
oligonucleotides (as tested in EMSAs, see section 3.3.3) were performed (also with ternary complex of 
protein, ATPγS and RNA), but did not yield X-ray diffracting crystals (see appendix section 7.3.4).  
 
3.2.8 Structural model of the entire DDX1 helicase including the SPRY domain 
To get a picture of the entire DDX1 including all three domains, the SPRY domain and canonical RecA-
like domains 1 and 2, a homology model of DDX1 was constructed. For this homology model only the 
basic helicase core of DDX1 without the C-terminal extension (residues 637-740) and without the SPRY 
domain and associated linkers (residues 70-284) was modeled. To find a suitable template for 
modelling, the PDB was searched for structures of DEAD-box proteins that harbor high sequence 
homology to DDX1. The highest BLAST[186] score of 443 (E-value 1.42352x10-43) was obtained for the 
sequence of the apo structure of the Methanococcus jannaschii protein MjDEAD[33] (PDB entry 1HV8) 
with a sequence identity of 29.15 % to DDX1 (Figure 3.2.10). Using Swiss-MODEL[184], a structure of the 
DDX1 helicase core was assembled by sequentially mutating residues of MjDEAD to the corresponding 
residues in DDX1 and optimizing the geometry.  
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Figure 3.2.10 Sequence alignment of DEAD-box proteins. The DEAD-box proteins MjDEAD (from M. jannaschii) and DDX3X 
(from H. sapiens) were aligned with DDX1 (from H. sapiens). Residues that are identical are colored in green. Secondary structure as 
predicted for human DDX1 with PSIPRED[177] is indicated above the sequence and colored according to domain allocation. RecA-
like domain 1 is colored in green, the SPRY domain is colored in blue and RecA-like domain 2 is colored in red. Conserved helicase 
sequence motifs (as explained in figure 1.3) are marked by blue bordering. The insertion in DDX3X that forms an elongated 
positively charged cavity is marked in brown. 
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The SPRY domain was placed by an educated guess based on the structure of the human DEAD-box 
helicase DDX3X[185] (PDB entry 2I4I) (Figure 3.2.10). DDX3X only shows 21.04 % sequence identity and 
with a BLAST score of 257 (E-value 5.091x10-22) only ranked 48 on the list of templates for homology 
modeling. However, similar to DDX1, DDX3X harbors an insertion domain, placed between conserved 
motifs I and Ia[185]. The insertion in DDX3X consists of ten residues that form an extended loop[185]. The 
DDX1-homology model was superposed with the structure of DDX3X using secondary structure 
matching (SSM)[46] and the SPRY domain was placed according to the position of the DDX3X-insertion 
(Figure 3.2.11). In this model the SPRY domain is oriented away from both the ATPase active site and 
RNA binding site on the surface between the two RecA-like helicase domains, suggesting that it neither 
interferes with ATP nor RNA binding (Figure 3.2.11 b). The DDX1 homology model and the structure of 
DDX3X represent helicases in the “open”-state. In general, upon binding of RNA substrate both RecA-
like domains come together and form the “closed”-state as seen e.g. in the RNA-bound structures of 
yeast Mss116p[35], Dbp5[25] or Drosophila VASA[31]. 
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Figure 3.2.11 Structural model of the entire DDX1 helicase. A homology model of the helicase core of DDX1 was constructed 
based on the structure of MjDEAD (PDB entry 1HV8). The SPRY domain structure was placed in the model of the helicase core 
based on the position of the insertion in DDX3X (PDB entry 2I4I). A, Domain organization of DDX1 is shown schematically. The 
position of the conserved helicase motifs I (=Walker A), motif Ia and motif II (=Walker B) is shown by circles. B, homology model of 
DDX1 in the open conformation, based on the structure of MjDEAD, is shown. Color code is the same as in A. C, topology map of 
the DDX1 homology model, showing the position of the conserved helicase motifs. 
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3.2.9 Summary of the structural studies 
The results of this section demonstrate how a divide and conquer approach succeeded in determining 
the structure of the distinctive feature of DDX1, the SPRY domain. The structure revealed three β-sheets, 
two of them stack together and form a β-sandwich and a third, small one forms a lid that closes over the 
β-sandwich core. A conserved surface patch was detected that is positively charged. This conserved 
patch, designated extended surface A, is not conserved in unrelated SPRY domains and does not match 
with the canonical interaction interface.  
The structure of the SPRY domain was placed in a homology model of the DDX1 protein helicase core, 
based on the structure of the related human helicase DDX3X.  
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3.3 Functional characterization of DDX1 
 
This chapter describes the functional characterization of DDX1 that was done using spectroscopic and 
biochemical methods. The functional results supplement the structural studies and helps to obtain a 
more complete picture of the unique DEAD-box protein DDX1. Initially, the recombinant protein-
material was tested for its suitability for biophysical assays. Recombinant DDX1 was stable, monomeric 
and correctly folded. Affinities for nucleotides were determined and a profound preference for ADP over 
ATP was observed. Nucleotide affinity was modulated by RNA binding – cooperativity was most 
pronounced for ATP. Furthermore, RNA binding was characterized in gel-shift experiments and 
analysed in detail by a combined spectroscopic assay, which further supported cooperativity in RNA 
and ATP binding. DDX1 did display an intrinsic ATPase activity that can be stimulated by addition of 
RNA. Despite the ability to hydrolyze ATP, DDX1 was unable to unwind duplex RNA substrate in a 
helicase assay. Concluding from the affinity and ATPase measurements, RNA and ATP binding to DDX1 
are tightly coupled.  
 
 
Biophysical properties of recombinant DDX1 
 
3.3.1 Folding and oligomerization of DDX1 
Correct folding of recombinant DDX1 (see section 3.1.2 on protein expression) was tested via CD 
spectroscopy (Figure 3.3.1). The spectrum of DDX1-728 showed the characteristic minima of a mixed α-
helical/β-sheet protein, which is typical for the canonical RecA-like helicase fold[37]. However, the strong 
negative signal that is usually observed at shorter wavelengths (arising from α-helical secondary 
structure elements)[193] is attenuated by the SPRY domain insertion that consists solely of β-strands 
(Figure 3.3.1 a). Recorded thermal denaturation curves can be fitted to a two-state unfolding process 
yielding a melting temperature of Tm=326 K and an enthalpy at the transition midpoint of 
ΔH=646.6 kcal mol-1, further supporting that the protein is folded correctly (Figure 3.3.1 b). Thermal 
denaturation of DDX1 was irreversible, as the protein was heavily aggregated in the cuvette after 
denaturation. 
As a control in the biophysical measurements (see section 3.3) and to test the specificity of the ATP 
binding and the hydrolysis parameters, a mutant variant of DDX1-728, where the catalytically important 
Walker A lysine residue was mutated to alanine (K52A), was also studied. The K52A variant showed 
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essentially the same behavior as WT protein during purification, gave the same CD-spectrum and the 
same melting point, indicative of correct folding (Figure 3.3.1 a and b). 
 
 
Figure 3.3.1 Folding and Oligomerization state of DDX1.  A, CD spectra of DDX1-728 (=WT) and DDX1-728 Walker A K52A 
(=K52A) protein constructs, depicted in green and blue respectively are shown. CD signal measured with 5 μM protein was 
converted to mean-residue-ellipticity (MRE). B, temperature dependent unfolding curves as monitored by recording the CD signal 
at 222 nm. The data were fitted to a two-state-unfolding process. The fits yield a melting temperature Tm of 325.6 ± 0.04 K and 
enthalpy at the transition midpoint ΔH of 646.6 ± 16.9kcal mol-1 for DDX1-728, depicted in green and a Tm of 326 ± 0.08 K and an 
enthalpy ΔH of 520.5 ± 19.7kcal mol-1 for DDX-728 WalkerA K52A, depicted in blue. C, spectrum of a gel-filtration run with 50 μM 
DDX1-728 in 40 μl, coupled to a static-light-scattering detector. UV absorbance at 280 nm is shown on the left y-axis and a peak at 
an elution volume of 13.6 ml was observed, which corresponds to a molecular weight of ~ 80 kDa. On the right y-axis the 
averaged molecular mass as determined by the MALS-data is plotted (in grey), which did correspond to 79.9+/-1.3 kDa. The 
dashed line represents the light scattering signal. D, data from dynamic light scattering measurements are shown. On the lower x-
axis, the combined autocorrelation function from 20 x four second measurements is plotted in grey and a fit to the data in black. 
The upper x-axis shows the distribution of the hydrodynamic radii by relative mass (amplitude of each bar indicates the 
percentage of the total mass of the sample) as obtained from the fit. The peak at a hydrodynamic radius of 3.9 nm corresponds to 
a molecular weight of 85.8 kDa. Peak width is 24.4 % RSD, which corresponds to a homogeneous sample. 
 
 
It has been reported that DDX1 forms dimers at high protein and low salt concentrations[135]. In fact 
recombinant DDX1 prepared during this thesis showed some aggregation (see Figure 3.1.3). Since 
formation of dimeric- or multimeric species complicates kinetic measurements, the formation of 
oligomers of DDX1 at the concentrations used in the biophysical assays was tested via static- and 
dynamic light-scattering (see materials and methods section 2.4.3). Even at concentrations of 50 μM, 
DDX1 did elute as a single peak from a size-exclusion column with a radius of gyration of 3.57 nm 
corresponding to a molecular weight of 79.9 +/- 1.3 kDa as determined from static light scattering data 
(Figure 3.3.1 c). DLS yielded a hydrodynamic radius of 3.96 nm and a corresponding molecular weight 
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of 85.8 kDa (Figure 3.3.1 d). This shows that aggregated protein contaminations were efficiently 
separated from the main fraction by the gel-filtration chromatography during protein purification (see 
Figure 3.1.3), as theoretical mass of DDX1 is 82.4 kDa. Furthermore, both SLS and DLS measurements 
are in perfect agreement with DDX1 being present as a monomeric species at the concentrations used 
in the biophysical assays. 
 
 
3.3.2 Characterization of conformational changes via limited proteolysis 
Limited proteolysis has been successfully applied to map nucleotide binding dependent 
conformational changes of DEAD-box proteins[194]. To investigate the stabilization of individual domains 
of DDX1 in different nucleotide bound states, construct DDX1-728 was studied by limited proteolysis. 
The protein was digested with trypsin, chymotrypsin and thermolysin in the presence or in the absence 
of AppNHp (Figure 3.3.2 and suppl. Figure 7.3.7). ADP was not included in the experiments, since it 
was not expected to induce any domain movement and did not show cooperative binding effects with 
RNA binding (see section 3.3.6). 
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Figure 3.3.2 Characterization of nucleotide dependent conformational changes by limited proteolysis. Construct DDX1-728 
was digested with trypsin and chymotrypsin for the indicated time points (in min) at 310 K. Degradation bands were excised from 
the gel and identified via MALDI-MS PMF. A, digest of a sample of apo DDX1-728 is shown. B, digest of a sample of DDX1-728 
incubated with 10 mM AppNHp is shown. 
 
Domain fragments generated by proteolysis were identical independent of the presence of AppNHp 
(Figure 3.3.2). Degradation bands were excised from the gel and further characterized by MALDI-MS 
PMF. They did correspond to the separated RecA-like domain 2 or to N- and C-terminally truncated 
DDX1 fragments. C-terminally truncated fragments were similar to constructs DDX1-655 and DDX1-694. 
N-terminally truncated fragments did lack all residues up to the SPRY domain. 
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Nucleotide affinity of DDX1 
 
 
 
3.3.3 RNA binding observed in gel-shift assays 
DEAD-box helicases bind ssRNA through a set of conserved signature motifs on top of RecA-like 
domains 1 and 2[31]. An electrophoretic mobility shift assay (EMSA) was used to detect binding of short 
strands of RNA to DDX1. A 13mer RNA of random sequence, a 10mer polyU or 10mer polyA RNA were 
tested for binding (see materials and methods, section 2.3.9). The sequence of the 13mer RNA was 
randomized according to a protocol from Jankowsky and colleagues, that is classically used in studies of 
DEAD-box helicases[157]. To be able to visualize the oligonucleotides, FAM-labeled RNAs were used and 
illuminated on native gels by excitation of the FAM group at 302 nm. To optimize migration behavior of 
DDX1 (theoretical pI 6.9) in native gels, several buffer conditions and gel compositions had to be tested. 
Problems in the gel-migration of DDX1 have been reported before and in these experiments the 
complex of radioactively labeled RNA with DDX1 could not be visualized[135]. After optimization, it was 
possible to separate free- and protein-complexed RNA in 40 mM CHES (pH 10) buffered 5 % / 15 % (w/v) 
gradient gels at 277 K.  
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Figure 3.3.3 RNA binding to DDX1 observed via gel-shift. A, Binding of a 13-mer RNA strand, fluorescently labeled with a FAM-
group at the 3’-end, to DDX1 was observed via a band-shift in a native gel. Increasing concentrations of DDX1-728 were incubated 
with 0.5 μM of labeled 13-mer RNA of indicated sequence for 20 min at 277 K. Reactions were separated on a 5 %/15 % (w/v) 
native acryl-amide-gel with CHES-NaOH pH 10 as running buffer. The FAM label was visualized by illumination at 302 nm. Protein 
was stained with Instant-blue to confirm co-migration with the RNA signal (see right side). B, same experiment as in A, but here 
10 mM of different nucleotides (as indicated) were added to the binding reaction.  
 
Binding of DDX1 to RNA was observed at relatively high protein concentrations (Figure 3.3.3 a). The 
position of the label on either the 3’- or 5’-end of the RNA substrate did not influence binding (suppl. 
Figure 7.1.9). All RNA species revealed a similar pattern of migration when incubated with DDX1, 
indicating that binding is sequence unspecific (suppl. Figure 7.1.10). Additional experiments were 
performed to investigate, whether the presence of nucleotides has an influence on DDX1 RNA binding 
or not. In the gel-based assay, no differences in the RNA binding affinity of DDX1 in the presence or 
absence of ADP, ATP or non-hydrolyzable ATP-analogs could be detected (Figure 3.3.7 b).  
Of note, binding of DDX1 to RNA and DNA/RNA hybrid substrates was also observed in helicase assays 
(see section 3.4) in which a DDX1-substrate complex was shifted to the gel-pockets (Figure 3.4.1), 
whereas no binding and corresponding gel-shift could be observed for labeled, single-stranded DNA 
(suppl. Figure 7.1.11).  
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These gel-shift experiments only provide a qualititative description of the nucleotide affinities of DDX1. 
In these experiments, the binding equilibrium is disturbed and quantification of intensities is unreliable, 
therefore extraction of any binding parameters was not performed. To obtain a quantitive description of 
nucleotide binding to DDX1 and to extract correct values for the nucleotide affinities, fluorescence 
spectroscopy was used. 
 
Cooperativity of RNA and ATP binding 
 
3.3.4 Equilibrium titration of mant-nucleotides 
The well-characterized fluorescent mant-labeled nucleotide analogs[195] were used to obtain a 
spectroscopically visible signal for nucleotide binding to DDX1. In spectroscopic experiments, 
fluorescence of the mant-group was excited directly by using UV-light at 356 nm and did increase upon 
binding to DDX1. This signal was used to characterize the affinity of DDX1 for ADP, ATP and RNA by a 
combination of different equilibrium titration experiments as described in the following. 
 
Another way, which would allow to directly probe mant-nt binding is to use fluorescence resonance 
energy transfer between tryptophan residues of the protein and the nt mant-group, which has been 
described in the literature before[58, 196, 197]. DDX1 contains nine tryptophan residues in its amino acid 
sequence, one located close to the Q-motif in RecA-like domain 1, whereas the other tryptophan 
residues are located in the SPRY domain or in RecA-like domain 2. A strong tryptophan-fluorescence 
signal was obtained by excitation at 296 nm, but no energy-transfer to mant-nts could be observed. This 
means if DDX1 was titrated with mant-nts, it would be hard to differentiate between the increase in 
fluorescence caused by addition of the mant-nt and the one caused by mant-nt binding to the protein. 
Therefore, in all experiments in this thesis mant-nts were titrated with protein and not the other way 
round, which is not a problem due to the monomeric nature of DDX1. 
 
For equilibrium titration experiments a constant concentration of mant-ADP was titrated with 
increasing amounts of DDX1 (Figure 3.3.4 a). The change in fluorescence due to binding can be fitted 
to the quadratic form of a single-site binding equation (Equation 8) resulting in a 
Kd,mantADP = 0.12±0.02 μM for mant-ADP binding (Table 3.4). To test specificity of binding, the same 
titration was performed with the K52A mutant variant. For this variant full saturation of mant-ADP with 
protein and a plateau in the binding curve is not reached, even at high protein concentrations. 
Extrapolation of the binding curve to saturating conditions results in a Kd,mantADP (K52A) = 31.4±4.9 μM, 
which represents more than 200 fold reduction in binding affinity (Figure 3.3.4 b).  
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Figure 3.3.4 DDX1 mant-ADP affinity assessed by equilibrium titrations.  A, in binding experiments 0.5 μM mant-ADP were 
titrated with DDX1 protein to obtain a Kd,mantADP. B, titration of 0.5 μM mant-ADP with DDX1 K52A variant is shown. To obtain 
affinity constants, binding data were fitted with the quadratic equation (Equation 8). Residuals from the fits (i.e. Δy between fit 
and actual data) are shown beneath the plots, where the y-axis represents 10 % of the binding amplitude. All parameters obtained 
from these experiments are shown in table 3.4. 
 
 
To obtain binding affinities for unlabeled ADP, the mant-ADP DDX1 complex was pre-assembled and 
mant-ADP was displaced by titrating in excess ADP (Figure 3.3.5 a). Fluorescence data of the 
competition experiment can be fitted with the cubic equation[164] (Equation 9), resulting in a 
Kd,ADP = 0.11±0.03 μM (Table 3.4). This value is close to the affinity for the mant-labeled ADP, indicating 
that the mant group has little influence on equilibrium binding, similar as reported for other systems[196]. 
Notably, when compared to the nucleoside-diphosphate affinities of other DEAD-box helicases[57, 58], Kd 
values for mant-ADP and ADP binding to DDX1 are smaller by at least two orders of magnitude.  
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Figure 3.3.5 DDX1 ADP and ATP affinities assessed by equilibrium titration in displacement experiments. A, in displacement 
experiments a pre-equilibrated mixture of 3 μM mant-ADP and 0.5 μM DDX1 was titrated with unlabeled ADP to obtain an ADP 
affinity (Kd,ADP). B, a pre-equilibrated mixture of 0.5 μM mant-ADP and 2 μM DDX1 was titrated with ATP to obtain a Kd,ATP. Titration 
was performed in the presence of an ATP-regenerating system.  
Data were fitted with a cubic binding equation (Equation 9). The mant-ADP affinity constant as determined beforehand was used 
as input parameter. Residuals from the fits (i.e. Δy between fit and actual data) are shown beneath the plots, where the y-axis 
represents 10 % of the binding amplitude. All kinetic parameters, obtained from these experiments are shown in table 3.4. 
 
 
To probe binding of adenosine-triphosphates, the same experimental setup as before was used and 
mant-ATP was titrated with DDX1 protein. However, no significant increase of mant-fluorescence was 
observed in the titration experiment with 6 μM DDX1 as highest concentration (and 0.5 μM mant-ATP). 
Furthermore, hydrolysis of mant-ATP by DDX1 during the time-span of the titration experiment could 
potentially complicate measurements. Therefore, the experimental characterization was limited to the 
measurement of ATP affinity in competition with the mant-ADP DDX1 complex. To counteract ATP 
hydrolysis by DDX1, an ATP regeneration system, containing PK and PEP, was added to the reaction 
mixtures. PK has a very low turnover rate and affinity for mant-ADP (Vmax of less than 2 % that of ADP), 
but rapidly converts ADP to ATP[195]. As expected from mant-ATP titrations, high concentrations of ATP 
were required to fully displace mant-ADP from DDX1 (Figure 3.3.4 b). A Kd,ATP = 129±26 μM for ATP was 
obtained from a fit of the titration curves, which is within the range of what has been reported for other 
DEAD-box helicases[57, 58, 75]. Though, this Kd value is higher by three orders of magnitude when 
compared to the affinity for ADP. 
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At closer inspection of the results of the characterization of ATP hydrolysis by DDX1 (section 3.3.8), this 
Kd,ATP value has to be handled with care, since under the experimental conditions of the ATP equilibrium 
titrations, a fraction of enzyme may be in an ADP bound state. In this case, even in the presence of the 
ATP regeneration system, the titration with ATP would not measure a Kd,ATP, but a combination of ATP 
binding and the following steps (-> see discussion 4.2.1). 
 
Since the fluorescent nucleotide mant-ADP exists in a mixture of the isomers 2’-mant-ADP and 3’-mant-
ADP, titrations were repeated, using 2’-deoxy mant-ADP (mant-dADP) to exclude isomer specific effects. 
This variant of mant-ADP has the mant group attached to the 3’ position of the ribose moiety and is 
unable to isomerize. 
Whereas the apparent binding amplitudes (i.e. the signal) were different, all affinities were essentially 
the same (suppl. Table 7.1 and suppl. Figure 7.1.12).  
 
 
3.3.5 Transient kinetics of mant-nucleotide binding 
The ADP affinity of DDX1, measured by equilibrium titrations, is unusually high, with a Kd smaller by at 
least two orders of magnitude when compared to values reported for other DEAD-box proteins[57, 58]. To 
validate this tight ADP binding, the affinity of DDX1 for Adenosine-diphosphates was also measured via 
transient kinetics. Pre-steady-state kinetic measurements were performed on a stopped-flow setup, to 
assess on- and off-rates for mant-nucleotide binding. Rapid mixing of excess mant-ADP with DDX1 
leads to an increase in fluorescence. Fluorescence traces of experiments in which constant 
concentrations of DDX1 were mixed with different mant-ADP concentrations can be fitted to the sum of 
two exponential functions (Figure 3.3.6). The initial fast phase scales with mant-ADP concentration, 
whereas the second slow phase is constant throughout the experiments. Data analysis was limited to 
the initial fast phase and the second slow phase was excluded, because the amplitude is very small and 
it might reflect off-pathway isomerisation, small nucleotide contaminations in the protein preparations 
or mant-isoform specific interactions. The increase of fluorescence, described by the fast phase was 
interpreted as the mant-ADP binding process, because it shows a linear dependence on the mant-ADP 
concentration. The mant-ADP association rate constant was determined from the slope of the [mant-
ADP] dependence of k1,fast giving an on-rate constant kon,mantADP = 0.95±0.12 μM-1s-1 for mant-ADP binding 
(Table 3.4). To obtain the off-rate constant, a chase experiment was performed, where DDX1 protein 
was pre-incubated with mant-ADP and subsequently mant-ADP was chased by mixing with excess 
amounts of unlabeled ADP. The time course of mant-ADP release can be described by a single 
exponential decay with a concentration-independent rate constant koff,mantADP = 0.15±0.0004 s-1 (Figure 
3.3.6, Table 3.4). 
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Thus, a resulting mant-ADP affinity of Kd,mantADP = 0.160±0.021 μM was calculated from the transient 
kinetics measurements, which corresponds well to the affinity of Kd,mantADP = 0.12 μM determined by 
equilibrium titrations (see above section 3.3.3).  
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Figure 3.3.6 DDX1 binding to mant-ADP and mant-dADP assessed by transient kinetics.  A, fluorescence traces obtained by 
rapid mixing of 2.5 (blue), 3.75 (green), 5 (yellow) and 7.5 μM (red) mant-ADP with 0.5 μM DDX1. Traces can be described by 
double exponential fits (black lines) and the corresponding rate constants k1,fast (squares) and k2 (triangles) are plotted below. The 
fast rate constant k1,fast (squares) scales linearly with mant-ADP concentration and the slope (0.954 as indicated) was used as on-
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rate for binding. B, same experimental setup as before, but here different concentrations of 2’-deoxy variant of mant-ADP (=mant-
dADP) were rapidly mixed with DDX1. C, fluorescence traces of chase experiments, where an equilibrated solution of 0.5 μM 
mant-ADP and 0.5 μM DDX1 was rapidly mixed with either 250 (green) or 500 μM (blue) unlabeled ADP. Single exponential fits 
(black lines) gave the kinetic off-rates for mant-ADP dissociation. D, same experimental setup as in C, but here the complex of 
DDX1 with mant-dADP was chased by excess ADP.  
Residuals from the fits (i.e. Δy between fit and actual data) are shown beneath the plots, where the y-axis represents 10 % of the 
binding amplitude. In the residual plots data points are depicted as hollow symbols. 
 
 
As before, to exclude isomer specific effects and to test whether the second phase in the time course of 
mant-ADP binding is due to different affinities of DDX1 for 2’- or 3’-mant-ADP, the experiments were 
repeated using 2’-deoxy mant-ADP. Binding of mant-dADP is identical to mant-ADP, but the second 
slow phase is less pronounced (Figure 3.3.6 b). The mant-dADP concentration-dependent first fast 
phase gives a kinetic on-rate constant kon,mantdADP = 0.817±0.043 μM-1s-1. Chase experiments with excess 
ADP give an off-rate koff,mantdADP = 0.074±0.0001 s-1 (Figure 3.3.6 d). The corresponding affinity 
Kd,mantdADP = 0.091±0.005 μM corresponds well to the results from equilibrium titration measurements 
with mant-dADP (Kd,mantdADP = 0.124, compare suppl. Table 7.1 and suppl. Figure 7.1.12). 
 
 
 
3.3.6 RNA modulates the nucleotide affinity of DDX1 
The established experimental setup of exploring DDX1 binding by an increase in mant-nucleotide 
fluorescence was used to determine affinities for ADP and ATP in the presence of RNA. To work under 
conditions of saturated RNA binding, 28 μM RNA was used in the titrations. Later experiments 
confirmed that under these concentrations DDX1 is saturated with RNA (see section 3.3.7). Three 
different RNAs were tested for their influence on DDX1 nucleotide binding (Figure 3.3.7). The 10mer 
polyA RNA and the 13mer RNA of random sequence[157] as mentioned before (see section 3.3.3) and a 
20mer RNA of random sequence (see methods for sequences, section 2.3.9). 
In the following text, to account for the ternary system of ATP and RNA binding to DDX1, the respective 
molecule that is present at saturating concentrations will be indicated in parentheses and subscript 
next to the given affinity constant. 
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Figure 3.3.7 RNA dependent nucleotide binding.  A, equilibrium titration experiments where 0.05 μM mant-dADP were titrated 
with DDX1 protein in the presence of saturating amounts (28 μM) of 10mer polyA RNA (circles) or 13mer random sequence RNA 
(squares) are shown. B, competition experiments in the presence of saturating amounts of the same RNAs are shown. For the 
experiments a complex of 0.2 μM mant-dADP and 1 μM DDX1 was titrated with ATP in the presence of an ATP-regeneration 
system. Titration data were fitted as described for figure 3.3.4 and corresponding rate constants are shown in table 3.4. Residuals 
from the fits (i.e. Δy between fit and actual data) are shown beneath the plots, where the y-axis represents 10 % of the binding 
amplitude. 
 
The affinity for mant-dADP remained unchanged by any of the three tested RNAs (Table 3.4). In 
contrast, the affinity for ATP was increased ~ 20 fold from an RNA-free Kd,ATP = 129±26 μM to a 
Kd(RNA),ATP (RNA-saturated) = 5.0±0.8 μM (Table 3.4). The propensity to stimulate ATP binding was 
identical between different RNAs tested (Figure 3.3.7 b). Notably, even in the presence of RNA with 
increased ATP affinity, the apparent ATP affinity is still 50 times lower when compared to that for ADP. 
Again in consideration of the results from ATP hydrolysis, this Kd(RNA),ATP value has to be interpreted with 
care, since it could be influenced by an enzyme that is mostly ADP bound under steady-state conditions 
(-> see discussion 4.2.1). 
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3.3.7 Quantification of RNA affinity by spectroscopic methods 
A minimal binding scheme that describes the transitions between the different nucleotide bound states 
of DDX1 was defined (Figure 3.3.8). This binding scheme helps to interprete the relationship between 
the affinity constants, obtained in the spectroscopic measurements. 
 
 
Figure 3.3.8 Scheme for nucleotide binding to DDX1. A minimal binding scheme for binding of ATP or mant-dADP (=mant) to 
the DDX1 helicase. This scheme was used to establish the relationships between the affinity constants and later on for global 
fitting of all titration data. The global fit according to this scheme allowed to obtain the affinities for RNA, Kd,RNA and Kd (ATP),RNA.(see 
table 3.4 and figure 3.3.9). 
 
So far, data for characterization of the dissociation constants of RNA in the minimal binding scheme are 
yet lacking. Initially, binding of RNA to DDX1 was observed in the EMSAs (see section 3.3.3) and different 
spectroscopic assays were used in attempts to quantify the binding affinity. However, all conventional 
approaches such as steady-state titration experiments with labeled RNA or labeled protein as well as 
FRET experiments with labeled Cys residues and via intrinsic Trp fluorescence or fluorescence 
anisotropy experiments failed to provide a signal for oligonucleotide binding to DDX1. Thus, the 
fluorescent mant-nucleotides were used in a more elaborate experimental setup. The complex of DDX1 
with mant-dADP was pre-assembled and ATP was added at low concentrations, where it partially 
displaces the complex. In a next step, the experimental acquisition was started by titrating RNA that 
binds to DDX1, promotes further ATP binding (probably by inducing the transition to the “closed”-state 
of DDX1, see section 4.2.1) and thereby leads to further mant-dADP displacement. Following this 
experimental approach RNA binding could be monitored by a decrease in mant-dADP fluorescence. 
RNA titrations were performed at different ATP concentrations (Figure 3.3.9). Although these data do 
not instantly provide affinity values for RNA, together with the data from previous titrations they were 
included in a global fit analysis based on the minimal binding scheme (Figure 3.3.8). Global fitting was 
done by numeric iteration using the software Dynafit[198, 199] (Figure 3.3.9 and suppl. Figure 7.1.13, see 
appendix Section 7.8 for the script file). 
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Figure 3.3.9 Global fit of RNA titrations to obtain the RNA affinity of DDX1. A, titration experiments to access RNA affinity are 
shown. Complexes of 1 μM DDX1, 0.2 μM mant-dADP and either 50 (circles), 100 (squares), 200 (triangles) or 400 μM (inverted 
triangles) ATP were titrated with 10mer-polyA-RNA. Titrations were conducted in the presence of an ATP-regeneration system. Fits 
that are shown were obtained by global numeric iteration using all previously measured titration data in the program Dynafit 
(BioKin Ltd., Watertown, MA). Residuals from the fits are shown beneath the plots. The affinities for RNA, Kd,RNA and Kd (ATP),RNA were 
obtained in the global fit and are shown in table 3.4. B, correlation between globally fitted values of selected affinity constants is 
shown. Affinity constants that are correlated are plotted on the x- and y-axis of each graph. The z-axis gives the number of counts 
for each individual correlation. This number of counts describes the convergence in the fit of the two parameters that were 
correlated. For the confidence intervals of individual kinetic parameters see suppl. figure 7.1.13. 
 
The optimized kinetic paramters, obtained from the global fit analysis, finally allowed to access the 
dissociation constants for RNA. DDX1 showed an RNA affinity with a Kd,RNA = 12.41±2.75 μM for RNA 
binding to nucleotide free- or mant-dADP bound DDX1. RNA binding to the ATP-bound form of DDX1 
was determined to be tighter with a Kd(ATP),RNA = 0.136±0.020 μM (Figure 3.3.9, Table 3.4). These Kd values 
for RNA binding contain important information on the difference between the RNA affinities of the ATP-
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bound form of DDX1 versus the nucleotide free form. The ratio between the two RNA affinities gives a 
~90 times tighter binding of RNA to the DDX1-ATP-form.  
Interestingly the Kd values for ATP binding to DDX1, obtained in the global fit, were slightly different to 
the values determined in the equilibrium titrations (Kd,ATP = 129 μM, Kd,(RNA),ATP = 5 μM, see section 3.3.6). 
Whereas ATP binding to the apo form of DDX1 was similar as before (Kd,ATP = 124 μM), ATP binding to the 
RNA bound form of DDX1 was determined to be tighter (Kd,(RNA),ATP = 1.4 μM, also see suppl. table 7.2).  
According to the minimal binding scheme (Figure 3.3.8), it follows that 
ATPRNAdRNAdRNAATPdATPd KKKK ),(,),(,      ..ei     
RNAATPd
ATPRNAd
ATPd
RNAd KK
K
K ),(
),(
,
,   [Equation 15] 
 so the ratio of the ATP-affinities would also predict a ~ 90 times tighter binding of RNA to the DDX1-
ATP-form, when using the Kd values from the global fit. When the ATP affinities, obtained from the 
equilibrium titrations are used, only a ~ 24 times tighter binding of RNA to the DDX1-ATP-form is 
calculated. The difference in the Kd values could be caused by small variations in the actual experimental 
concentrations that, however, have a large influence on the global fit. They could also result from a 
slightly incorrect determination of Kd for ATP by the equilibrium titration experiments as mentioned 
before. 
 
Notably, when the same RNA titration experiments were performed in the presence of ADP instead of 
ATP (at ADP concentrations that lead to partial displacement of the mant-dADP – protein complex) the 
mant-fluorescence spectrum was unchanged (suppl Figure 7.1.14). This confirms the previous results 
from the equilibrium titrations in which RNA did not influence ADP binding (section 3.3.6) and further 
supports the assumption that ADP and RNA binding to DDX1 are not coupled. 
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Table 3.4. nucleotide binding affinities of DDX1 
 Molecules in subscript and parentheses next to an affinity constant indicate the respective molecule that is present at  
 saturating concentrations. The errors represent the standard error from the fits.”+” means addition of a molecule, “-“ 
 means the experiment was performed without the molecule. 
* please note that the Kd values for ATP measured via equilibrium titration have to be carefully interpreted, since - in conclusion from the 
ATPase data - they might be influenced by a fraction of DDX1 that is always ADP bound(see discussion section 4.2.1) 
mant-ADP binding    
Kd,mantADP 0.124 ± 0.017 μM 
Kd,mantADP (K52A) 31.4 ± 4.9 μM 
    
ADP binding    
Kd,ADP 0.116 ± 0.034 μM 
    
ATP binding*    
Kd,ATP 129.3* ± 25.8 μM 
 
 
 
 
transient kinetics 
mant-ADP binding    
kon,mantADP 0.954 ± 0.120 μM-1s-1 
koff,mantADP 0.1530 ± 0.0004 s-1 
-> Kd,mantADP (calculated ratio) 0.160 ± 0.021 μM 
    
mant-dADP binding    
kon,mantdADP 0.817 ± 0.043 μM-1s-1 
koff,mantdADP 0.0740 ± 0.0001 s-1 
-> Kd,mantdADP (calculated ratio) 0.091 ± 0.005 μM 
 
 
 
 
RNA dependent nucleotide binding 
mant-dADP binding (+RNA)    
Kd(RNA),mantdADP 0.095 ± 0.019 μM 
    
ATP binding (+RNA)*    
Kd(RNA),ATP 5.04* ± 0.79 μM 
 
 
 
 
RNA binding 
RNA binding (-ATP)    
Kd,RNA 12.41 ± 2.75 μM 
    
RNA binding (+ATP)    
Kd(ATP),RNA 0.136 ± 0.020 μM 
 
Of note, the global fit included the RNA titration- as well as all previous titration data. These previously 
determined binding affinities for (mant-) ADP/ATP were not included as fixed parameters, moreover the 
original primary titration data were used. In this approach these data were fitted numerically in contrast 
to the analytical fitting methods that were applied before (see figure 3.3.4 – 3.3.7). With exception of 
the described variance in Kd,(RNA),ATP, numerical and analytic fitting resulted in similar values for the kinetic 
parameters, showing robustness of the global fit (see suppl. table 7.2). 
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Enzymatic function of DDX1 
 
3.3.8 ATPase activity of DDX1 
DEAD-box helicases, like all other P-loop containing proteins, do hydrolyze ATP[200], though the energy 
of ATP hydrolysis is most probably not directly required for RNA remodeling and unwinding[73]. 
Although all DEAD-box helicases share the common RecA-like core fold, they show significant variation 
in hydrolysis rates between different orthologs[56].  
Recombinant DDX1 exhibits an intrinsic ATP hydrolysis activity that was observed in a coupled ATPase 
assay[161] (suppl. Figure 7.1.16). This ATPase activity could be specifically attributed to DDX1 by 
measuring the apparent ATPase rate of the DDX1 K52A mutant. This K52A variant is abolished in its 
enzymatic activity, excluding that the observed activity of WT protein arose from potential 
contaminantions (suppl. Figure 7.1.15). 
A minimal reaction scheme for ATP hydrolysis by DDX1 was established that includes a potential 
conformational change of the enzyme to an active conformation (Figure 3.3.10). 
 
 
 
Figure 3.3.10 Minimal reaction scheme for ATP hydrolysis The enzyme (=E) DDX1 binds its substrate (=S) ATP, a process defined 
by the affinity constant Kd. The substrate bound complex (=ES) undergoes a potential conformational change to an activated 
conformation (=ES*). Then ATP is hydrolyzed (described by kcat) and the product (=P) ADP is slowly released, due to the high ADP 
affinity of DDX1. In the classical Michaelis-Menten analysis all steps that lead from the enzyme-substrate complex (ES) to the 
enzyme product released state (E+P) are represented by the apparent rate constant k2 (depicted in grey). Classically, it is assumed 
that dissociation of EP is fast and can be ignored in the forward reaction. For simplicity the influence of RNA was not incorporated 
in the scheme. 
 
The apparent rate of ATP hydrolysis at different ATP concentration was measured under conditions of 
excess ATP over protein. Initial reaction velocities of individual hydrolysis traces at different ATP 
concentrations were fitted to the hyperbolic Michaelis-Menten-equation (Equation 6, Figure 3.3.11 a). 
An apparent Km,ATP = 1.75±0.33 mM was obtained, a value that is similar to the reported Km for DDX1[135]. 
Notably, the determined Km,ATP for ATP is ten times higher when compared to the Kd,ATP for ATP, 
suggesting that binding is not rate limiting and substrate turnover and subsequent release have an 
essential influence on the reaction velocity. Thus, Km,ATP would not be a simple measure for the ATP 
affinity (defined by koff,ATP / kon,ATP = Kd,ATP), but be influenced by all further processes leading to product 
formation and release (k2 in Figure 3.3.10, i.e. (koff,ATP +k2) / kon,ATP = Km,ATP). This is in good agreement with 
the fact that the reaction product is ADP, which is bound much more tightly than ATP.  
The maximal apparent hydrolysis rate kcat(ATP) = 0.096±0.005 s-1 (at saturating ATP) that was determined is 
low, but still within the lower range of what has been reported as intrinsic, i.e. unstimulated activity for 
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other DEAD-box proteins[201]. Strinkingly, this hydrolysis rate kcat(ATP) is almost equal to the off-rate 
koff,mantADP for mant-ADP and the predicted off-rate koff,ADP for ADP (as estimated from the values for mant-
ADP, see section 3.3.5). This suggests that ADP product release (koff,ADP) is the rate-limiting step and the 
actual kcat(ATP) for ATP hydrolysis might be higher (compare kcat and koff,P in Figure 3.3.10), but is not 
detected in the coupled assay that only monitors free ADP. 
 
 
Figure 3.3.11 ATPase activity of DDX1.  A, ATP concentration dependence of the intrinsic steady-state ATPase rate per molecule 
DDX1 is shown. For the assay 1 μM DDX1 was incubated with the respective concentrations of ATP-MgCl2 and initial reaction 
velocities = maximal rates (per min) were plotted. These apparent rates were fitted to the hyperbolic form of the Michaelis-
Menten equation. B, RNA concentration dependence of the ATPase rate, fitted with the quadratic equation (Equation 7). 1 μM 
DDX1 was incubated with indicated concentrations of a 20mer RNA in the presence of 2 mM ATP-MgCl2. Residuals from the fits 
(i.e. Δy between fit and actual data) are shown beneath the plots, where the y-axis represents 10 % of the maximal reaction rate. 
 
 
Different short ssRNAs were used to stimulate DDX1 ATPase activity. Stimulation of the hydrolysis rate 
did not differ for RNAs ranging from 10 to 20 nucleotides in size and which had a different sequence 
(suppl. Figure 7.1.16). When the stimulation of hydrolysis by tRNA was tested, a ten times higher 
concentration was required to achieve the same stimulatory effect as with unstructured ssRNA (suppl. 
Figure 7.1.17). Additionally, ssDNA did not influence ATPase activity (suppl. Figure 7.1.16).  
A 20mer ssRNA (for sequence see materials and methods section 2.3.9) was used to determine the RNA 
concentration dependent stimulation of the ATPase rate under conditions of saturating (10 mM) ATP-
MgCl2 concentrations. Unexpectedly, a stimulation of the initial reaction velocity by RNA titration was 
not observed under those conditions. The maximal ATPase rate measured at 10 mM ATP-MgCl2 in the 
presence of different RNA concentrations was the same as in the absence of the RNA (suppl. Figure 
7.1.18) and Michaelis-Menten curves could not be measured. Therefore, RNA concentration dependent 
stimulation of ATPase activity was measured at 2 mM ATP-MgCl2, which corresponds approximately to 
the Km,ATP of unstimulated DDX1. Under those conditions, ATP hydrolysis could unambigiously be 
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measured in dependence of the concentration of the 20mer ssRNA with an apparent Km,RNA  (at 2 mM 
ATP-MgCl2) = 87.2±11.9 nM (Figure 3.3.11 b, Table 3.5). The maximal apparent hydrolysis rate obtained 
by RNA stimulation, kcat(RNA) = 0.11±0.0028 s-1 (at saturating RNA), is highly similar to kcat(ATP) , the maximal 
apparent hydrolysis rate at ATP saturation in the absence of RNA. A possible explanation for this finding 
is that RNA promotes ATPase activity solely by stimulating ATP binding, but not hydrolysis. Another 
possibility is that the reaction is limited by ADP release, as suggested before, and a higher kcat(RNA) can 
not be detected, since only released ADP is monitored in the assay. 
 
Under conditions of saturating RNA concentrations (40 μM), the maximal apparent hydrolysis rate was 
observed at all ATP concentrations within the concentration range of the experiments (0.5 – 10 mM 
ATP-MgCl2, suppl. Figure 7.1.19). This finding is in line with the significantly increased ATP affinity in 
the DDX1-RNA complex. (see section 3.3.6) Thus, it seems that ATP and RNA mediated effects on ATP 
hydrolysis by DDX1 are tightly coupled. 
 
 
Table 3.5. ATP hydrolysis activity of DDX1 
 Parantheses indicate the respective molecule that is present under saturating conditions. The errors represent the 
  standard error from the fits.    * at 2 mM ATP-MgCl2 
ATP titration    
Km,ATP 1.75 ± 0.33 mM 
kcat(ATP) 0.096 ± 0.005 s-1 
    
RNA titration *    
Km,RNA  87.2 ± 11.9 nM 
kcat(RNA) 0.110 ± 0.003 s-1 
 
 
 
 
3.3.9 Helicase activity of DDX1 
DDX1 harbors the signature motifs of an RNA-helicase (Figure 3.1.1) and to test for a potential helicase 
activity, an unwinding assay was established.  Initially up to 41 nucleotides long DNA/RNA-hybrids were 
used as substrate that have been used in studies of the helicase activity of DDX1 before[111]. 
Fluorescently (either FAM or Fl) labeled DNA oligonucleotides were annealed to RNA oligonucleotides 
to generate hybrid substrates. These hybrid substrates were incubated with DDX1 in the presence of 
nucleotides. Separation of the fluorescently-labeled from the unlabeled strand by a putative DDX1 
helicase activity was analyzed by electrophoresis on native acryl-amide gels. To avoid immediate re-
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annealing of separated strands, an excess of unlabeled competitor DNA was included in the reaction 
(Figure 3.3.12 a). Double-stranded and single-stranded substrate could clearly be separated on the gel. 
Incubation of the double-stranded substrate with DDX1 either in the absence of nucleotide or in the 
presence of ATP or ADP did not result in species, corresponding to single-stranded substrate (Figure 
3.3.12 a). Instead, a shift of the fluorescencently labeled species to the gel-pockets could be observed 
upon incubation with DDX1. Staining of the acryl-amide gel with InstantBlue® showed that the protein 
is retained in the gel-pockets (suppl. Figure 7.1.20). This means that a fraction of the DNA/RNA 
substrate is complexed with DDX1, therefore trapped in the gel-pockets and does not migrate into the 
gel. Please note that buffer and running conditions were optimized for a proper separation of ssRNA 
and dsRNA in the experiment and that these conditions are incompatible with the EMSA conditions (see 
section 3.3) that would have allowed the protein to properly migrate into the gel. 
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Figure 3.3.12 DDX1 helicase displacement assay. A, a solution of 20 μM DDX1-728 was incubated with 10 mM nucleotides and 
0.25 μM DNA/RNA substrate as indicated. Reactions were incubated at 310 K for 60 min and then separated on a 15 % TBE-gel. To 
avoid re-annealing of unwound substrate a 400 fold excess of unlabeled competitor DNA was included in the reactions. DNA/RNA 
substrate was designed according to Li, Monckton and colleagues 2008[111] B, a solution of 10 μM DDX1-728 was incubated with 
10 mM nucleotides and 0.25 μM DNA/RNA substrate as indicated. Reaction conditions were as in A. Black smear marked with * is 
an artifact of the dye used for gel-loading. DNA/RNA substrate was designed according to Jankowsky and colleagues, 2008[157]. 
 
To exclude that DNA/RNA substrate unwinding deficiency of DDX1 is due to long stretches of paired 
nucleotides and processivity issues, a substrate with a shorter duplex region and a single-stranded RNA 
overhang was designed, according to Jankowsky and colleagues 2008[157]. This substrate was incubated 
with DDX1 and different nucleotides (Figure 3.3.12 b). No unwinding activity could be observed. 
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Similarly to experiments with long substrates, the labeled species was retained in the gel-pockets, 
together with the protein (suppl. Figure 7.1.20). 
 To complement the helicase studies, in addition to the DNA/RNA hybrids, a dsRNA was used for the 
unwinding assay (Figure 3.3.13).  
 
 
Figure 3.3.13 DDX1 helicase assay with dsRNA substrate. A solution of 10 μM DDX1-728 was incubated with 10 mM nucleotides 
and 0.5 μM dsRNA substrate as indicated. DED1, a DEAD-box protein from yeast that is involved in translation initiation and is 
supposedly active as a RNA helicase on short substrates, was included as a positive control[59] (suppl. Figure 7.3.12 (DED1 
purification) and suppl. Figure 7.1.21 (DED1 helicase activity). For a negative control with the DED1 protein, see suppl. 
figure 7.1.20. Reactions were incubated at 310 K for 60 min and then separated on a 15 % (w/v) TBE-gel (pH 8.3). * marks an artifact 
of the dye used for gel-loading. The dsRNA substrate was designed according to Jankowsky and colleagues, 2008[157]. 
 
DDX1 was unable to unwind dsRNA substrates, but did bind them, evident through the fluorescence 
signal of a dsRNA/protein complex that was retained in the gel-pockets. In contrast, when the dsRNA 
was incubated with the yeast DEAD-box protein DED1 no substrate shift to the gel-pocket was 
observed. DED1 did unwind the duplex substrate (Figure 3.3.13).  
In conclusion, the results from the unwinding assays show that recombinant DDX1 is unable to unwind 
short RNA/RNA and RNA/DNA duplexes under the buffer and reaction conditions used. In contrast, the 
homologous yeast DEAD-box protein DED1 was active under the given conditions. However, a general 
functional deficiency of recombinant DDX1 is unlikely as the protein was proven to be activity as an 
ATPase (Figure 3.3.11) and due to the cooperative binding of RNA and ATP (see section 3.3.6). 
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3.3.10 Summary of the functional studies 
The results of the functional characterization of DDX1 revealed its unique enzymatic properties. DDX1 
did exhibit an ATP affinity in the range of other DEAD-box proteins, but showed one of the highest ADP 
affinities to be ever reported. The affinity for ADP was higher by a factor of more than 1000 when 
compared to the affinity for ATP, but ATP affinity was stimulated by RNA binding. However, even in the 
RNA bound form the affinity of DDX1 for ATP was 50 times lower than the affinity for ADP.  
Data sets from different spectroscopic titration experiments were combined in a global fit to access the 
RNA affinites of DDX1. In accordance with cooperative binding of RNA and ATP, an increased RNA 
affinity was obtained for the ATP bound form of DDX1. DDX1 was enzymatically active as an RNA 
stimulated ATPase, though, it showed a deficiency in its potential DEAD-box specific helicase activity. 
RNA stimulated ATPase activity further substantiated cooperativity in RNA and ATP binding. 
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4. Discussion 
In this thesis the novel human DEAD-box protein DDX1 was characterized both structurally and 
functionally. This discussion is therefore splitted in three major parts. It starts with the structural 
characterization of the SPRY domain and its role in the context of the entire DDX1 protein. Then the 
functional characterization of DDX1 is discussed. Finally a conclusion is drawn from the presented 
results and an outlook on future developments is given. 
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4.1 Structural studies 
 
The SPRY domain structure – a modular interaction platform 
within DDX1 
 
This work reports the structure of the SPRY domain of DDX1. The SPRY domain is a unique feature of the 
otherwise canonical DEAD-box helicase DDX1. The SPRY domain adopts a compact β-sandwich 
conformation and constitutes a modular interaction domain. In this section, the putative interaction 
surface and the role of the domain for the function of DDX1 will be discussed. Two putative scenarios 
for substrate binding to the SPRY domain are conceivable. It could directly mediate the interactions of 
DDX1 with other proteins or it could also enhance the RNA binding surface of DDX1.  
 
4.1.1 Overall structure of the DDX1 SPRY domain reveals differences to other SPRY 
domains 
The structure of the SPRY domain of DDX1 revealed the conventional SPRY fold[98], consisting of two 
layers of concave shaped β-sheets that stack together (Figure 3.2.3). Previous structural studies on 
SPRY domains have identified loops, which connect both β-sheets on one side of the domain as the 
canonical interaction surface A[101, 105]. In close proximity to these canonical interaction loops, in the SPRY 
domain of DDX1 a patch on the β-strand surface was identified that is positively charged and highly 
conserved. This surface region was therefore entitled extended surface A (Figure 3.2.9). Considering 
the overall structure of the SPRY domain of DDX1, the closest structural homolog is the SPRY domain 
from Ash2L[107], despite bearing low sequence similarity. Ash2L plays a critical role in the regulation of 
histone methyltransferases by interacting with components of the MLL protein family[202]. As the 
function of Ash2L in activating histone methylation is distinct from the cellular activities known for 
DDX1[110-112, 135], one can not deduce similarities in the proteins that interact with the respective SPRY 
domain. Indeed, whereas the core structure is almost identical, the loops that form interaction surface A 
show significant differences in their conformation and their length between the two proteins (Figure 
3.2.6). Similarly, comparison of DDX1 SPRY with SPRY domains of SOCS box proteins (SPSB) in complex 
with interacting peptides[101, 105] revealed highest divergence in the peptide binding loops of surface A. 
Although a peptide interaction region within the DDX1 SPRY domain has not been determined, the 
binding mode must be different, if the conventional peptide binding region is used at all. Taking a 
closer look at two SPRY domain structures for which protein-protein interations have been reported in 
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the literature[107, 203], further suggests that a putative interaction region within the DDX1 SPRY domain 
might differ and may not include the canonical interaction loops after all. 
The first example is the Ash2L-SPRY domain, where five residues have been identified via site-directed-
mutagenesis that are essential for the interaction with the protein RbBP5[107]. Based on this finding, the 
region encompassing the five residues has been suggested to be an RbBP5 binding pocket. This 
binding pocket, however, is not found in DDX1-SPRY. 
The second example is the SPRY domain of the protein Trim5α. A number of structures of more distantly 
related SPRY domains of Trim (Tripartite motif) proteins have been reported[203-208]. Trim proteins 
regulate the innate immune response to infection and the SPRY domain of Trim5α restricts HIV-1 
infection by binding to the retrovirus capsid[203, 207]. Comparison of the structure of the SPRY domain of 
Trim5α (PDB entry 2LM3[203]) with DDX1 SPRY (Z-Score of 13.2, overall rmsd of 2.3 Å for the alignment of 
140 residues[192]) revealed largest structural differences in the loop between β3 and β4 (Figure 4.1.1). 
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Figure 4.1.1 Comparison of DDX1 SPRY with the distantly related SPRY domain of Trim5α The superposition of DDX1 SPRY 
with Trim5α SPRY[203] as obtained from the DALI server[192] is shown. Both proteins are depicted in ribbon representation. DDX1 
SPRY is depicted in green and Trim5α SPRY is depicted in blue. The region of highest divergence, the loop connecting β-strands 3 
and 4 (referring to DDX1) is indicated by more intense color shading and labeled v1 loop. For the NMR structures of Trim5α SPRY 
loop v1, the different states i.e. models in the ensemble are indicated by differentially colored ribbon chains. The ten lowest 
energy conformations calculated using NOE restraints[203] are shown. 
 
Whereas in the DDX1 SPRY structure this loop could be modeled unambiguously into the electron 
density, in the SPRY domain of Trim5α the loop, designated v1 (for variable loop 1), was found to be 
highly flexible and was not be resolved in the crystal structure[203, 207]. In the DDX1 SPRY structure the 
equivalent loop contacts the solvent and has low B factors, excluding that its rigid conformation is a 
crystallization artifact. In Trim5α several different conformations of loop v1 (which in Trim5α comprises 
30 residues) could be determined via NMR measurements [203]. The different conformations of the 
mobile v1 loop confer structural plasticity, which may allow interaction with multiple epitopes[203, 209]. In 
contrast to all Trim SPRY structures, such a modular v1 loop – like structural adaptation to interaction 
partners is unlikely for DDX1 SPRY, since the corresponding v1 loop is short (five residues) and rigid 
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(Figure 4.1.1). Of note, similar to DDX1, in Trim5α an anti HIV-1 function (distinct from capsid binding) 
could be mapped to the SPRY domain, however, in contrast to DDX1[136] this HIV-1 restrictive function is 
unknown[210]. 
 
 
 
 
4.1.2 The SPRY domain might influence the enzymatic activity of DDX1 due to its 
central position within the helicase core 
To enable a glimpse on the DDX1 protein in its entirety, the SPRY domain crystal structure was placed in 
a homology model of the helicase core. In other P-loop containing proteins, additional domains can 
regulate enzymatic activity by interaction with P-loop motifs[211, 212]. Such regulation has specifically 
been reported for kinases[213, 214] and GTPases[211, 215]. Furthermore, a lid subdomain covers the ATP 
binding site in the kinase group of P-loop containing proteins, which is not present in the RecA 
group[212]. In the conformation of the homology model, the SPRY domain would neither show a kinase 
or GTPase like interaction with the P-loop, nor would it form a lid (as in the kinase group) and sterically 
block ATP or RNA substrate binding (Figure 3.2.11). Nevertheless, the SPRY domain could still influence 
enzyme catalysis, since it is directly connected to the P-loop (containing the essential catalytic Walker A 
motif) with its N-terminal linker and to the strand that precedes motif Ia (involved in RNA binding) with 
its C-terminal linker, suggesting that it may be involved in communication between the ATPase site and 
the RNA binding surface. It has been speculated that such a signaling task is performed by the the 
conserved helicase motif III in other DEAD-box proteins[30, 216, 217]. However, the exact functional 
contribution of motif III is a matter of debate in the field as mutations in the conserved motif III 
sequence showed different effects in various DEAD-box proteins[30, 216, 218, 219]. In DDX1, the SPRY domain 
could support motif III or even take over its function. The direct linkage of the essential motif for ATP 
hydrolysis with an RNA binding motif in DDX1 would facilitate the transduction of potential allosteric 
signals[220, 221] via the SPRY domain between the catalytically important residues (Figure 4.1.2). 
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Figure 4.1.2 Putative communication pathways between conserved helicase motifs and the SPRY domain. The DDX1 
homology model is depicted in the same orientation as in figure 3.2.11, but a zoom-in on RecA-like domain 1 and the SPRY 
domain is shown. Conserved motifs I and II (Walker A and B) essential in ATP binding and hydrolysis are colored in red, motif Ia 
involved in RNA binding is colored in yellow. Residues that directly connect motif I and motif Ia to the SPRY domain are depicted 
in grey. Residues of interaction surface A are depicted in dark blue, residues of extended surface A in light blue. Red lines indicate 
the linkage of the SPRY domain to RecA-like domain 1. Black arrows indicated the course of the peptide strand from N- to C-
terminus. RecA-like domain 1 is colored in green, the SPRY domain in brown. ATP and RNA are depicted as sticks and were placed 
in the model according to their positioning in the structure of VASA (PDB entry 2DB3 [31].  
  
Facilitated by a potentially flexible linkage to the rest of the protein, the SPRY domain may alter its 
orientation upon transition between the different helicase states (suppl. Figure 7.4.1). For instance, in 
the “closed”-state of DDX1 the SPRY domain could enlarge the RNA binding surface on top of the two 
RecA-like domains. It may act as an extension of RecA-like domain 1 and support motifs Ia, Ib and Ic in 
RNA binding. A similar function has been observed for the C-terminal extension of yeast Mss116p, but in 
this DEAD-box protein the RNA binding surface of RecA-like domain 2 is extended[35]. The potential 
function of the SPRY domain in RNA binding is discussed in detail in section 4.1.5.  
 
Extended insertion domains can also be found in other RNA helicases. In the structures of S. cerevisiae 
Mtr4 and Ski2 a large helical bundle is present at the C-terminus that is connected to the helicase core 
via a stalk containing β-barrel[222, 223]. These insertions constitute RNA binding domains, but are 
dispensable for the function of the helicase[222]. In contrast, the SPRY insertion domain in DDX1 is not 
protruding at the N- or C-terminus, but is positioned directly within the helicase core (Figure 3.2.11 c). 
It is therefore plausible that the SPRY domain insertion directly influences the helicase activity of the 
enzymatic core. Construct DDX1ΔSPRY, lacking the SPRY domain, displayed functional deficiencies in 
ATP hydrolysis, but it is unclear so far, whether they were caused by aggregation of the recombinant 
protein or do have a functional significance (see appendix, section 7.3.6).  
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The homology model shown here (Figure 3.2.11), represents the “open”-state of DDX1, where the two 
RecA-like domains are flexible in their relative orientation to each other and are separated in space[224]. 
In this conformation, surface A and the region entitled extended surface A would both be freely 
accessible, suggesting that they could bind to putative interaction partners and thereby bring them in 
proximity to RecA-like domain 1 (Figure 3.2.11). The interaction of SPRY domains with other proteins 
will be discussed in the following two sections.  
 
 
4.1.3 SPRY domains interact with DEAD-box helicases 
Interestingly, reports are accumulating that show an interaction of SPRY domain containing proteins 
specifically with DEAD-box helicases[100, 225-227]. The best characterized example is the SPRY domain of 
D. melanogaster GUSTAVUS that interacts tightly with the DEAD-box RNA helicase VASA[100] (Figure 
3.2.6). The SPRY-DEAD-box interaction is intriguing in comparison to DDX1, which is a DEAD-box 
helicase with a “built-in” SPRY domain. As the VASA 20-residue-interaction stretch is not conserved in 
DDX1, the helicase is most probably not able to bind to its own SPRY domain via surface A (Figure 
3.2.9). In VASA the SPRY interaction sequence (comprising residues 184-203) is located in an N-terminal 
extension outside of the DEAD-box helicase core[44, 100]. As the structure of the VASA helicase only 
contains residues 202-621[31], there is no structural information of the SPRY interaction region in the 
context of the entire DEAD-box protein. Recent studies with the sea urchin Strongylocentrotus 
purpuratus GUSTAVUS protein suggested that it has two binding sites on S. purpuratus VASA and in 
addition to the binding site at the N-terminal extension, it also interacts with the DEAD-box core[228]. 
Mutational analysis indicated that S. purpuratus GUSTAVUS may interact with the N-terminal extension 
and the DEAD-box core of VASA independently through two separate binding surfaces[228]. 
Other recently identified SPRY-mediated protein-protein interactions include the helicases DDX41[225] 
and RIG-I [226, 227]. The SPRY domain of the E3 ubiquitin ligase TRIM21 interacts directly with RecA-like 
domain 1 of DDX41[225]. Only the core elements of RecA-like domain 1 of DDX41 are necessary for this 
interaction and extensions are dispensable[225].  
The SPRY domain of the protein TRIM25, implicated in innate immunity signalling, interacts with the 
CARD-1 domain of the SF2 helicase RIG-I[206, 226, 227]. 
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Figure 4.1.3 Scheme for the interaction of an SPRY domain with the DEAD-box helicase core. For several helicases a protein-
protein interaction with SPRY-domain containing proteins has been shown. In these cases the SPRY domain (brown) interacts with 
the helicase core. DDX1 is a DEAD-box protein with a ‘built-in’ SPRY domain that could potentially interact with RecA-like 
domain 1 and thereby regulate enzymatic activity. RecA-like domains 1 (green) and 2 (blue) are drawn as spheres, connected by a 
short linker. Conserved helicase motifs, involved in ATP hydrolysis and in RNA binding are highlighted in orange. Note that the 
SPRY domain of DDX1 is connected to RecA-like domain 1 via a flexible linker. 
 
The implications of the interaction of SPRY domains with helicases have not been investigated so far 
and interaction sites have not been mapped in detail. The only exception is D. melanogaster VASA, 
where a 20-residue peptide, corresponding to the motif at the N-terminal extension that interacts with 
the SPRY domain has been structurally characterized[101] (Figure 3.2.6 b and d, Figure 3.2.7 b). 
However, the second interaction motif within the helicase core has not been identified yet. Also in other 
DEAD-box proteins, the region in the helicase core, responsible for the protein-protein interaction with 
SPRY domains has remained elusive.  
In DDX1 two scenarios for the role of the SPRY domain with respect to its potential interaction with the 
helicase core are conceivable. Firstly, DDX1 might have acquired the SPRY domain from one of its 
interaction partners by domain swapping during evolution. A domain swap could rescue a specific 
function that was lost by mutation[229] or regulate protein folding and aggregation[230]. Secondly, it could 
also be possible that the SPRY domain insertion serves a helicase regulating function. Instead of 
recruiting protein factors, it may interact with the DDX1 helicase core that is in immediate proximity on 
the same polypeptide chain (Figure 3.1.1). This may constitute an auto-regulatory mechanism (Figure 
4.1.3). Future experiments will be directed on the exact influence of this domain on DDX1 activity. If it is 
possible to extract details from the mechanism of the intramolecular “SPRY domain – DDX1 helicase 
core” interaction and regulation, this would greatly advance the understanding of other DEAD-box 
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proteins. Since DDX1 represents a unified SPRY-helicase in one polypeptide chain, it is an ideal model 
for studying the so far unknown relationship between SPRY domains and DEAD-box helicases. A 
detailed description of the helicase core - SPRY interaction region has to wait until structural 
information on full-length DDX1 are available, but details on the protein-protein interaction site of the 
DDX1 SPRY domain are discussed in the following. 
 
 
4.1.4 A conserved SPRY surface patch as a potential protein-protein interaction region 
In addition to their specific interaction with DEAD-box proteins in some cases, SPRY domains have 
generally been described as protein-protein interaction platforms[98, 99]. It is plausible that the SPRY 
domain within DDX1 also mediates interactions of the helicase with other proteins. Specifically the fact 
that DDX1 is found in the multi-protein HSPC117 complex[108, 114] implies that protein-protein 
interactions have to be formed, which may involve the SPRY domain. 
In DEAD-box helicases the relative orientation of the two RecA-like domains is crucial for the activity[31, 
36], but is modulated by protein-protein interactions of the helicase core. Prominent examples include 
eIF4AIII in the exon junction complex (EJC)[23, 24] and Dbp5 in the nuclear pore complex (NPC)[25, 231] that 
both alter their conformation upon binding of interaction partners to the helicase core. In contrast to all 
other DEAD-box proteins, DDX1 harbors the additional SPRY domain. This domain may establish 
protein-protein interactions independent of the two RecA-like domains of the helicase core. Such a 
mechanism would allow the RecA-like domains that are not involved in the interaction, to freely adopt 
different conformations and for the helicase core to perform its catalytic function unaffected by the 
interactions. This furthermore suggests, that inclusion of the SPRY interaction module might have 
equipped DDX1 with the possibility to interact with other proteins irrespectively of the conformational 
state of the helicase core (“open”- or “closed”-state), since it would simply not be involved in the SPRY 
domain – protein interactions. Supporting the role of the DDX1-SPRY domain in mediating protein-
protein interactions, in studies, where specific fragments of DDX1 have been shown to interact with 
other proteins[93, 109, 110] (also see suppl. Figure 7.6.1), those peptide fragments always comprised the 
SPRY domain. 
 
Structural comparison of the DDX1-SPRY domain with other SPRY domain structures has indicated 
differences in the canonical protein-protein interaction loops (see section 4.1.1). At a closer inspection 
of the sequence of the interaction loops, a difference in a putative DDX1-SPRY interaction surface 
becomes even more apparent. Notably, binding studies on other SPRY domain containing proteins 
have shown that protein-protein interaction sites are highly conserved to the extent that proteins are 
functionally interchangeable throughout mammalian species [105, 205]. In the SPRY domain of SPSB 
proteins, this conservation of protein-protein interaction sites leads to the recognition of a 
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“ELNNNL/DINNNN” consensus motif in the respective interaction partner [101, 106]. Therefore, one could 
assume that the residues that form a protein-protein interaction site in the DDX1 SPRY domain are also 
highly conserved. However, at closer inspection of the sequence conservation two arguments indicate 
that the canonical interaction surface A does not exist in the DDX1 SPRY domain. Firstly, its sequence is 
not conserved from other SPRY domains to DDX1 SPRY (Figure 3.2.7). Secondly, the residues that 
would correspond to surface A in DDX1 SPRY are not conserved amongst DDX1 homologes from 
different model organisms (Figure 3.2.8). This suggests that surface A is not the protein-protein 
interaction region of the SPRY domain of DDX1. 
Moreover, high conservation amongst DDX1 homologs from different model organisms was detected in 
the extended surface A region (Figure 3.2.8). In light of the pronounced conservation of the protein-
protein interaction region across species in other SPRY domains, one might therefore assume that 
extended surface A mediates protein-protein interactions. Extended surface A is not conserved among 
SPSB SPRY domains and is an exclusive feature of DDX1 (Figure 3.2.7). The extended surface A might 
be a novel feature of the DDX1-SPRY domain and replace the canonical surface A as interaction region. 
In general, protein-protein interaction interfaces are either characterized by hydrophobic residues, 
particularly aromatic residues, or they are mediated by opposite charge pairs[232-234]. Extended surface A 
contains only two surface exposed hydrophobic residues, one of them (W119) being aromatic, but 
instead harbors positively charged residues leading to an overall highly positive surface charge (Figure 
3.2.9). Such a conserved, positive electrostatic surface potential has also been observed for the peptide 
binding site of SPRY domains from mammalian SPSB proteins[105], further strengthening a similar role of 
DDX1’s extended surface A in mediating protein-protein interactions. 
 
Although SPRY domains have been described as protein-protein interaction platforms[98] and the SPRY 
domain within DDX1 therefore may well serve such a function, insertion domains in DEAD-box helicases 
usually serve RNA-binding functions[35, 42, 185]. Such a role for the DDX1 SPRY domain can not be excluded 
and will be discussed in the following section. 
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4.1.5 The possible role of the SPRY domain in tethering RNA substrates to the DDX1 
helicase core 
In many DEAD-box proteins, additional domains were shown to function in tethering RNA substrates[40-
42] or in extending the RNA binding site of the helicase core[35, 39]. This suggests that instead of providing 
a protein-protein interaction platform within DDX1, the SPRY domain may also serve as an RNA binding 
platform. Whereas DNA binding sites can be identified by their specific fold that is able to interact with 
the major groove of dsDNA[235-237], for RNA that predominantly exists as a single stranded species and is 
therefore structurally more flexible, binding sites on the protein are much more difficult to predict [238-
240]. In contrast to DNA interactions that mostly involve the phosphate backbone, RNA interactions are 
more often established via specific interaction with the bases or specific secondary structures 
(independent from the sequence) are recognized[240, 241].  
For the human DEAD-box protein DDX3X, which is the only other DEAD-box protein that harbors an 
insertion at an equivalent position than the SPRY domain in DDX1 within RecA-like domain 1, a function 
of the insertion domain in RNA binding has been discussed[185]. In the structure of DDX3X the insertion 
creates an elongated, positively charged cavity that is positioned close to the 3’-end of a potential 
bound RNA substrate and is therefore expected to be involved in RNA binding and positioning[185]. The 
SPRY domain of DDX1 may likewise be involved in positioning of RNA substrate, possibly via the 
conserved, positively charged extended surface A. For human DDX19 a patch of highly positive surface 
potential was suggested to mediate the interaction with mRNA[48].  
 
In general, in the “open”-state of DEAD-box proteins, duplex RNA substrate is exclusively bound by 
RecA-like domain 2[36]. In contrast, for DDX1 Liu and colleagues reported that a construct, lacking RecA-
like domain 2 binds to viral dsRNA[137]. It is therefore tempting to speculate that in this construct the 
canonical RecA-like domain 1 does not bind RNA, but the SPRY domain insertion mediates the RNA 
binding. 
 
For the DEAD-box proteins YxiN and HerA additional domains supplementing the helicase core have 
been shown to adopt an RRM fold[40, 242-245] (also see Figure 1.5). RRM are one of the few domains, where 
the fold is a strong hint for a function in RNA binding[238]. The SPRY domain of DDX1 does not adopt an 
RRM fold, but nevertheless it is interesting to note that additional domains of DEAD-box proteins can 
clearly function in RNA binding. Structures of these DEAD-box supplementing RRM domains in complex 
with short RNA substrates have revealed base specific interactions with few signature nucleotides, 
whereas the majority of interactions is unspecific via electrostatic interactions with the phosphate 
backbone[39, 42]. In YxiN lysine residues of the RRM generate an electropositive stretch that establishes 
salt bridges to the RNA phosphate backbone[39]. Despite not adopting the RRM fold, the SPRY domain of 
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DDX1 similarly harbors several lysine residues in extended surface A (see Figure 3.2.6) that also 
generate a positive surface patch (see Figure 3.2.8).  
Even though from the current opinion on SPRY domains, being protein-protein interaction modules is 
more likely, future studies, however, will show, whether a role in RNA binding can be excluded – up to 
now RNA tethering may be possible. Independent of its role in protein- or RNA binding, the linkage of 
the SPRY domain to the remainder of DDX1 is of particular interest and will be highlighted in the next 
section. 
 
 
 
 
 
4.1.6 N- and C-termini of the SPRY domain may constitute a flexible linker 
SPRY domains are found as modular insertions in a number of different proteins[204, 205, 208, 246-250]. 
Structural data is available only on isolated SPRY domains so far and they have never been crystallized 
in the context of the full polypeptide chain of their associated proteins. Thus, information on the linkage 
of the SPRY domain to the rest of the protein is lacking[98]. Inability to crystallize proteins containing a 
SPRY domain may already hint at its flexible linkage to the rest of the polypeptide chain. 
In DDX1, the regions that connect RecA-like domain 1 to the SPRY domain (residues 69 to 84) and the 
SPRY domain to RecA-like domain 1 (residues 270 to 285) show low conservation (Figure 3.1.1 and 
Figure 3.2.8). These regions are not part of the compact SPRY domain fold and they can also not be 
assigned to the helicase core, suggesting that they correspond to linkers that connect the SPRY 
insertion with DDX1. In partial proteolysis experiments protease cleavage was mainly detected in these 
regions (Figure 3.1.4), indicating that they are flexible. Furthermore, at both, N- and C-terminus, 
residues corresponding to the potential flexible linkers were found to be disordered in the crystal 
structure and could not be modeled unambiguously into the electron density (see section 3.2.3). For 
the N-terminal linker region secondary structure prediction suggested an α-helical region (Figure 
3.1.1), which would slightly restrict flexibility, but the respective residues in the structure do not form a 
helix (Figure 3.2.3). For the C-terminal linker region, the last five residues pack against strand β1, form 
strand β16 and enlarge β-sheet 1, whereas they can not be modelled in the other chain (Figure 3.2.3 b). 
However, by sequence alignment those C-terminal residues are not associated with the SPRY 
domain(Figure 3.2.7) and in other SPRY domains the C-terminus normally comes together with the N-
terminus and point away from the SPRY β-sandwich (Figure 3.2.6 c). It is likely that the conformation of 
this β-addition module of C-terminal residues is an crystallization artifact, caused by removing the SPRY 
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domain from the rest of DDX1 and that those residues are part of a linker region in the full-length 
protein.  
Flexible linkers are found in many proteins, e.g. they form the hinge region in immunoglobulins and 
they are usually enriched in proline, serine and threonine residues[251]. In protein kinases, hinge regions, 
characterized by glycine repeats, allow domain movements that are important for the catalytic 
function[252-254]. The potential N- and C-terminal linker regions of the SPRY domain do not harbor long 
glycin repeats, but nevertheless contain many proline and glycin residues that would allow flexibility 
(Figure 3.2.8). Flexible linkage of the SPRY domain to the helicase core would enable domain 
movement[252, 255]. The SPRY domain may change its relative orientation to the rest of the protein and act 
as a gatekeeper by obstructing the active site or by interacting with residues essential for catalysis 
(Figure 4.1.3). Furthermore, the linker regions directly connect the important motifs of the helicase 
core with the SPRY domain and could therefore be important to transduce signals as discussed before 
(see section 4.1.2). 
As mentioned above it is important to note that the potential SPRY linker regions are unconserved 
across different species (Figure 3.2.6). Residues involved in protein binding or fold stabilization are 
usually conserved[256] as they are exposed to evolutionary selective pressure, which would not be the 
case for the linker regions. It is not clear whether variations in the linker residues reflect differences in 
SPRY domain flexibility which may influence enzymatic parameters. Especially, the C. elegans DDX1 
homolog shows profound differences in the linker regions, as they display sequence deviations and are 
considerably shorter when compared to the human ortholog. Irrespectively of individual sequence 
differences, flexible linkage of the SPRY domain to the remainder of the DDX1 protein might be an 
essential functional characteristic.  
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4.2 Functional studies 
 
Distinctive mechanistic features of DDX1 - synergistic effects 
of ATP and RNA binding 
The results of the detailed biochemical and biophysical characterization of DDX1 as described in 
section 3.3, revealed unique characteristics when compared to other DEAD-box helicases – an unusual 
high ADP affinity and a tight coupling between RNA- and ATP binding. In the following, a model is 
presented that can explain the cooperativity between RNA- and ATP binding to DDX1. Furthermore, the 
implications of the nucleotide binding and of the enzymatic activities in ATP hydrolysis and RNA-
duplex-unwinding will be discussed. 
 
 
4.2.1 ATP and RNA both have the propensity to induce the “closed”-state of the 
helicase 
Based on the experimental data obtained from the functional analysis of DDX1 (reported in section 3.3) 
a model was developed to explain the observed cooperativity in ATP and RNA binding to DDX1 (Figure 
4.2.1). In this model either RNA or ATP binding alone are sufficient to induce a conformational transition 
in DDX1 from the “open”- to the “closed”-state of the helicase. Formation of the “closed”-state would 
result in an increase of affinity for both substrates.  
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Figure 4.2.1 Model for cooperative ATP and RNA binding to DDX1. According to the model either ATP (upper pathway) or RNA 
(lower pathway) binding alone can induce the “closed”-conformation of the DDX1 helicase, thereby increasing DDX1’s affinity for 
the respective other molecule. Numbers 1 and 2 delineate RecA-like domains 1 and 2. For simplicity the SPRY domain insertion in 
RecA-like domain 1 is omitted. 
 
The model as presented in Figure 4.2.1 is based on experimental findings from both the ATPase activity 
assay and the equilibrium titrations and gives a framework to the observed effects. 
The steady-state ATPase activity assay (see results section 3.3.8) showed strong coupling of RNA 
binding and ATP hydrolysis – whereas, at saturating RNA concentrations, the maximal hydrolysis rate 
was observed already at relatively low ATP concentrations, at saturating ATP concentrations no increase 
in the apparent ATPase rate by addition of RNA could be detected. 
Furthermore, the results from the equilibrium titration experiments (see results section 3.3.6) are also 
in accordance with cooperative binding of ATP and RNA to DDX1. They showed an increased ATP 
affinity for the RNA bound form of DDX1 and an increased RNA affinity in the ATP bound state. 
 
In general, only in the “closed”-state of DEAD-box proteins, a functional ATPase site and the full binding 
surface for RNA are assembled[31, 36]. It is therefore conceivable that the observed stimulation of ATP 
hydrolysis by RNA binding of DDX1 is achieved via induction of the conformational transition from the 
Discussion 
 129
“open”- to the “closed”-state upon RNA binding (Figure 4.2.1 lower panel). In the “closed”-, RNA bound 
state, DDX1 is then hydrolysis competent. Furthermore, the “closed”-state has the highest ATP affinity. 
In this scenario the main factor for stimulation of ATP hydrolysis would be this increase in ATP affinity. 
High ATP affinity of an RNA bound “closed”-state is also supported by the results from the equilibrium 
titration experiments (see section 3.3.6). 
Similarly, ATP binding could also induce the transition to the “closed”-state (Figure 4.2.1 upper panel). 
Formation of the “closed”-state by ATP binding would explain the increased RNA affinity that is 
detected in the presence of ATP. As observed in X-ray structures of DEAD-box helicases, in the “closed”-
state RNA is bound by both RecA-like helicase domains, forming a high-affinity RNA binding site[23]. In 
contrast in the “open”-conformation of the ADP- or apo-state, only RecA-like domain 2 binds the RNA[36]. 
Such a mechanism of conformational transition induced by ATP binding is in full agreement with results 
from the ATPase assay (Figure 3.3.10 b). At high, saturating ATP concentrations the “closed”-state is 
formed and no further stimulation of hydrolysis by RNA is observed. 
Furthermore, global fitting analysis of all recorded equilibrium titration data showed that ADP binding 
does not increase the RNA binding affinity of DDX1, as also apparent from the minimal binding scheme 
(Kd,ADP = Kd,RNA,ADP, i.e. Kd,RNA = Kd,ADP,RNA see Figure 3.3.8), since RNA did not influence ADP binding. This 
pronounced difference of observed RNA affinity in the ATP-bound and ADP-bound/nucleotide-free 
state further supports the model in which DDX1 cycles between a high RNA affinity ATP-bound 
“closed”-state and a lower RNA affinity ADP-bound “open”-state. In this case, the “closed”-state would 
represent the “active” form of the enzyme, whereas the lower RNA affinity ADP-bound or nucleotide 
free “open”-state would represent an “inactive” form. 
 
RNA helicases can either function as processive remodelers or immobile clamps[18, 19, 37]. The observed 
mechanism of cooperative ATP and RNA binding to DDX1 rather supports a function of DDX1 in RNA 
clamping than in processive unwinding or remodeling (see section 4.2.6). Recently functions in 
substrate clamping have been reported for a number of DEAD-box proteins[19, 90]. In this scenario, ATP 
hydrolysis by DDX1 is required prior to release of the RNA substrate and enzyme recycling.  
 
Importantly, it has to be mentioned, that the Kd values for ATP, calculated from the equilibrium 
titrations, are inherently flawed, because probably they do not represent a simple displacement of 
mant-ADP by ATP. This becomes apparent at closer inspection of the ATP hydrolysis. The measured 
kcat(ATP) which is almost equal to the koff,mantADP for mant-ADP and the expected koff,ADP for ADP suggests 
that ADP product release is the rate-limiting step of the ATP hydrolysis reaction. Therefore, under 
steady-state conditions DDX1 would be mostly in the ADP bound state. This would imply that in the 
equilibrium titration experiments addition of ATP leads to an accumulation of ADP bound enzyme, in 
spite of the presence of the ATP regeneration system, since ADP release would be slower than ATP 
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hydrolysis by DDX1. The ATP equilibrium titration experiment would then not simply measure a Kd,ATP for 
ATP binding, but a combination of ATP binding and the following steps. As a consequence the 
calculated Kd values for ATP have to be handled with care and are difficult to interpret. The actual Kd 
values for ATP might be smaller, meaning that the ATP affinity would get underestimated.  
Nevertheless two things can be clearly stated from the observations. Firstly, there is a huge preference 
of DDX1 for ADP over ATP and a large difference in affinity between the nucleotides. Secondly, the 
presence of RNA leads to an ATP affinity increase irrespective of the exact Kd value. Thus, cooperativity in 
binding of ATP and RNA is definitely an essential characteristic of DDX1. 
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4.2.2 Adenosine-nucleotide affinity of DDX1 – escape from an ADP stalled complex 
The previous section focused on the relationship between ATP and RNA binding to DDX1, however, 
already at closer inspection of the different affinities for ATP and ADP interesting features become 
evident. For several DEAD-box helicases nucleotide affinities have been determined experimentally[60]. 
DDX1’s binding affinity for ATP is within the range of what has been reported[57, 58], even when taking 
inaccuracies of the ATP equilibrium titrations (due to a high steady-state fraction of ADP bound 
enzyme) into account (Table 4.1). In contrast to ATP, DDX1’s affinity for ADP is extremely tight and 
higher by a factor of almost 500 when compared to ADP affinities of other DEAD-box proteins[57] (Table 
4.1). Strikingly, the difference in affinity between the two nucleotide species is in the range of three 
orders of magnitude. Such a pronounced difference in the affinities between ATP and ADP has not been 
observed for any other DEAD-box helicase to date[34, 45, 60, 196]. It can be assumed that the ADP bound 
form represents the inactive state of DDX1, since only in the ATP bound form a high affinity for the RNA 
substrate is established, allowing a productive working cycle (see section 4.2.1). 
In the cellular environment, the ATP concentration is around 1-10 mM and hence it is five- to ten-fold 
higher when compared with the concentration of ADP[257-259]. Thus, the high ADP affinity of DDX1 most 
likely causes the protein to be predominantly found in the ADP bound form and the ATP-state to be 
barely populated. However, this would render DDX1 as an inactive protein (unable to undergo repeated 
cycles of ATP hydrolysis), and the existence of a nucleotide-exchange-factor (NEF) reminiscent of G-
proteins for DDX1 is conceivable. Such an exchange factor has also been described for the yeast DEAD-
box protein Dbp5 (human DDX19)[67], where the N-terminal domain of Nup159 (Nup214 in H. sapiens) 
binds to Dbp5, opens the RecA-like domains and leads to ADP release[25, 67]  (Figure 4.2.2). A similar 
mechanism might apply for DDX1 as well and would facilitate to overcome inactivation, caused by the 
high ADP affinity. Such a mechanism with an external NEF could provide means to regulate DDX1[19, 260]. 
Similar as described for Dbp5[19, 67, 260], regulated ADP release may prevent off-target activity, i.e. binding 
to any RNA that is not a designated DDX1 target. This could be essential for spatial activation, since as 
this study shows, DDX1 is promiscuous in its RNA specificity (like most DEAD-box proteins[37]) and as 
previously shown, it is found in several cellular compartments, where it is involved in different cellular 
processes[91, 117]. 
Recently it has been demonstrated that NEFs not only facilitate spatial activation, but in the case of 
small GTPases are directly responsible for specific targeting of their associated enzyme to a designated 
cellular compartment[261]. In this example the GTPase specific NEF harbors a subcellular localization 
signal and recruits its associated GTPase to specific membrane compartments[261, 262]. Similarly DDX1 
might be recruited specifically to its designated place of action – for instance one might imagine 
localization to the nucleus, where tRNA splicing takes place in human cells[263] – by an associated NEF. 
This would be of special importance, since DDX1 does not harbor a nuclear localization signal (NLS). For 
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yeast, where tRNA processing involves other pathways and takes place in the cytoplasm[264, 265], there 
would be no need for a transport, however, no DDX1 homologue could be detected in S. cerevisiae 
anyways. Since DDX1 is found in a complex with other factors in the tRNA processing HSPC117 
complex[108], one of those proteins could potentially function as such a NEF. NEFs can modulate the 
thermodynamic and kinetic properties of their associated enzymes, when incorporated in a ternary 
complex with respect to a binary complex consisting only of enzyme and substrate[266, 267]. A putative 
NEF for DDX1 should fulfill two functions, it should accelerate the ADP release and it should shift the 
affinity towards ATP.  
 
In principle, in accordance with the cooperativity model, RNA may bind to the ADP-form of DDX1, 
thereby stimulating ATP affinity and inducing nucleotide exchange. However, it is questionable, 
whether the small amount of RNA that is bound in the low-RNA affinity ADP-form of DDX1 is capable of 
achieving this. Furthermore, even in the RNA bound form, there is still a pronounced preference for ADP 
(by a factor of 50) over ATP. This rather suggests that other factors than RNA like e.g. a NEF must come 
into play. Such factors would help to escape a “hen and egg” scenario: which binds first, RNA or ATP? 
RNA is preferentially bound in the ATP-form, ATP affinity is increased in the RNA-bound form of DDX1, 
but where to start? 
 
 
 
4.2.3 Comparison of the cooperativity in ATP and RNA binding with other DEAD-box 
proteins  
To enable a classification of the different nucleotide affinities and cooperativity effects, observed for 
DDX1, experimentally determined affinity constants were compared with those available in the 
literature (Table 4.1). DDX1 showed a significantly increased affinity for ATP in the presence of 
saturating amounts of RNA (see results section 3.3.6). Elevated ATP affinities have been described for 
RNA-bound-states of other DEAD-box proteins, though the changes in affinity have been reported to be 
modest [57, 58] (Table 4.1). One may anticipate that in the presence of RNA substrates, DDX1 requires ATP 
in order to exert its function - be it simple clamping, translocation or unwinding – thus, rationalizing the 
coupling of RNA binding to an increase in ATP affinity. 
 
Interestingly for the human eIF4A (the traditional model DEAD-box helicase) a similar situation as with 
DDX1 was observed[75]. In both proteins, the RNA affinity is higher in the ATP bound state when 
compared to the nucleotide free or ADP bound state. However, in eIF4A the overall RNA affinity is much 
lower[75] (Table 4.1).  
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Table 4.1 Comparison of nucleotide affinities of DEAD-box proteins. (RNA) means affinities were determined in the presence of 
 RNA, (mant) means affinities have only been determined for mant derivatives. 
DEAD-box 
protein 
Kd(ATP) Kd(ADP) Kd(RNA)  KM(ATP) kcat 
DDX1  
(H. sapiens) 
129 μM 0.11 μM 12.4 μM  1750 μM 0. 1 s-1 
DED1  
(S. cerevisiae) 
n.a. n.a. 0.02 μM[59]  300 μM[59] (RNA) n.a. 
Mss116  
(S. cerevisiae) 
126 μM[58] 43 μM[58] 0.117 μM[58]  250 μM[58] (RNA) 0. 26 s-1 [58] 
DbpA  
(E. coli) 
72 μM[57] 51 μM[57] 0.016 μM[57]  65 μM[57] (RNA) 0. 01 s-1  [57, 58] 
eIF4A  
(H. sapiens) 
80 μM[75] 30 μM[75] 5 μM[75]  80 μM[75] n.a. 
 
 
Influence of ATP and RNA on binding affinities 
DEAD-box 
protein 
Kd(ATP) +RNA Kd(ADP) +RNA Kd(RNA) +ATP Kd(RNA) +ADP KM(RNA) +ATP kcat +RNA 
DDX1  
(H. sapiens) 
5.0 μM 0.1 μM (mant) 0.136 μM 12.4 μM 0.087 μM 0.11 s-1 
DED1  
(S. cerevisiae) 
n.a. n.a. 0.012 μM[59] n.a. n.a. 5.6  s-1[59] 
Mss116  
(S. cerevisiae) 
80 μM [58] 92 μM [58] 0.047 μM[58] 0.336 μM[58] 0.2 μM[58] 1. 5 s-1 [58] 
DbpA  
(E. coli) 
51 μM[57] 23 μM[57] 0.011 μM[57] 0.01 μM[57] 0.001 μM[57]  5 s-1 [57] 
eIF4A  
(H. sapiens) 
10 μM[75] 8 μM[75] 1 μM[75] 40 μM[75] 1 μM[75] 0.017 s-1 [75] 
 
In general, coupling of ATP and RNA binding has been reported for other DEAD-box proteins as well[78, 
80], but the cooperative effects for DDX1 are the most pronounced that have been observed so far 
(Table 4.1) and a cooperativity model as introduced for DDX1 in this thesis (Figure 4.2.1) has not been 
proposed for any other DEAD-box protein before. 
At closer inspection of the different DEAD-box proteins, depicted in table 4.1, one interesting example is 
the bacterial DEAD-box protein DbpA. For DbpA a situation is encountered that is very much in contrast 
to the cooperative mode of nucleotide binding in DDX1. DbpA is specifically activated in its ATPase 
activity by 23S rRNA (500-2000 fold increase in kcat)[57, 72, 268]. However, in this case, RNA binding does not 
significantly increase the ATP affinity[57] (Table 4.1), which implies that ATPase stimulation is achieved 
by different means than in DDX1 and here the cooperativity model does not apply. 
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Other DEAD-box proteins that display cooperativity effects similar to DDX1 include e.g. DED1 and eIF4A 
(Table 4.1). For those two proteins conserved helicase motif IV has been reported to be important for 
the cooperativity between ATP and RNA binding[218, 269]. Motif IV can only contribute to cooperativity in 
the “closed”-state. This means the fact that cooperative effects mediated by Motif IV have been 
observed for DED1[59, 269],  and eIF4A[75, 269] implies that either ATP- or RNA binding can induce domain 
closure. This linkage of cooperativity effects with formation of the “closed”-state of DEAD-box proteins 
is very much in line with the DDX1 cooperativity model (Figure 4.2.1). 
 
Only in a few cases coupling between RNA and ADP binding has been reported for DEAD-box 
proteins[270], which is not observed in DDX1. This absence of coupling suggests that ADP does not have 
the propensity to induce structural changes in DDX1 as e.g. transition to a higher RNA affinity “closed”-
state of the helicase. This is in agreement with studies on eIF4A, where the γ-phosphate group of ATP 
has been proposed to mediate changes in the protein conformation[194]. Similarly, in the RNA induced 
“closed”-state, preferred binding of ATP versus ADP may be mediated by additional contacts with the γ-
phosphate group. 
 
Studies with the Bacillus subtilis DEAD-box helicase YxiN have directly addressed cooperative binding of 
ATP and RNA by FRET experiments[80]. It has been reported that both, ATP- and RNA binding are 
required for formation of the “closed”-state of the helicase[77, 80]. Such a situation would be in contrast to 
the DDX1 cooperativity model and to the experimentally observed intrinsic ATPase activity of DDX1 in 
the absence of RNA substrate, since the “closed”-state has to be assembled in order to create the 
ATPase active site[36]. Conserved helicase motif VI in RecA-like domain 2 can only make its essential 
contributions to ATP hydrolysis if both helicase domains come in close proximity[34]. A construct of 
DDX1 that was devoid of motif VI at the N-terminus (by truncation) was ATPase deficient (see appendix 
section 7.3.1). Therefore, one may rather assume a functional difference between the bacterial YxiN 
protein and human DDX1 (that can presumably adopt the “closed”-, ATPase active state even in the 
absence of RNA). In line with this hypothesis YxiN does barely exhibit any intrinsic ATPase activity[271]. 
 
Structural studies on other helicases also support the DDX1 cooperativity model. X-ray structures of the 
SF1 helicase Upf1 in the AppNHp bound state have revealed that ATP binding alone can already induce 
the “closed”-state of RecA-like domains 1 and 2[38]. In contrast, the ADP bound state of Upf1 did not 
show domain closure. Similar observations have been made in the ADP bound structure of the DECD-
box helicase UAP56, which adopts the “open”-state[26]. Domain closure in the ATP bound state without 
RNA being present, but maintenance of the “open”-state with ADP bound, as observed in these 
structures, is in line with the cooperativity model. Furthermore, maintenance of the “open”-state, could 
explain the lack of influence of ADP on RNA affinity in DDX1. 
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In addition to the functional and structural studies on other DEAD-box helicases, some reports have also 
specifically investigated mechanistic details of DDX1. The following sections will focus on enzymatic 
activities of DDX1 and refer to what is known on the specific function of this protein in the literature so 
far. 
 
4.2.4 RNA binding - Sequence specificity 
The helicase core of DEAD-box proteins interacts exclusively with the sugar phosphate backbone of 
oligonucleotides[31], resulting in sequence unspecific RNA binding per se[13]. In DDX1 this helicase core is 
supplemented with the SPRY domain (Figure 3.1.1) and one could imagine a role for this SPRY insertion 
in RNA binding (see section 4.1.5). 
Previously, a preferential binding of DDX1 to polyA RNA sequences has been reported[109]. However, in 
the present study, no differences in binding affinities were observed between 10mer poly A, 10mer 
poly U or 13mer mixed sequence RNA in EMSAs (Figure 3.3.3 and suppl. Figure 7.1.10). Furthermore, 
RNA molecules of different length and sequence, did stimulate nucleotide binding and hydrolysis to the 
same extent (Figure 3.3.7). This suggests, that the SPRY domain does not impose any sequence 
constraints on the substrate and uncomplexed DDX1 would therefore bind to almost any accessible 
oligonucleotide sequence.  
The promiscuity in RNA sequence and length might even be essential for a DDX1 function as a general 
RNA processing enzyme. This has been noted for other DEAD-box proteins before - two prominent 
examples include Mss116 and eIF4AIII that both have to be promiscuous in RNA binding to fulfill their 
cellular function[19, 37]. The lack of specificity of DDX1 for certain RNA sequences could be easily 
overcome via recruitment to a specific target by interacting factors. Protein factors that e.g. interact 
with DDX1 in the HSPC117 complex could also constrain binding to specific structural elements in the 
substrate. Structural specificity has been described for DpbA related bacterial DEAD-box proteins, which 
recognize a RNA hairpin structure[272]. Consistent with a function of interacting factors in recruitment to 
specific substrates, the complex of DDX1 with CGI-99 and ASW has been found to be associated with 
cruciform DNA in pull-down experiments[113]. Noteworthy, in the gel-shift experiments, recombinant 
DDX1 alone did not bind to these DNAs and in addition, they did not influence ATPase activity (suppl. 
Figure 7.1.16).  
These cruciform DNAs partially resemble the fold of the pre-tRNA (though they are in B-form and tRNA 
is in A-form[273]), the substrate of the DDX1-containing HSPC117 complex[114]. Thus, besides binding 
single stranded RNA without any sequence constraints, DDX1 might be targeted to specific structures 
by the HSPC117 complex.  
 
    Discussion 
136 
Irrespective of the binding to RNA substrates and stimulation of ATP hydrolysis by these interactions, 
the ATPase rate may be further influenced by additional factors as discussed in the following.  
 
 
 
 
 
4.2.5 ATPase activity of DDX1 might be stimulated by external factors 
The apparent rate of ATP hydrolysis by DDX1 is low, when compared to other DEAD-box helicases[56] 
(specifically in RNA bound form, Table 4.1). A low kcat for DDX1 has been reported in another study 
before, where a discontinous assay for the quantification of ATP hydrolysis was used[135]. Concluding 
from the results of the coupled ATPase assay and the equilibrium titrations, the observed rate of 
hydrolysis may be limited by ADP release, which might be the rate limiting step of the reaction. The 
actual kcat would then not be measured by simply detecting free ADP. A single turnover experiment 
could help to avoid the limitation by ADP release in the coupled ATPase assay and to determine the 
actual kcat value. However, due to the low ATP affinity this is hardly possible. 
Another reason for a low ATPase activity of DDX1 might be the formation of an auto-inhibited state. 
Such an autoinhibition was for instance described for DDX19, the human homologue of the Dbp5[28]. In 
the “open”-state, DDX19 is repressed by binding of an N-terminal α-helix between the two RecA-like 
domains[28] (Figure 4.2.2). This repressing element is part of an N-terminal extension of DDX19 that 
does not belong to the conserved helicase fold. If a similar autoinhibition mechanism applies to DDX1, 
the SPRY insertion is the prime candidate for an ATPase-repressing domain.  
The DEAD-box protein DDX19/Dbp5, but also eIF4A, is specifically stimulated in its ATP hydrolysis 
activity by binding of the co-factors Gle1-IP6 and eIF4G, respectively[19]. These factors activate their 
DEAD-box partner by stimulating RNA release[62] (Figure 4.2.2). For Dbp5, the ATPase stimulating 
function of Gle1-IP6 is further coupled to ADP-exchange by Nup159[67]. Similarly, in DDX1 external 
factors may also regulate both, RNA release and ADP exchange. 
 
In general, ATP hydrolysis is not the main enzymatic activity of DEAD-box proteins, but rather means to 
support substrate unwinding[18]. Whereas hydrolysis of ATP could be measured in the experiments 
performed during this thesis, unwinding of double-stranded oligonucleotides by DDX1 was not 
observed. This enzymatic deficiency will be discussed in the next section. 
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Figure 4.2.2 The ATPase cycle of Dbp5 is regulated by an RNA release- and a nucleotide exchange-factor. The DEAD-box 
protein Dbp5 (DDX19 in H. sapiens) displays a slow intrinsic ATPase activity due to an α-helical extension that binds to the ATPase 
site in the “open”-state of the helicase. The ATPase cycle is accelerated by binding of the co-factors Gle1- InsP6 and Nup159. Gle1- 
InsP6 activates the ATPase reaction by stimulating RNA release. The nucleoporin Nup159 (Nup214 in H. sapiens) acts as a 
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nucleotide exchange factor to remove ADP after hydrolysis. It is conceivable that DDX1 requires similar factors to stimulate its 
enzymatic activity, since for DDX1 ADP affinity is exceptionally high and the basal ATPase rate is slow. The factors of the 
pentameric HSPC117 complex are candidates for such activities. Structures of different enzymatic states are depicted that have 
been accessible by X-ray crystallography. Apo Dbp5 is in the “open”-state of the helicase(upper left) and forms the “closed”-state 
upon binding of RNA and ATP (upper right). Binding of Gle1 after ATP-hydrolysis leads to a separation of both RecA-like domains 
and RNA release (lower right).  Finally Nup159 binds and acts as an ADP-exchange-factor, which helps to reset the enzyme (lower 
left). All structures except for the apo-form represent S. cerevisiae proteins. Inositol hexakisphosphate (InsP6) acts as a small 
molecular tether for the Gle1-Dbp5 interaction (represented as stick model in the structures and omitted from the cartoon 
representation). 
Note that in the nucleotide- and co-factor-free state, RecA-like domains 1 and 2 display high flexibility in their orientation. In the 
crystal structure of the apo-form “open”-state, the distance between both domains is larger than in the defined “open”-state with 
Gle1 bound. 
 
 
4.2.6 Helicase deficiency of DDX1 hints towards a clamping function 
Recombinant DDX1 clearly showed an ATP hydrolysis activity (Figure 3.3.10), however, in the gel-based 
helicase assay recombinant DDX1 was unable to separate DNA/RNA or RNA/RNA substrates (Figure 
3.3.11). This is in contrast to previous reports from the lab of Roseline Godbout that has shown efficient 
unwinding of relatively long RNA or DNA/RNA hybrid substrates[111]. The same oligonucleotide 
substrates as described in these studies were tested, but could not be separated by DDX1 during this 
study. These substrates harbor long stretches of 29 paired nucleotides, which is too long to be 
efficiently processed by most DEAD-box helicases that commonly do not unwind duplexes, exceeding 
one-and-a-half helical turns[157]. To exclude that the substrate is not unwound by DDX1 due to 
processivity problems, shorter double-stranded oligonucleotides were tested. These shorter 
oligonucleotides have a 13-bp duplex region and have been used as model substrates for several DEAD-
box proteins[49]. Nevertheless, no unwinding could be observed for the oligonucleotides with shorter 
duplex region (Figure 3.3.12). Interestingly, another study suggested that isolated recombinant DDX1 
does not exhibit any RNA unwinding activity and only exerts its function in protein complexes that were 
co-immunoprecipitated with DDX1[109]. 
Although, it can not be completely excluded that the FAM- or the Fl-label hinders unwinding, 
positioning at the 3’- or 5’-end of either DNA or RNA substrate did not make any difference in the 
displacement reaction. In the gel-shift experiments DDX1 did bind to ssRNA despite the presence of a 
FAM-label. Additionally the label is comparably small (380 Da) and DEAD-box helicases contact only ~ 
10 nucleotides[274]. Since all double-stranded oligonucleotides were much longer, DDX1 could simply 
bind to a part of the potential substrate that does not impose any sterical hindrance.  
Since unspecific RNA binding was observed in EMSA- and equilibrium titration experiments (Figure 
3.3.3 and 3.3.7), it is unlikely that the sequence of the double-stranded substrate is one of the factors 
that prevented unwinding. Furthermore, all assays for measuring the unwinding activity of DEAD-box 
proteins that have been described in the literature so far, assume sequence independent unwinding[49, 
157, 275] .The construct DDX1-728 used in the assays, lacks only 12 residues from the C-terminus when 
compared to full-length DDX1 (Figure 3.1.1). Most probably these residues that belong to a C-terminal 
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extension (that is not part of the helicase core) are not essential for the enzymatic activity as they are 
completely unconserved (in contrast to the rest of the protein, see Figure 3.1.1). Moreover for many 
DEAD-box proteins, it was shown that constructs, truncated down to the basic RecA-like helicase core 
are active in dsRNA unwinding[31, 54, 276]. 
 
The failure in detecting for separation of double-stranded substrate by the DDX1 construct (as used in 
this thesis) (Figure 3.3.11) could be due to missing co-factors or incorrect folding of the recombinant 
protein. Binding of adenosine-nucleotides and RNA could be measured and affinity values were in the 
range of what has been reported for other DEAD-box proteins[57, 58] (Table 4.1). This suggests that 
residues, essential for ATP binding, especially the P-loop, must be in the correct conformation. 
Furthermore, the RNA binding surface on top of RecA-like domains 1 and 2 is almost certainly correctly 
assembled. Thermal stability of DDX1 was in the range of stable proteins[277] and ATP hydrolysis activity 
could be observed (Figure 3.3.1 and 3.3.10). All those results indicate that the recombinant protein is 
most likely properly folded. This leaves only the lack of co-factors as a possible cause of the helicase 
deficiency, which has been suggested in another report before[109].  
On the other hand, it is possible that the basic function of DDX1 is RNA clamping and that it serves as a 
structural scaffold for the assembly of larger protein complexes. For instance, DDX1 could help to 
position the HSPC117 complex components on tRNA substrate. Such an assembly function has e.g. 
been described for the DEAD-box proteins Dbp5 and eIF4AIII that both clamp on mRNA substrates[23-25]. 
In DDX1, the observed pronounced preference for ADP over ATP supports a scaffolding function 
(Figure 3.3.5). As mentioned before, DDX1 may need an activating nucleotide exchange factor for ADP 
release. In the absence of such a factor, as it was the case in the helicase assay, DDX1 remains bound to 
ADP and RNA. Local activation by co-factors has been reported for the “clampers” Dbp5[25, 278] and 
eIF4AIII[279] (Figure 4.2.2).  
The DEAD-box protein DED1 (suppl. Figure 7.3.12) that has been used as a positive control in the 
displacement assay, nicely illustrates the functional differences between a processive helicase and a 
clamping, scaffolding enzyme. During translation initiation the model DEAD-box protein eIF4A clamps 
onto the 5’-end of the mRNA and helps to assemble the components of the cap-binding complex[280], 
until it is locally activated by eIF4G[61, 62]. eIF4A only serves a scaffolding function and it is not capable of 
unwinding secondary structures in the 5’ untranslated region (UTR) of the mRNA. The more processive 
helicase DED1 is required to unwind these secondary structures in the 5’ UTR to facilitate ribosome 
scanning[281]. Likewise DDX1 may assemble the components of the tRNA processing complex[114] on the 
substrate, but leave the actual “work” to the enzymatically active HSPC117. 
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4.3 Conclusion and Outlook 
 
4.3.1 DDX1 is a novel, human DEAD-box protein involved in a plethora of cellular 
functions 
In this thesis the human DEAD box protein 1, DDX1 was characterized both structurally and functionally. 
DDX1 differs from other proteins of its helicase-family by a large insertion in the conserved helicase 
core. This work verified that the insertion corresponds to a SPRY domain. In other proteins, SPRY 
domains interact with the DEAD-box helicase core of a different protein[100, 225, 226] and DDX1 seems to be 
the first example of a DEAD-box protein with a “built-in” SPRY domain. DDX1 was found to be 
conserved from H. sapiens to C. elegans, but no yeast-homolog could be detected. Previous studies 
sparked high interest in DDX1, since it was shown to be involved in mRNA- and tRNA- processing and to 
play an important role in human pathogenesis as it is amplified in tumor tissue[91] and is an essential 
host factor for HIV-1 replication[135].  
Here, a variant of DDX1 was designed that can be expressed in bacterial cells and offers an easy and fast 
access to recombinant material. Experiments showed that DDX1 is not only structurally distinct from 
other DEAD-box proteins, but also its enzymatic parameters are very different when compared to 
reported values of other DEAD-box proteins[60]. The established protocols for the preparation of 
recombinant DDX1 can be used for future studies on the HSPC117 complex and its role in tRNA 
processing. 
 
4.3.2 Structural characterization of the SPRY domain  
The SPRY domain was crystallized and its structure was determined to near atomic resolution. This 
represents the first structural information of DDX1 and the HSPC117 tRNA ligation complex in general. 
The SPRY structure shows two layers of concave shaped β-sheets that stack together to form a compact 
β-sandwich conformation and a third small β-sheet that forms a lid over the β-sandwich core. In 
comparison with complex structures of other mammalian SPRY domains, it was observed that the 
conformation of previously described interaction loops[101, 105] is different in the DDX1 SPRY domain and 
residues located at the canonical interaction surface A are not conserved. Conserved, however, was a 
positively charged surface patch that differs from the canonical interaction surface. The high 
conservation combined with the charge distribution, suggests that this surface patch may mediate 
peptide-binding or could potentially also enlarge the RNA-interaction surface of DDX1. The SPRY 
domain is the putative element that establishes the interaction of DDX1 with HIV-1 Rev protein as it was 
shown that the Rev-binding domain is contained entirely within the N-terminal region of DDX1[135]. 
Therefore, the SPRY structure provides the basis for further studies on the role of DDX1 in HIV-1 
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replication and the detailed biochemical characterization of the SPRY interaction platform and the 
recruitment to the Rev protein. 
 
 
4.3.3 Functional characterization of DDX1  
DDX1 displayed an ATP affinity, similar to other DEAD-box proteins, but showed an unusually tight ADP 
binding. The difference in the affinities between adenosine-di- and triphosphates that was determined 
is so profound that in the cytoplasm it would lead to “ADP-stalling” and inactivate DDX1. This suggests 
that an nucleotide exchange factor as described previously for DDX19[67], is potentially required for ADP 
release. External co-factors of the HSPC117 complex may take over this function and by acting as 
nucleotide exchanger could also direct spatial activation and distribution of DDX1. Despite an 
experimentally verified ability to hydrolyze ATP, recombinant DDX1 was helicase deficient, in contrast 
to the yeast DEAD-box helicase DED1. This deficiency hints again to the requirement of co-factors and a 
function of DDX1 in substrate clamping. DDX1 did not display RNA-sequence specificity. 
A tight coupling between the binding of RNA and ATP to DDX1 was observed across all experiments. 
Cooperativity in RNA and ATP binding can be explained by a model of DDX1 in which both substrates 
can induce the conformational transition to the “closed”-state of the helicase by their own. This model is 
corroborated by the observed intrinsic ATPase activity, which requires a “closed”-state. 
The kinetic data extend the working model for eukaryotic DEAD-box proteins by introducing synergistic 
effects of ATP and RNA binding that have not been observed to such an extent before. Further in vivo 
experiments can make use of the cooperativity model and the reported affinity and binding constants 
for ATP, ADP and RNA for an in-depth analysis for the hijacking function of viral transcripts and their 
modulatory propensity.  
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Figure 7.1.1 Sequence alignment of human DDX1 with MjDEAD (1HV8). The complete sequence of human DDX1 (aa 1-740) 
was aligned with the sequence of a DEAD-box protein from the hyperthermophile Methanococcus jannaschii. The structure of the 
M. jannaschii protein was solved and deposited in the PDB as 1HV8 [33]. Conserved sequence motifs and the domain boundaries 
are indicated in blue. The large SPRY-domain insertion between Walker A and B motifs is indicated in brown. Secondary structure 
is indicated by h=α-helix and s=β-strand. For DDX1 secondary structure was predicted using psipred [177]. Pairwise sequence 
alignment was done using needle (http://www.ebi.ac.uk/Tools/psa/emboss_needle). 
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Figure 7.1.2 Sequence alignment of human DDX1 with yeast Dbp2.  Human DDX1 is aligned with the closest yeast homologue, 
the DEAD-box protein Dbp2p. The Walker A motif (sequence GSGKT) is highlighted in both sequences to show disparities in the 
alignment of the C-terminal RecA-like domain. 
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Figure 7.1.3 Purification of the separated SPRY domain. A construct of the separated SPRY domain of DDX1 (amino acids 72-
283) was purified by initial Ni2+, followed by heparin affinity chromatography. Elution fractions from the heparin column were 
loaded on a 15% SDS-gel. 
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Figure 7.1.4 Limited proteolysis of the SPRY domain with Trypsin, Chymotrypsin and Thermolysin. A Construct of the SPRY 
domain of DDX1 (amino acids 72-283) was digested with different proteases (1 μg protease per 1600 μg protein) and reactions 
were quenched at the indicated time points (in min).  Reactions were separated on a 15% SDS-gel and degradation bands were 
identified by MALDI-MS.  
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Figure 7.1.5 Long loops cover hydrophobic patches on the surface of the SPRY domain., On both sides of the SPRY β-
sandwich fold extended loops are found that clamp the compact domain. A, on the concave side, loop D (depicted in purple) 
covers a hydrophobic patch. B, on the convex side the loop between β14 and β15 (depicted in purple) covers a hydrophobic 
patch of β-sheet 2. A ribbon representation of the β-sandwich fold of the SPRY domain is shown. β-sheet 1 is depicted in blue, β-
sheet 2 in red and β-sheet 3 in green. The different strands and N- and C-termini are labeled.  
 
 
 
 
Figure 7.1.6 Hydrogen bonds stabilize the β-sandwich fold. The SPRY domain is depicted in ribbon representation with β-
sheet 1 in blue, β-sheet 2 in red and β-sheet 3 in green. A, hydrogen bond between Tyrosine 135 ofstrand β6 and Glycine 148 of 
strand β7 (3.4 Å) that holds both sheet together is shown. B, hydrogen bond between Lysine  173 ofstrand β10 and Alanine 215 of 
the loop connecting strand β12 and strand β13 (2.6 Å) that stabilizes the fold is shown.  
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Figure 7.1.7 Sequence conservation of the DDX1-SPRY domain amongst model organisms. A few residues on the surface 
form a conserved patch that is distinct from surface A. A, the sequence conservation between different eukaryotic model 
organisms was mapped on the structure of the human DDX1-SPRY domain. Surfaces A and B, formed by the loops that connect 
the β-strands are indicated by grey shading. B, residues that form the conserved surface patch, designated surface X, are shown as 
sticks. C, a surface representation of the sequence conservation is shown with the conserved residues that from surface X shown 
as sticks.  
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Figure 7.1.8 Comparison of DDX1 SPRY with the distantly related SPRY domain of Trim21. The superposition of DDX1 SPRY 
with Trim21 SPRY(PDB entry 3ZO0/2VOL[205])[205] as obtained from the DALI server[192] is shown. Both proteins are depicted in 
ribbon representation. DDX1 SPRY is depicted in green and Trim21 SPRY is depicted in blue. The region of highest divergence, the 
loop connecting β-strands 3 and 4 (referring to DDX1) is indicated by more intense color shading and labeled v1 loop. 
DALI superposition resulted in a Z-Score of 14.6 and an overall rmsd of 2.1 Å for the alignment of 138 residues[192] 
 
 
 
 
 
 
 
 
Figure 7.1.9 Binding of DDX1 to 5’-labeled RNA observed via gel-shift. Binding of a 13-mer RNA that was labeled at the 5’-end 
with a FAM-label to DDX1 was observed via a band-shift in a native gel. 10 μM of DDX1-728 were incubated with labeled 13-mer 
RNA of indicated sequence and 10 mM of different nucleotides (as indicated) for 20 min at 277 K. Reactions were separated on a 
5%/15% native acryl-amide-gel with CHES-NaOH pH 10 as running buffer. The FAM label was visualized by illumination at 302 nm. 
Protein was stained with Instant-blue to confirm co-migration with the RNA signal (right side). 
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Figure 7.1.10 Binding of DDX1 to poly A or poly U sequences observed via gel-shift. Binding of a fluorescent FAM-labeled RNA 
(labeled at the 3’-end) to DDX1 was observed via a band-shift in a native gel. Increasing concentrations of DDX1-728 were 
incubated with labeled 10-mer RNA of indicated sequence for 20 min at 277 K. Reactions were separated on a 5%/15% native 
acryl-amide-gel with CHES pH 10 as running buffer. A, binding of DDX1 to a 10mer poly-A sequence is shown. B, binding of DDX1 
to a 10mer poly-U sequence is shown. 
The FAM label was visualized by illumination at 302 nm. Protein was stained with Coomassie-brilliant-blue to confirm positioning 
at the same height as the RNA signal (see right side). 
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Figure 7.1.11 Binding of DDX1 to RNA only. Binding of DDX1 to the same sequence of either fluorescent FAM-labeled RNA or 
DNA (labeled at the 3’-end) was observed on a native 15 % (w/v) TBE (pH 8.3) helicase gel. 10 μM of DDX1-728 were incubated 
with labeled 13-mer oligonucleotide[49] (either RNA or DNA, sequence as in figure 7.1.9) for 60 min at 277 K. Reactions were 
separated on a 15 % (w/v) native acryl-amide-gel with 0.5 x TBE pH 8.3 as running buffer. The FAM label was visualized by 
illumination at 302 nm. 
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Figure 7.1.12 DDX1 equilibrium titrations with mant-dADP.  A, to obtain a Kd,mantdADP  0.05 μM mant-dADP were titrated with 
DDX1 protein. B, to obtain an ADP-affinity (Kd,ADP) a mixture of 0.2 μM mant-dADP and 3 μM DDX1 was titrated with unlabeled 
ADP. C, a mixture of 0.2 μM mant-dADP and 1 μM DDX1 was titrated with ATP to obtain a Kd,ATP. Titration was conducted in the 
presence of an ATP-regenerating system.  
Binding data in A were fitted with the quadratic equation and the resulting affinity constant was used as input parameter for the 
competition experiments in B and C that were fitted with the cubic equation. All parameters obtained from these experiments are 
shown in table 7.1. 
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Figure 7.1.13 Confidence Intervals of parameters from global fit. All equilibrium titration experiments were fitted globally by 
numeric iteration in the program Dynafit[198]. The affinity constants obtained by the global fit are shown in table 3.4. A, confidence 
interval for the optimization of the kinetic parameter for ATP binding, Kd,ATP is shown. Best fit values for the parameter are plotted 
against the sum-of-squares of the deviation to the actual data. The final value that was reported is marked with a dashed square. 
B, confidence interval for the optimization of the kinetic parameter for RNA binding, Kd,RNA is shown. Representation as in A C, 
confidence interval for the optimization of the kinetic parameter for RNA binding to ATP-saturated DDX1, Kd(ATP),RNA is shown. 
Representation as in A. 
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Figure 7.1.14 Effect of RNA titration on ADP binding.  A, to test a potential influence of ADP on the RNA affinity of DDX1 a 
titration experiment was performed. A complex of 0.2 μM mant-dADP and 1 μM DDX1 was partially displaced by addition of 3 μM 
ADP. In a next step the actual experiment (as shown in the plot) was started by titrating 10mer polyA RNA. No RNA stimulated 
ADP binding (which would lead to a significant decrease in fluorescence) could be observed.  
 
 
 
 
 
 
 
 
 
 
Figure 7.1.15 DDX1 ATPase activity of K52A variant.  A variant of DDX1, where the canonical Walker A lysine had been replaced 
with an alanine was tested for its ATP hydrolysis activity in a coupled assay. 1 μM DDX1 K52A was used and during the time coure 
of the experiment 1 μM 20mer RNA (see mat&meth), 1 μM 10mer polyA RNA and 1 μM DDX1 WT were added as indicated. For the 
assay 4 U LDH and 2.8 U PK were mixed with 1 mM ATP in 50 mM Tris buffer pH 8.0, containing 0.5 mM NADH, 0.8 mM PEP, 
250 mM NaCl, 1 mM EDTA and 15 mM KCl. Reactions were started by addition of 5 mM MgCl2 and 1 μM of DDX1 K52A. Decrease in 
A340 is monitored and serves as a measure for the consumption of ATP (=generation of ADP). The K52A variant of DDX1 was 
ATPase deficient, which shows that the activity observed for WT DDX1 is protein specific and not cause by contaminations. 
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Figure 7.1.16 DDX1 ATPas stimulation by RNA and DNA.  DDX1 (construct DDX1-728) exhibits an intrinsic ATPase activity that 
can be stimulated by single stranded RNA or DNA/RNA hybrids, but not by dsDNA. For the assay 4 U LDH and 2.8 U PK were mixed 
with 1 mM ATP in 50 mM Tris buffer pH 8.0, containing 0.5 mM NADH, 0.8 mM PEP, 250 mM NaCl, 1 mM EDTA and 15 mM KCl. 
Reactions were started by addition of 5 mM MgCl2 and the indicated concentrations of protein. Decrease in A340 is monitored and 
serves as a measure for the consumption of ATP (=generation of ADP). 
 A, intrinsic ATPase activity of 1 μM DDX1-728 with a rate of 0.01 ΔAbs/min, which equals 1.61 μM (NADH)/min. B, RNA-stimulated 
ATPase rate of 0.03 ΔAbs/min equals 4.82 μM (NADH)/min. RNA that was used to stimulate was a 29-mer according to [111]. Note 
that the stimulation of the hydrolysis rate of 1 μM DDX1 by 0.5 μM RNA did not differe between different oligonucleotide 
sequences that were tested. All short RNA did stimulate hydrolysis activity by a factor of ~ 3. C, ATP-hydrolysis is stimulated by a 
DNA/RNA hybrid, which gives an ATPase rate of 0.038 ΔAbs/min that equals 6.13 μM(NADH)/min. DNA RNA hybrid corresponds to 
41mer DNA annealed to a 29-mer RNA according to [94] D, double-stranded DNA does not stimulate the ATPase rate of DDX1. 
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Figure 7.1.17 DDX1 ATPase stimulation by tRNA.  DDX1 exhibits an intrinsic ATPase activity that it not stimulated by DNA, but 
can be stimulated by high concentrations of tRNA. A, intrinsic ATPase activity of 1 μM DDX1-728 does not get stimulated by 
addition of DNA B, intrinsic ATPase activity does not get stimulated by addition of dsDNA C, highly structured tRNA-Phe does 
barely stimulate ATPase activity D, only at high concentrations of tRNA-Phe, a stimulating effect on ATPase activity is seen. 
 
 
 
 
 
Figure 7.1.18 ATPase activity of DDX1. RNA concentration dependence of the ATPase rate at saturating ATP concentrations and 
high concentrations of RNA is shown. 1 μM DDX1 was incubated with indicated concentrations of a 20mer RNA in the presence of 
10 mM ATP-MgCl2. The measured maximal initial reaction velocity (= ATPase rate) did not differ from measurements with 10 mM 
ATP-MgCl2 in the absence of RNA. 
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Figure 7.1.19 ATPase activity of DDX1. ATP concentration dependence of the ATPase rate at saturating RNA concentrations is 
shown. 1 μM DDX1 was incubated with indicated concentrations of ATP in the presence of 40 μM 20mer RNA. The measured 
maximal initial reaction velocity (= ATPase rate) did not differ in measurements with different ATP concentrations. 
 
 
 
 
 
 
 
Figure 7.1.20 DDX1 helicase gels, stained with Coomassie. The 15 % (w/v) native TBE-gels (pH 8.3) that were used for the DDX1 
helicase assay (see section 3.3.9, figures 3.4.1 and 3.4.2) were stained with InstantBlue® Coomassie stain to visualize the protein. In 
contrast to the EMSA gels (see section 3.3.3), in this case the protein did not enter the TBE-gels, but was stuck in the gel pockets. A, 
InstantBlue® Coomassie stain of the helicase gel, depicted in figure 3.4.1 a. B, InstantBlue® Coomassie stain of the helicase gel, 
depicted in figure 3.4.1 b. C, InstantBlue® Coomassie stain of the helicase gel, depicted in figure 3.4.2. 
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Figure 7.1.21 DED1 helicase assay with dsRNA substrate. A solution of 10 μM DED1 was incubated with 10 mM nucleotides and 
0.5 μM double-stranded RNA substrate as indicated. Reactions were incubated at 310 K for 60 min and then separated on a 15 % 
TBE-gel. The dsRNA substrate was designed according to Jankowsky, 2008[157]. 
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7.2 Supplementary tables 
 
Table 7.1 mant-dADP dependent equilibrium binding constants 
mant-dADP binding    
Kd,mantdADP 0.1237 +/- 0.028 µM 
    
ADP binding (mant-dADP)    
Kd,ADP 0.0963 +/- 0.0038 µM 
    
ATP binding (mant-dADP)    
Kd,ATP 129.3 +/- 25.8 µM 
 
 
 
Table 7.2. nucleotide binding affinities of DDX1 obtained in the global fit (by numeric iteration) 
mant-ADP binding    Δanalytical fit 
Kd,mantADP 0.5036 ± 0.2559 μM 0.3796 μM 
     
     
ATP binding     
Kd,ATP 124.927 ± 21.088 μM 4.373 μM 
Kd,(RNA),ATP 1.4  ± 21.088 μM 3.64 μM 
     
     
 
 
 
Table 7.3 Truncated constructs of DDX1 used in crystallization screens. 
Construct Co-factor/substrate Screens 
DDX1-432 apo JCSG suite 
DDX1-432 AppNHp JCSG suite 
DDX1-610 apo Classics 
DDX1-610 ATPγS Classics, JCSG suite 
DDX1-610 AppNHp Classics, JCSG suite 
DDX1-655 AppNHp Classics 
DDX1-694woSPRY apo JCGS suite, PEG suite 
   
-> constructs listed in the table did not form X-ray diffracting protein crystals with the screening conditions tested 
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7.3 Supplementary results on construct design, characterization 
and crystallization 
 
7.3.1 C-terminally truncated DDX1 constructs 
Based on analysis of the degradation products of full-length DDX1 by MALDI-MS combined with 
secondary structure predictions, several C-terminally truncated protein variants were generated to map 
for stable domain boundaries. Out of the generated fragments, constructs DDX1-655, DDX1-648 and 
DDX1-610 (see domain boundaries in Figure 3.1) were found in the soluble fraction upon bacterial 
expression.  These three C-terminally truncated variants of human DDX1 could be purified to higher 
homogeneity than all other constructs. 
All three constructs were used in crystallization experiments and activity assays (see Table 7.3). 
Unfortunately they did not yield protein crystals (see section on crystallization below) and were ATPase 
deficient (data not shown). This functional defect was probably caused by too stringent truncation as in 
the case of DDX1-610 already signature motif VI was missing. Due to the mentioned problems the 
constructs were abandoned and not used for further characterization of DDX1. 
 
 
7.3.2 RecA-like domain 1 of DDX1 
DEAD-box proteins consist of two RecA-like helicase domains that are connected by a flexible linker and 
can therefore sample a variety of different orientations of the two domains relative to each other. This 
flexibility interferes with crystallization. To be able to study the arrangement of the unique SPRY domain 
of DDX1 in the context of RecA-like domain 1 (where the SPRY domain forms an insertion) a modular 
approach was undertaken. The separated RecA-like domain 1 of DDX1 including the SPRY domain 
(amino acids 1-432, see Figure 3.1) was cloned. This construct, designated DDX1-432 could be 
expressed as a soluble protein in E. coli and purified to high homogeneity. The construct was stable and 
used in crystallization trials (see Table 7.3).  
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7.3.3 Co-crystallization of C-terminally truncated DDX1 in complex with non-
hydrolyzable ATP-analogs 
Purifications protocols were established for the generation of several DDX1 constructs that almost 
represent the full-length protein, only bearing slight C-terminal truncations (see section 7.3.1). The 
constructs DDX1-674, DDX1-694 and DDX1-728 were used in crystallization experiments. Out of the 
three constructs, DDX1-674 could be purified to highest homogeneity as assessed by SDS-gels (Figure 
7.3.1 b). 
 
 
 
 
Figure 7.3.1 Size exclusion chromatography run with DDX1-694/674. Fractions of S6 size-exclusion chromatography runs were 
separated on a 15% SDS-gel and identity of bands checked by MALDI-MS. A, protein construct DDX1-694 that is C-terminally 
truncated at Arg 694 was purified by a combination of 4 chromatographic steps. B, construct DDX1-674 was purified to high 
homogeneity by a combination of 4 chromatographic steps. 
 
DLS measurements with protein DDX1-674 (Figure 7.3.2 b) showed a peak width of the distribution of 
hydrodynamic radii of only 24.4 % RSD. Using temperature-dependent CD-unfolding a melting point of 
323.6 +/- 0.08 K was determined (Figure 7.3.2 a), indicating a reasonable stable protein, suitable for 
structural studies.  
 
 
    Appendix 
Appendix 178 
 
Figure 7.3.2 Stability and homogeneity of DDX1-674 construct. A CD melting curve of DDX1-674 monitored at 222 nm and 
fitted to a two-state-unfolding process yields a Tm of 323.6 +/- 0.08 K. CD values are in mean residue ellipticity = MRE. B, Data from 
DLS measurement with DDX1-674. The combined autocorrelation function (grey circles) is shown on the lower x-axis and a fit to 
this data is depicted as a black line.. The upper x-axis shows the distribution of the hydrodynamic radii by relative mass (amplitude 
of each bar indicates the percentage of the total mass of the sample) as obtained from the fit. The fit did yield a peak in the mass-
distribution of hydrodynamic radii at 4.15 nm (corresponding to a molecular weight of 95.38 kDa) and a peak width of 24.4 % RSD, 
which indicates a high degree of sample homogeneity. 
 
Crystallization trials were set-up using commercially available screens (see methods section 2.5.1). 
DDX1-674 at 20 mg/ml (= 250 μM) was screened in apo and in complex with 10 mM ATPγS and 
AppNHp, however, no crystal formation was observed. In contrast, a variant of DDX1-674, where the N-
terminal His-Tag had been cleaved off during purification (=DDX1-674ΔHis-Tag), showed crystal 
formation in the presence of an eightfold molar excess of ATPγS. Crystals were small and heavily 
intertwined. Crystal formation was observed with reservoir solutions containing either 10 % (w/v) PEG 
8000, 0.1 M CHES-NaOH pH 9.5, 0.2 M NaCl or 8 % (w/v) PEG 8000, 0.1 M Tris-HCl pH 8.5 (Figure 7.3.3).  
 
 
Figure 7.3.3 Crystals of DDX1-674ΔHis-Tag with ATPγS. DDX1-674ΔHis-Tag (without the N-terminal His-tag) at a concentration 
of 8 mg/ml = 105 μM, mixed with 8 x excess = 840 μM ATPyS, was used to set-up JCSG II screen (Qiagen). A, Crystal formation was 
observed after 2 days in condition A4 = 0.2 NaCl, 10% w/v PEG 8000, 0.1 M CHES pH 9.5. B, similar crystals formed in condition A12 
= 8% w/v PEG 8000, 0.1 M Tris pH 8.5. Crystal plates were stored at RT.  
 
Extensive screening around the two initial hit conditions was performed. Different PEG concentrations 
and different buffer pH values did neither improve crystal size nor lead to single crystals. Furthermore, 
Appendix 
 Appendix 179
the influence of additives on the crystals in the initial hit condition was tested, but did not show 
favorable effects. In the present form, the crystals are small and intergrown and can therefore not be 
used for X-ray diffraction experiments.  
 
7.3.4 Co-crystallization of DDX1 in complex with RNA  
A number of structures of DEAD-box proteins could be determined in complex with RNA[37] (PDB entries 
2DB3, 2HYI, 2J0S, 3I5X). In these structures RNA stabilizes the helicase core by binding across the two 
RecA-like domains, bridging them and bringing them close together[23, Bono, 2006 #114, Sengoku, 2006 #78, Del Campo, 2009 
#77], ensuring a rigid scaffold required for crystallization. The longest, stable DDX1 construct, DDX1-728 
was complexed with 10-mer poly A RNA and used for crystal screening. For this experiment DDX1-728 
protein (200 μM = 17 mg/ml) was mixed with 1000 μM 10-mer poly A RNA and incubated at 277 K for 20 
min, before setting-up the crystallization trials using the JCSG core suite (Qiagen, Hilden, Germany). 
Upon inspection of the plates immediately after setting the drops, heavy protein precipitation was 
observed in most wells of the JCSG screens. 
 
 
Figure 7.3.4 Crystallization of DDX1 in complex with 10mer poly A RNA. Exemplary conditions are shown that led to the 
growth of “bubbles” from protein precipitate after two days of incubation at room temperature. Conditions are from the JCSG 
core suite (Qiagen). A, B1 = 20 % w/v PEG 8000, 0.2 M MgCl2, 0.1 M Tris pH 8.5. B, C5 = 1.4 M tri-Na citrate, 0.1 M HEPES pH 7.5. C, 
G7 = 0.2 M NaCl, 1 M tri-Na citrate, 0.1 M Tris pH 7.0. D, D5 = 0.2 M Mg formate. 
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Within two days of incubation at 297 K, “bubble”-like protein conglomerates grew from the precipitate 
in several conditions around pH 7.0 in the JCSG screens (Figure 7.3.4). In a condition with magnesium 
formate elongated shapes were found that showed some sharp edges (Figure 7.3.4 d). Screening 
around the hit-conditions did not help to transform the “bubbles” into protein crystals.  
 
Furthermore, co-crystallization screening was also conducted with a different RNA substrate. The 14mer 
RNA that was used for the EMSAs (see section 3.4.3) (and was thereby confirmed to bind to DDX1) was 
employed to form a DDX1-RNA complex. To this purpose 200 μM (=17 mg/ml) DDX1-728 was mixed 
with 5 mM AppNHp, 10 mM MgCl2 and 1200 μM 14mer RNA  to form a ternary complex and used for 
screening in the JCSG core suite (Qiagen, Hilden, Germany). Two conditions of JCSG screen IV yielded 
small protein crystals (see Figure 7.3.5). In well A3, in 40 % (v/v) 2-Methyl-2,4-Pentanediol, 0.1 M CAPS 
pH 10.5 small rectangular crystals appeared after two days. In well B9, in 30 % (w/v) PEG 4000, 0.1 M Tris 
pH 8.5, 0.2 M MgCl2 intertwined rods grew after one day. For both conditions fine-screens were set-up in 
96-well format. For condition A3, 35 % (v/v) – 45 % (v/v) MPD and pH values from 9 to 11 were screened. 
For condition B9, 25 % (v/v) – 35 % (v/v) PEG 4000 and Tris pH 8.0 to 9.0 were screened. Crystals could 
not be reproduced in any of the fine-screens.  
 
 
Figure 7.3.5 Crystallization of DDX1 in complex with AppNHp and a 14mer RNA. Two conditions of the JCSG core suite IV 
(Qiagen, Hilden, Germany) are shown that led to the growth of crystals. A, condition A3 = 40 % (v/v) 2-Methyl-2,4-Pentanediol, 0.1 
M CAPS-NaOH pH 10.5 showed growth of small crystals, marked by blue circles. B, condition B9 = 30 % (w/v) PEG 4000, 0.1 M Tris-
HCl pH 8.5, 0.2 M MgCl2 led to the growth of intertwined rods. 
 
In conclusion, co-crystallization of DDX1 with RNA substrate was extensively tested, but the amorphous 
aggregates or small crystals obtained, were unsuitable for X-ray diffraction experiments. Two different 
RNA sequences of varying length and protein in AppNHp- or apo- form were probed to stabilize a 
protein conformation that forms crystals. No growth of crystals, appropriate for structural studies was 
observed in any of the tested screens.  
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7.3.5 Transient crystal formation by using in situ proteolysis 
To facilitate crystallization of stable fragments of DDX1, in situ proteolysis was employed. In this 
approach small quantities of a protease are added to the protein crystallization sample[282]. The protease 
slowly digests the protein and once stable fragments are produced, they can start to form crystals[282]. To 
this purpose a sample of recombinant DDX1 (construct DDX1-694) was spiked with protease and then 
immediately used to set-up crystallization screens, without assessing the efficacy of proteolysis, without 
purification of any degradation fragment and without stopping the proteolysis reaction[283]. Protein at 
20 mg/ml (= 250 μM) was mixed with 0.2 mg/ml (= 8 μM) chymotrypsin (1:100 dilution) and used for 
screening at 297 K. Chymotrypsin preferably cleaves hydrophobic residues and cleavage sites are likely 
to be less frequent than sites for other proteases[282]. Crystal formation was observed after three days in 
JCSG screen I (Qiagen, Hilden, Germany), condition A1 (20 % (w/v) PEG 8000, 0.1 M CHES-NaOH pH 9.0) 
and A2 (20 % (w/v) PEG 6000, 0.1 M BICINE-NaOH pH 8.5) (Figure 7.3.6). 
 
 
 
Figure 7.3.6 Crystals obtained by in-situ proteolysis. In situ proteolysis was used to obtain crystals with construct DDX1-694. A, 
SDS-gel showing the degradation of aliquots of the crystallization sample (DDX1-694 and chymotrypsin) after 2 hours and after 5 
days. B, In an in-situ proteolysis experiment DDX1-694 at a concentration of 20 mg/ml was mixed with 0.2 mg/ml chymotrypsin 
and used to set-up JCSG I screen (Qiagen). Crystal formation was observed after 3 days in well A1 = 20% w/v PEG 8000, 0.1 M 
CHES-NaOH pH 9.0 (depicted here) and A2 = 20% w/v PEG 6000, 0.1 M BICINE-NaOH pH 8.5. Crystal plates were stored at RT. C, 
Optimized crystal found in a screen around the original hit conditions at 15% w/v PEG 6000, 0.1 M BICINE-NaOH pH 8.5. UV-
pictures show Tryptophan-Fluorescence of protein-crystals. 
 
Initial crystals consisted of multiple intergrown plates. By screening around the original hit condition, 
single crystals of a diameter of ~ 26 μm were obtained (Figure 7.3.6 c). Yet, crystal size was not 
sufficient for diffraction measurements and was resistant to optimization. After ten days, these crystals 
disappeared, which may be explained by the ever progressing proteolysis by chymotrypsin.  
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7.3.6 DDX1 without the SPRY insertion = DDX1ΔSPRY 
Extensive partial proteolysis experiments were conducted with construct DDX1-694 and several 
commercially available proteases (Figure 3.4, 7.3.7 and 7.3.8). Peptide fragments, obtained in these 
partial proteolysis experiments were identified via MALDI-MS PMF (Figure 3.4). Based on these results, 
the entire SPRY domain was removed from DDX1 to facilitate structural studies on the helicase core.  
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Figure 7.3.7 Limited proteolysis of DDX1 with Thermolysin, Chymotrypsin and proteinase K. Construct DDX1-694 was 
digested with Thermolysin or Chymotrypsin proteases (1 μg protease per 1600 μg protein) and reactions were quenched at the 
indicated time points (in min). Degradation bands were identified by MALDI-MS.  
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Moreover, another partial proteolysis experiment was performed, where the products of a 24 h digest of 
DDX1-728 with trypsin were loaded on a Ni2+-NTA affinity column (Figure 7.3.8). Fragments, 
corresponding to the SPRY domain (according to MALDI-MS PMF) were found in the flow-through, 
whereas RecA-like domains 1 and 2 were retained and could be eluted with an Imidazole wash. This 
further suggested that RecA-like domains 1 and 2 potentially interact tightly, but the SPRY domain does 
not and is separated from the core fold. 
 
 
 
Figure 7.3.8 Products of limited proteolysis, separated via Ni2+-affinity chromatography. Construct DDX1-694 was digested 
with trypsin over night. Digested protein sample was then loaded on a Ni2+-affinity column. The column was extensively washed 
and then the bound protein was eluted by flushing the column with Imidazole. The lower two bands at around 28 kDa that are 
seen in the DDX1 digest lane, were not bound to the Ni2+-NTAbeads. Those two bands correspond to the SPRY domain according 
to MALDI-MS. Apparently this domain does not extensively interact with the rest of the protein that stays bound to the Ni2+-NTA, 
due to the presence of a His-Tag.  
 
 
To create a DDX1 constructs that lacks the SPRY domain, initially the entire region coding for the SPRY 
domain was removed (Asp70 – Pro284). Domain boundaries were inferred from the MALDI-MS PMF 
results and refined based on sequence alignment of the entire sequence of human DDX1 with other 
helicases (see Figure 3.2.12). However, due to solubility problems of this initial construct, further 
constructs harboring less stringent SPRY domain excisions were designed. 
Several of these constructs of human DDX1, lacking the SPRY domain, were screened for expression and 
solubility. Out of a few constructs that were expressed as stable proteins in E. coli, only one did not show 
aggregation on a size exclusion column. This construct, designated ‘DDX1-694ΔSPRY’ did comprise 
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amino acids 1-68 and 248-694 of DDX1, i.e. the stretch comprising Asp70 to Phe247 had been removed. 
The construct was purified as WT DDX1 protein (Figure 7.3.9, see materials and methods, section 2.3.3). 
 
 
Figure 7.3.9 His-Trap chromatography run with DDX1-694ΔSPRY. The construct of DDX1 lacking the SPRY domain (DDX1-
694ΔSPRY) was purified by Ni2+ affinity chromatography. Elution fractions were separated on a 15% SDS-gel. 
 
The purified and concentrated construct DDX1-694ΔSPRY (see materials and methods, section 2.3.3) 
was tested for its folding and stability via CD measurements (Figure 7.3.10). The spectrum and the 
stability were similar to WT DDX1 protein (compare Figure 3.3.1). 
 
 
 
Figure 7.3.10 Folding of DDX1-694ΔSPRY. On the left side a CD spectrum of DDX1-694ΔSPRY is shown. CD signal measured with 
5 μM protein was converted to mean-residue-ellipticity (MRE). On the right side, the temperature dependent unfolding curve as 
monitored by recording CD signal at 222 nm is shown. The data were fitted to a two-state-unfolding process. The fit yields a 
melting temperature Tm of 324.7 ± 0.10 K for DDX1-694ΔSPRY. 
 
 
In contrast to WT DDX1 protein, purified recombinant construct DDX1-694ΔSPRY still displayed large 
heterogeneity after four column purification steps, detected in DLS measurements (Figure 7.3.10).  
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Figure 7.3.11 DLS measurements with DDX1-694ΔSPRY. The construct of DDX1 lacking the SPRY domain (DDX1-694ΔSPRY) was 
purified by 4 chromatography steps and then measured in a dynamic light scattering setup. A, combined autocorrelation function 
from 20 four second measurements is plotted in grey and a fit to the data in black. B, the distribution of the hydrodynamic radii by 
relative mass (amplitude of each bar indicates the percentage of the total mass of the sample) as obtained from the fit is shown. 
The fit did yield a peak in the mass-distribution of hydrodynamic radii at 3.99 nm (corresponding to a molecular weight of 87.13 
kDa. Peak width is 50.4 % RSD, which corresponds to a heterogeneous sample.  
 
 
After extensive optimization construct ‘DDX1-694ΔSPRY’ was obtained in quantities suitable for 
crystallization experiments. This construct did not show crystal formation in ‘apo’ and revealed large 
sample heterogeneity in DLS measurements (Figure 7.3.11). For this reason no crystal screening with 
RNA was conducted with the ‘DDX1-694ΔSPRY’ construct. Furthermore, construct “DDX1-694ΔSPRY” 
was tested for its ability to hydrolyze ATP and was found to be ATPase deficient.  
 
 
 
 
 
7.3.7 Purification of DED1 
A Plasmid coding for DED1 from S. cerevisiae - pET22b(DED1) was kindly provided by Isabelle Iost 
(Laboratoire ARN: Régulations Naturelle et Artificielle, INSERM U869, Université Victor Segalen, 146 rue 
Léo Saignat, 33076 Bordeaux, France). 
DED1 was expressed in E. coli and purified as described in Iost and colleagues, 1999[59] and Fairman and 
colleagues, 2004[81]. Relatively pure DED1 protein could already be obtained by a single HisTrap Ni2+ 
affinity column run (Figure 7.3.12). 
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Figure 7.3.12 Purification of the yeast protein Ded1p. A construct of the yeast DEAD-box helicase Ded1p (in vector pET22b) that 
is involved in translation initiation was obtained from Isabelle Iost. The protein was expressed in E. coli and purified by initial Ni2+-
NTA affinity chromatography. Elution fractions from the Ni-beads were loaded on a 15% SDS-gel. Bands that were identified via 
MALDI-MS are indicated on the right.  
 
 
 
 
 
 
 
7.4 Comments on DDX1 crystallization experiments 
 
7.4.1 Crystallization of full-length DDX1 
No crystals of the DDX1 helicase in its entity were obtained. As could be seen from limited proteolysis 
experiments (Figure 7.3.7), DDX1 consists of three major domains – RecA-like domains 1 and 2 and the 
SPRY domain – that are connected by flexible linkers. Individual domains were identified as relatively 
protease resistant elements, but the connecting linker regions get readily cleaved (Figure 3.4). The 
flexibility in the domain linkage and in the orientation of the domains relatively to each other probably 
precludes the formation of ordered protein crystals (Figure 7.4.1 left side).  
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Figure 7.4.1 Flexible linkage of the three DDX1 domains. The three domains that form DDX1 are connected by flexible linkers. 
Upon binding of ATP and RNA, helicase domains 1 and 2 come close together and form the conformationally more rigid “closed” 
state. The orientation of the SPRY domain in this “closed” state is unknown and it might wobble between different conformations 
(indicated by dashed arrows). The SPRY domain is depicted in brown, RecA-like domain 1 in green and RecA-like domain 2 in blue. 
 
For many other DEAD-box proteins well-diffracting crystals were obtained by complexing the proteins 
with RNA in co-crystallization experiments(Sengoku, Nureki et al. 2006). These nucleic-acid-bound 
structures show that the RNA binds on top of RecA-like domains 1 and 2 and keeps the helicase in a 
relatively rigid “closed” conformation(Mallam, Del Campo et al. 2012). In contrast to the proteins, whose 
structures could be solved by these means, DDX1 bears the large SPRY domain in its helicase core 
(Figure 7.4.2 right side). This domain may also interact with RNA and probably influences DDX1 
function. Since the domain insertion is large (~ 24 kDa) and positioned at a prominent location in the 
helicase core, it most probably has an influence on the conformation of the protein and on the relative 
orientation of the two helicase domains.  
Two different RNAs were tested in crystallization experiments. No X-ray diffracting protein crystals of 
DDX1 in complex with RNA and ATP analogues were obtained. It could be shown by biophysical 
experiments though that the RNA oligomers used in crystal screening bind to DDX1 with relatively high 
affinity. Therefore, the inability to form crystals was attributed to domain flexibility or other structural 
determinants within the protein. Since the SPRY domain differentiates DDX1 from other DEAD-box 
helicases (that formed crystals with RNA) it is well possible that this domain insertion is one major 
element that hinders crystal formation. Therefore, a variant of DDX1 was engineered that lacks the SPRY 
domain. This construct did not crystallize, which might this time be due to folding problems of the 
mutilated protein variant. To speculate on the complete DDX1 protein and to build a homology model, 
it was presumed that the structure of DDX1 without the SPRY domain resembles the canonical DEAD-
box helicase core. This assumption is valid due to significant sequence homology to other DEAD-box 
proteins (Figure 3.2.11). Several structures of such a helicase core have been deposited in the PDB[33, 
Hogbom, 2007 #12], which eased the search for a suitable modeling-template (Figure 7.1.1). Nevertheless due 
to the metabolic impact of human DDX1 a validation of the core structure by X-ray crystallography 
would be of interest. 
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7.4.2 Crystallization of DDX1 helicase domain 1 
Extensive crystallization experiments have been conducted with construct DDX1-432, representing 
helicase domain 1/RecA-like domain 1. A structure of the separated RecA-like domain 1 of DDX1 would 
reveal the arrangement of the SPRY domain within the conserved helicase core. This would give 
important information on the possible influence of this domain on ATP-binding and ATP-hydrolysis, 
depending on its orientation to the ATPase active site. The SPRY domain might sterically obstruct the 
ATP-binding-site or it might interact with residues essential for ATP hydrolysis. Depending on the 
position of the SPRY domain with its surface charges, a structure would also give important clues on the 
role in binding RNA substrate. The SPRY domain may enlarge the RNA-binding site of helicase domain 1, 
formed by motifs Ia, Ib and Ic. A similar function has been observed for the C-terminal extension of yeast 
Mss116p[35].  
The separated helicase domain 1, construct DDX1-432 did not crystallize. For many other DEAD-box 
proteins structures of the separated helicase domains have been solved[29, 40, 45]. For DDX1 again the 
SPRY insertion probably constitutes a major flexible element in helicase domain 1 that hinders 
crystallization. For further structural studies on DDX1 it might prove very helpful to crosslink the SPRY 
domain to the rest of the helicase. A crosslink could reduce flexibility and confer the ability to form 
ordered protein crystals. Such a crosslink has recently successfully been used for the crystallization of 
the chaperone DnaK in the ATP state[284].  
Moreover components of the pentameric HSPC117 may interact with DDX1 directly via the SPRY 
domain (see section on SPRY structure). Addition of a DDX1-SPRY interacting component to the 
crystallization sample could also facilitate the formation of an ordered protein crystal by a great deal. 
 
 
7.4.3 DDX1 conformational changes by nt binding – limited proteolysiss 
Peptide fragments obtained by limited proteolysis of DDX1 in the presence or absence of nucleotides 
are identical (Figure 3.3.2). However, concluding from nucleotide binding and ATPase data, a 
conformational change upon binding of ATP is expected. There could be several reasons, why this 
conformational change is not reflected in the experimental limited proteolysis degradation pattern. 
First protease sites may not be influenced by the altered protein conformation and remain accessible 
for cleavage. Especially linker regions between the individual domains most probably display only 
minor positional changes between the “open”- and “closed”-state of the helicase. Second, AppNHp 
might not constitute an ideal replacement for ATP. Third, nucleotide might be constantly exchanged at 
the active site, which would make loops temporarily available for protease cleavage even in the 
presence of ATP analogues.  
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7.4.4 Structural studies on the HSPC117 tRNA ligation complex 
Besides gaining structural insights into DDX1, major interest also lies in determining the three-
dimensional structure of the entire human HSPC117 complex[119], which is involved in tRNA 
processing[114] (see Introduction section 1.3.1). Individual components of the HSPC117 complex were 
cloned and recombinantely expressed in E. coli. Proteins were either insoluble or showed aggregation at 
concentrations necessary for structural studies. Due to this lack in availability of recombinant HSPC117 
complex components, crystallization experiments with the entire complex were not conducted. A 
possibility to rescue aggregated complex components might be co-expression. In this thesis mixing of 
bacteria lysates, expressing individual complex components has been tested. This combination of 
lysates did not assist the solubilization of aggregated protein (Figure 3.1.5). Actual bacterial co-
expression of the proteins from the same vector may help to obtain soluble material from Fam98b and 
HSPC117. To explore which protein components can be expressed together, extensive interaction 
studies with the individual components are necessary (Figure 3.1.6). These interaction studies can 
already be conducted with the recombinant material from DDX1, CGI-99 and Fam98b. The 
establishment of expression and purification protocols for these proteins is described in this thesis (see 
section 3.1.4).  
Moreover, the concomitant expression of all five complex components in bacteria might constitute 
another salvage strategy. Yet a further possibility to obtain material for structural studies on the 
complex could be expression in eukaryotic cells. The vector PFBDM, containing four of the complex 
components, DDX1, HSPC117, Fam98 and CGI-99 is available (cloned by Maike Gebhardt)[285]. This vector 
is suitable for the expression of eukaryotic protein complexes in insect cells[285]. Expression in insect cells 
offers additional advantages to bacterial expression, including post-transcriptional-modification of the 
peptides[286]. This constitutes the most promising approach to obtain material for determening the 
molecular structure of the HSPC117 complex in ensuing studies. 
Since in the complete HSPC117 complex, all five protein components interact in a stoichiometric 
fashion and constitute a relatively stable particle[108], it is imaginable that they form X-ray diffracting 
crystals. 
Of note the structure of the Pyrococcus horikoshii HSPC117/RtcB homologue ‘PH1602-extein protein’ has 
been solved and deposited in the PDB[287] (1UC2). This structure can guide the design of constructs for 
the recombinant expression of human HSPC117 in insect cells. 
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7.4.5 The SPRY domain and the HSPC117 complex-components may control the 
enzymatic cycle of DDX1 
 
The SPRY domain provides a putative protein-protein interaction platform within DDX1 and primary 
candidates for docking are the factors of HSPC117 complex. Binding of co-factors to the SPRY domain 
can potentially modulate DDX1’s enzymatic activity by influencing catalytically important residues via 
allosteric pathways. In addition, the SPRY domain seems to be flexibly connected to the helicase core 
and could change its relative orientation and thereby sterically block the active site. Furthermore, the 
putative function of the SPRY domain in extending the RNA binding surface of the helicase provides 
means of functional regulation of DDX1(Figure 7.4.2).  
The HSPC117 complex contains four proteins, additionally to DDX1, out of which three are poorly 
characterized. Complex components may act as nucleotide exchange factor or activate the ATPase cycle 
by stimulating RNA release. In addition, in the cell, they could direct DDX1 to a specific substrate (Figure 
7.4.2). 
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Figure 7.4.2 Roles of the SPRY domain and the HSPC117 complex in controlling the enzymatic activity of DDX1. The SPRY 
domain insertion within DDX1 is a putative protein-protein interaction platform, but may also extend the RNA interaction surface. 
It seems to be flexibly connected to the helicase core and in this way may conditionally block the active site. Due to the spatial 
proximity to the conserved helicase motifs, it could also modulate ATPase and helicase activity. The SPRY domain potentially 
interacts with factors of the HSPC117 tRNA ligation complex. HSPC117 complex component may act similar to factors in Dbp5- 
and eIF4A-DEAD box helicase complexes. They could constitute a nucleotide-exchange-factor and ATPase activating factor. They 
could also direct DDX1 to specific (structured) substrates. 
 
 
 
 
7.4.6 Approaches for future studiess 
The results from this work are the basis for deeper understanding of DDX1’s metabolic role and the 
function of DEAD-box proteins in general. They enhance the working model for eukaryotic DEAD-box 
proteins by introducing synergistic effects of ATP and RNA binding and by potentially providing each 
molecule on its own with the ability to induce conformational changes of the protein. The data also 
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have to be incorporated in the current mechanistic models of DDX1 to explain its cellular role and to 
devise in vivo experiments.  Using the functional details reported in this thesis, upcoming studies can 
concentrate on several cellular aspects of DDX1.  
The role of DDX1 in viral replication, specifically its interaction with HIV-1 REV protein[135], is definitely 
worthwhile further investigation. Affinity and binding constants for ATP, ADP and RNA can serve as the 
basis for an in-depth analysis for the hijacking function of viral transcripts and their modulatory 
propensity.  
It could be rewarding to experimentally evaluate the role of extended surface A of the SPRY domain in 
RNA binding. Spectroscopic assays for assessing the RNA affinity have been established (see chapter 
3.3.7), which paves the way for mutagenesis studies. Altering the charge of the identified positively 
charged patch by replacing residues could potentially change RNA affinity[288]. This, of course, would 
argue for a role of the SPRY domain in binding and tethering of RNA substrates to the helicase. Such a 
function could be conditional as it is dependent on the individual orientation of the SPRY domain 
relatively to the helicase core (suppl. Figure 7.4.1).  
 
Research on the function of DDX1 in tRNA ligation can be further focused on structural studies of the 
HSPC117 complex. Here the structure of the SPRY domain of DDX1 is reported that provides a potential 
docking platform for the other HSPC117 complex protein components. Crystallization experiments 
could use cross-linking of the SPRY domain to either the DDX1 helicase core or to other protein factors 
in the complex. Arresting of the flexible SPRY domain could greatly facilitate protein crystal formation. 
The recombinant expression of some of the HSPC117 complex components, besides DDX1, is described 
in this thesis and with some additional optimization these proteins could be used for co-crystallization 
experiments. Remaining factors of the complex can be obtained e.g. from insect-cell expression. Prior to 
crystallization though, extensive interaction studies with the five protein components are necessary. 
 
The general role of DDX1 in RNA processing is given a biochemical groundwork by the data in this 
thesis. The spectroscopic assays that were established for measurement of nucleotide affinity of DDX1 
can be used for extensive mutagenesis studies. The implication of mutations in the conserved surface 
patch of the SPRY domain on RNA binding parameters can easily be accessed. Furthermore, the 
implications of those mutations on DDX1’s enzymatic parameters like e.g. ATP hydrolysis are 
worthwhile to be investigated. A detailed mutational analysis of DDX1 should also include the 
conserved helicase motifs. This can provide an answer to the question, which residues are involved in 
establishing the cooperativity between ATP and RNA binding. Additionally, it will be very interesting to 
see, whether RNA binding may rescue ATP binding deficiencies of different Walker A and B motif 
variants. 
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7.5 General figures on helicase structure and mechanisms 
 
 
 
Figure 7.5.1 Helicase superfamilies 1 and 2, classification.The phylogenetic relationship between the SF1 and SF2 helicase 
families is shown, based on data from Jankowsky and Fairman-Williams 2010[12].  
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Figure 7.5.2 Strand-annealing and “chaperone-like” functions of DEAD-box proteins. A, DEAD-box proteins can accelerate 
the RNA duplex formation of two strands in solution without requirement of ATP. If strand annealing occurs intramolecular this 
can facilitate RNA folding. B, DEAD-box proteins can act as RNA-chaperones by non-specific unfolding of local structure. The less 
stable misfolded conformation is more readily “attacked” and unwound by DEAD-box helicases than the stable native structure. 
The helicase thereby shifts the equilibrium towards the native RNA state. 
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7.6 Details on the functions of DDX1  
 
Table 7.6.1 Functions of DDX1 in RNA processing 
 (involvement as shown in previous studies) 
Interaction Localization Implication Reference 
 colocalization with cleavage bodies in 
discrete nuclear foci 
pre-mRNA processing [91] 
Binding to RNA cleavage 
stimulation factor (CstF-64) 
 pre-mRNA processing [91] 
 Component of mRNA transporting granules 
together with HSPC117 and CGI-99 
mRNA transport [115] 
Interaction with 
heterogeneous nuclear 
ribonucleoprotein K (hnRNP K) 
and poly(A) RNA 
 transcription regulation [109] 
 Found in cytoplasmic stress granules in an 
RNP complex with YN-1 and MBNL1 
(muscleblind-like) 
splicing [116] 
Competes with 14-3-3 
proteins for binding to 
KSRP(Kunde, Musante et al. 
2011) (K homology splicing 
regulatory protein) 
 AU-rich element mediated 
decay (AMD) 
[117] 
Together with DDX21, DHX36 
and TRIF it forms a receptor 
that recognizes viral dsRNA 
and elicits type I interferon 
(IFN) and cytokine responses. 
In the complex only DDX1 
binds directly to viral RNA 
 Innate immune system 
(sensor of viral RNAs) 
[137] 
Binds to RelA and thereby 
enhances nuclear factor 
kappaB-mediated 
transcription 
 transcription regulation [110] 
 Is recruited to sites of DNA damage 
containing RNA-DNA structures 
DNA repair [111] 
 
 
 
 
Posttranslational modification may also play a role in the regulation of DDX1 activity as in vivo it is 
phosphorylated in its helicase core and in the C-terminal region (Figure 7.6.1)[111, 289]. 
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Figure 7.6.1 Interaction of DDX1 with proteins involved in RNA procesing. The regions of DDX1 that interact with other 
proteins are colored. Regions that interact with hnRNP K (heterogeneous nuclear ribonucleoprotein K) are coloured in purple, 
with RelA (p65) in red, with HIV Rev (regulator of virion) in green, and with CstF (Cleavage stimulation factor), MBNL1 
(muscleblind-like), KSRP (K homology splicing regulator protein) in grey. Additionally phosphorylation sites are marked.  
 
For the DDX1 homolog from Gallus gallus expression levels during development were investigated. 
Highest levels of DDX1 were found at early stages of development and tissue maturation was 
accompanied by a decrease in expression[290]. 
 
 
 
Table 7.6.2 Role of DDX1 in formation and progression of tumors 
 (DDX1 in cancer progression) 
Type of Cancer Involvement Reference 
Neuroblastoma DDX1 is overexpressed; 
DDX1 is coamplified with MYCN 
[79, 110, 111] 
Retinoblastoma DDX1 is overexpressed; 
DDX1 is coamplified with MYCN 
[79, 110, 111] 
testicular germ cell tumors DDX1 activates transcription in testicular germ cell tumors and 
is a critical factor for testicular tumorigenesis 
[112] 
Wilms tumor DDX1 is amplified in Wilms tumor [291] 
alveolar rhabdomyosarcoma 
cell lines 
DDX1 is amplified [114] 
Breast cancer Elevated DDX1 mRNA levels and elevated cytoplasmic DDX1 
protein levels are associated with relapse and poor survival 
[124] 
 
 
 
Table 7.6.3 Functions of DDX1 in viral replication pathways 
 (hijacking of the body’s own helicase) 
Virus Function Reference 
JC virus (polyoma virus) high DDX1 expression renders cells susceptible to infection;  
DDX1 binds to the transcriptional control region of  JCV 
together with CstF-64, which leads to productive expression and 
accumulation of viral transcripts 
[98, 99] 
Coronavirus DDX1 binds to nonstructural protein 14 and colocalizes with 
viral RNA in the cytoplasm; 
Mutation of helicase motif II (DEAD) in DDX1 eliminated 
colocalization and replication of coronavirus, indicating an 
essential role for ATP hydrolysis and enzymatic activity of DDX1 
[131] 
Hepatitis C virus DDX1 binds to the 3’ untranslated-region (3’UTR) together with 
five other cellular proteins 
[132] 
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HIV type 1 DDX1 is involved in HIV-1 mRNA trafficking;  
DDX1 interacts with the regulator of virion (Rev) protein and 
plays an important role in the nuclear export of unspliced 
mRNAs via the Rev-CRM1 pathway;  
DDX1 promotes oligomerization of Rev on Rev-response-
element (RRE) mRNA, which is essential for the export; 
DDX1 can specifically bind to Rev in the absence of RNA and has 
an RRE RNA stimulated ATPase activity; 
RNA silencing experiments provide evidence that DDX1 is 
required for both Rev activity and production of HIV-1 virus 
particles; 
DDX1 cooperates with other DEAD-box helicases to modulate 
the HIV-1 Rev function 
[102-107] 
 
 
 
Figure 7.6.2 HIV-1 utilizes DDX1 for export of viral mRNAs via the Rev pathway. The Rev/RRE export pathway for unspliced 
viral mRNAs in HIV-1 is depicted. Rev protein binds to RRE on the mRNA assisted by DDX1. Oligomerization of Rev on RRE is 
essential for the export. 
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7.7 List of primers 
 
Cloning primers 
name Sequence [5’ -> 3’] application 
DDX1_NheI_fwd GGGAAGGGCTAGCATGGCGGCCTTCTCCG Amplify the DDX1 ORF, 
primer contains NheI 
site for cloning into 
pET28a 
DDX1_NotI_rev GGGATCGCGGCCGCTCAGAAGGTTCTGAACAGCTG Amplify the DDX1 ORF, 
primer contains NotI 
site for cloning into 
pET28a 
Fam98b_NheI_fwd1 TAGATGCTAGCATGAGAGGGCCGGAGCCGGG Amplify Fam98b from 
PFBDM, primer 
contains NheI site for 
cloning into pET28a 
Fam98b_XhoI_rev1 TAGATCTCGAGTTACCAGGACATGAAAGAAAAAT Amplify Fam98b from 
PFBDM, primer 
contains XhoI site for 
cloning into pET28a 
CGI-99_NheI_fwd1 TAGATGCTAGCATGTTCCGACGCAAGTTGACGGCTCTCG Amplify CGI-99 from 
PFBDM, primer 
contains NheI site for 
cloning into pET28a 
CGI-99_XhoI_rev1 TAGATCTCGAGTCATCTTCCAACTTTTCCCAGTCTGTG Amplify CGI-99 from 
PFBDM, primer 
contains XhoI site for 
cloning into pET28a 
ASW_NdeI_fwd2 TATAATCATATGGCGGGGGATGTGGGC GGTCGC Amplify the ASW ORF, 
primer contains NdeI 
site for cloning into 
pET28a 
ASW_BamHI_rev1 TAGATGGATCCTTATCAGGGCCAAGTAACATGTTG Amplify the ASW ORF, 
primer contains BamHI 
site for cloning into 
pET28a 
 
Site-directed-mutagenesis primers (mutations are underlined, introduced nucleotides are italic) 
name Sequence [5’ -> 3’] application 
DDX1_genBamHI-pGEX_f GCAGCCATATGGATCCGCTAGCATGGCGGC Generate a BamHI 
site at the N-terminus 
of DDX1 to clone it 
into pGEX-4T-1 
vector 
DDX1_genBamHI-pGEX_r GCCGCCATGCTAGCGGATCCATATGGCTGC see above 
DDX1_StopVal610_f CGGTGTTCCTTATGTTTGATAAGTCACTCTGCC Introduce double 
stop-codon after 
Val610 to generate 
pET28a(DDX1-610) 
DDX1_StopVal610_r GGCAGAGTGACTTATCAAACATAAGGAACACCG see above 
DDX1_StopArg648_f CAACAGAAAAAGAAAGGTGATAAACCATGTATGTAGC Introduce double 
stop-codon after 
Arg648 to generate 
pET28a(DDX1-648) 
DDX1_StopArg648_r GCTACATACATGGTTTATCACCTTTCTTTTTCTGTTG see above 
DDX1_StopSer655_f CCATGTATGTAGCTGATAAGGAAAAGGG Introduce double 
stop-codon after 
Ser655 to generate 
pET28a(DDX1-655) 
DDX1_StopSer655_r CCCTTTTCCTTATCAGCTACATACATGG see above 
DDX1_StopGlu674_f CATTTCTCAGGTTGAGTGATAAATAAAGGTACC Introduce double 
stop-codon after 
Glu674 to generate 
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pET28a(DDX1-674) 
DDX1_StopGlu674_r GGTACCTTTATTTATCACTCAACCTGAGAAATG see above 
DDX1_StopArg694_f CGGTCAGAAAAGGTGATAACTGCTGGTGGTG Introduce double 
stop-codon after 
Arg694 to generate 
pET28a(DDX1-694) 
DDX1_StopArg694_r CACCACCAGCAGTTATCACCTTTTCTGACCG see above 
DDX1_StopHis728_f GACATCTTTCCTGCATTGATAATACCTTCCTAAC Introduce double 
stop-codon after 
His728 to generate 
pET28a(DDX1-728) 
DDX1_StopHis728_r GTTAGGAAGGTATTATCAATGCAGGAAAGATGTC see above 
DDX1_StpLys432_f CATGGGTTGACTTAAAATGATAAGACTCTGTTCC Construct of 
separated RecA-like 
domain 1 (including 
the SPRY domain) 
DDX1_StpLys432_r GGAACAGAGTCTTATCATTTTAAGTCAACCCATG see above 
DX1SPRY_1gBamH-f GTTTATGAAACTCTGAAAGGATCCCAGGAAGGCAAAAAAG Gen BamHI site after 
Lys69 to remove 
SPRY domain 
DX1SPRY_1gBamH-r CTTTTTTGCCTTCCTGGGATCCTTTCAGAGTTTCATAAAC see above 
DX1SPRY_2gBamH-f CAAACAAAGTTTGGATCCAATGCTCCGAAAGC Gen BamHI site 
before Asn285 to 
remove SPRY domain 
DX1SPRY_2gBamH-r GCTTTCGGAGCATTGGATCCAAACTTTGTTTG see above 
DX1SPRY_3gBamH-f CGGTGAAGAGGGATCCAAGTTTCCACCAAAAG Gen BamHI site 
before Lys248 to 
remove SPRY domain 
DX1SPRY_3gBamH-r CTTTTGGTGGAAACTTGGATCCCTCTTCACCG see above 
DX1_WlkrA_KtoA_f GAAACAGGAAGTGGCGCAACTGGTGCTTTTAG Mutate Lys52 to Ala 
(Walker A) 
DX1_WlkrA_KtoA_r CTAAAAGCACCAGTTGCGCCACTTCCTGTTTC see above 
DX1SPRY_4gXhoI-f CAAACAAAGTTTCTCGAGAATGCTCCGAAAGCTC Generate XhoI site 
downstream of the 
SPRY domain to clone 
it as BamHI-XhoI 
fragment 
DX1SPRY_4gXhoI-r GAGCTTTCGGAGCATTCAGGAGAAACTTTGTTTG see above 
   
SPRY_Gly84BamH-f GAAAAACAACAATTAAAGGATCCGCTTCAGTGCTG Generate BamHI site 
after Gly84 to 
truncate N-term of 
SPRY domain 
SPRY_Gly84BamH-r CAGCACTGAAGCGGATCCTTTAATTGTTGTTTTTC see above 
SPRY_Ser100BmH-f CATATGACAGAGGATCCGCTTTTGCAATTGGG Generate BamHI site 
after Ser100 to 
truncate N-term of 
SPRY domain 
SPRY_Ser100BmH-r CCCAATTGCAAAAGCGGATCCTCTGTCATATG see above 
SPRY_StopAla261_f CTCTTTCCAAGGCATGATAAGGTTACATTG Generate double 
stop-codon after 
Ala261 to truncate C-
term of SPRY domain 
SPRY_StopAla261_r  CAATGTAACCTTATCATGCCTTGGAAAGAG see above 
 
 
Sequencing primers 
DDX1_NheI_fwd GGGAAGGGCTAGCATGGCGGCCTTCTCCG Sequence N-terminus of 
DDX1 
DDX1_seq_1 TCTTTCCAAGGCACCGGATG Sequence middle region of 
DDX1 
DDX1_NotI_rev GGGATCGCGGCCGCTCAGAAGGTTCTGAACAGCTG Sequence C-terminus of 
DDX1 
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pET_bone_for ATGCGTCCGGCGTAGAGGATC Sequence pET28a MCS from 
N-terminus 
pET-28b_back_r GCGGTGCAAGCGGGCCGAAAGGTTCGAATATACG Sequence pET28a MCS from 
C-terminus 
 
 
 
7.8 Numerical data analysis with Dynafit 
 
To extract RNA binding affinities of DDX1, all equilibrium titration data for the binding of mant-labeled 
and unlabelled ATP/ADP in the presence and absence of RNA was fitted globally by numeric iteration 
using Dynafit[198] (see results section 2.4.7, Biokin ltd). The Dynafit input script file (in *.txt format) 
contains the binding mechanism, that gets converted to a system of equations to describe the 
alterations of the different species. The parameters of the equations are optimized to obtain a minimal 
deviation of the simulations to the input data traces. 
The script file first contains the tasks, meaning the form of data (equilibrium titration or temporal 
progress or …), the actual operation mode (here “fit”) and the binding model. 
Then the mechanism and the corresponding rate constants are defined. 
The file contains estimated initial values for the rate constants to be optimized, indicated by the “?” 
behind the values. By putting “??” behind a value the programme does do a sensitivity analysis and 
calculates the confidence intervals for each parameter. 
Amplitudes are represented by response parameters that correspond to the change in signal upon 
formation of 1 unit (μM in this case) of the defined signal-producing species (i.e. the difference between 
basal signal and the signal of a defined species/complex). Response parameters were fitted globally as 
parameter “binding1” and are therefore named in the script file directly next to each input dataset, thus 
the [response] line is empty, but the [parameters] line contains the global response parameter 
“binding1”. Concentrations are named directly next to the input data so the [concentrations] line is also 
empty.  
 
;-------------------------------------------------------------- 
;mant-dADP complexed with DDX1 (=H), then a fraction is displaced by adding ATP 
;further displacement is achieved by titrating 10mer polyA-RNA (see 19.06.13) 
;  
;---------------------------------------------------------------------- 
 
[task] 
 
 data  = equilibria 
 task  = fit  
; confidence =     monte-carlo 
model = KEAGlobalEqu 
 
 
[mechanism] 
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  H + mant <===> Hmant        :     Kdmant    dissoc 
  H + ATP <===> HATP          :     KdATP    dissoc 
  Hmant + RNA <===> HmantRNA  :     KdRNA    dissoc 
  HATP + RNA <===> HATPRNA    :     KdRNA2    dissoc 
  H + RNA <===> HRNA          :     KdRNA    dissoc 
 
 HRNA + mant <===> HmantRNA    :     Kdmant    dissoc 
 ; HRNA + ATP <===> HATPRNA   :     Kd2    dissoc 
 
[constants] 
 
    Kdmant   = 0.088 
    KdATP   = 129 ?? 
 
    KdRNA   = 10 ?? 
    KdRNA2  = 0.01 ?? 
 
     
     
   
 
 
[responses] 
 
[equilibria] 
 
[concentrations] 
 
[parameters] 
 
Binding1 = 2500 ? 
Binding2 = 2500 ? 
 
 
[data] 
 
    directory ./current/dynafit_input_data/10merRNA_titration 
     
 
variable       RNA 
 
; Kd2   = 1 * (KdATP * KdRNA2) /KdRNA  
 
 
file 50_µM_ATP_10mer.txt  
concentration mant = 0.2, H = 1 , ATP = 50 
response Hmant = 1 * Binding1 
response HmantRNA = 1 * Binding1 
offset = 6000 ? (1000..9000) 
 
 
 
file 100_µM_ATP_10mer.txt  
concentration mant = 0.2, H = 1 , ATP = 100 
response Hmant = 1 * Binding1 
response HmantRNA = 1 * Binding1 
offset = 6000 ? (1000..9000) 
 
 
file 200_µM_ATP_10mer.txt  
concentration mant = 0.2, H = 1 , ATP = 200 
response Hmant = 1 * Binding1 
response HmantRNA = 1 * Binding1 
offset = 6000 ? (1000..9000) 
 
 
 
 
file 400_µM_ATP_10mer.txt  
concentration mant = 0.2, H = 1 , ATP = 400 
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response Hmant = 1 * Binding1 
response HmantRNA = 1 * Binding1 
offset = 6000 ? (1000..9000) 
 
;-------------------------------------------------------------- 
;this is where previous titration data is included in the global fit 
;I'm not sure, whether it works this way 
;  
;---------------------------------------------------------------------- 
 
directory ./current/dynafit_input_data/mant-dADP_binding 
     
variable       H 
 
file mant_dADP_binding.txt  
concentration mant = 0.05 
response Hmant = 1 * Binding1 
offset = 6000 ? (1000..9000) 
 
 
 
directory ./current/dynafit_input_data/competition_binding_ATP 
     
variable       ATP 
 
file ATP_competition_1.txt  
concentration mant = 0.2, H = 1 
response Hmant = 1 * Binding1 
offset = 6000 ? (1000..9000) 
 
 
 
directory ./current/dynafit_input_data/competition_binding_ATP_RNA 
     
variable       ATP 
 
file 8_µM_10mer_polyA.txt  
concentration mant = 0.2, H = 1 , RNA = 8 
response Hmant = 1 * Binding1 
offset = 6000 ? (1000..9000) 
 
 
 
;mesh      linear from 0 to 30 step 0.15 
 
[output] 
 
   directory   ./current/output 
 
[[Settings] 
 | Interrupt = 500 
 
 Level             =  95.0 
 Minsteps   = 40 
MaxSteps  = 100 
OnlyConstants     =  n 
DetailedReport    =  y 
 
Figure 7.8.1 Dynafit script file  
Dynafit script file as used for the numerical data fitting. Parameters fitted globally are named as constants, whereas the semi-
global fitted parameters are named in the [parameters] section.  
 
The [parameters] optimized during the fit contain the response parameters for each data-set. Next the 
input data is defined with the specific directory within the biokine folder. The initial species 
Appendix 
 Appendix 205
concentrations, the complex constituting the response parameter and the actual parameter for the 
response are defined. 
The offsets were fitted locally as indicated by their positioning next to each data set (the “?” behind the 
values as the fitting command). The values in brackets give the constraints, i.e. the upper and lower 
limits for the parameter. Last the output directory for the result files is specified and no filter is applied 
to the data sets (since they have already been formatted and scaled manually before). 
The result of the Dynafit run is a parameter file containing the optimized parameters with their 
respective standard errors and the simulated curves. 
Note that all concentrations in the script file have to correspond to the same concentration, which is μM 
in this case, leading to an output in μM. The input data has to be in *.txt files, not containing any space 
in the file-names. 
 
7.9 List of abbreviations 
aa  amino acid 
ADP  adenosine-5‘-diphosphate 
ATP  adenosine-5‘-triphosphate 
AppNHp adenosine-5’-[(β,γ)-imido]triphosphate 
ATPγS adenosine-5’-(γ-thiol)-triphosphate 
APS  ammonium persulfate 
a.u.  arbitrary units 
bp  base pair 
BSA  bovine serum albumin 
CD  circular dichroism 
C-terminus  carboxy terminus 
Δ  differential or delta, i.e. without 
DDX1 DEAD-box helicase 1 
dpi  dots per inch 
DTE  dithioerythritol 
DNA  desoxyribonucleic acid 
mRNA messenger-ribonucleic acid 
E. coli  Escherichia coli 
EDTA  ethylene diamine tetraacetic acid 
g  gram 
g  gravity 
h hour 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IPTG  isopropyl-β-D-thiogalactosid 
K  degree Kelvin 
Kd  dissociation constant 
Km michaelis-menten constant 
kon on-rate constant 
koff off-rate constant 
kDa kilo Dalton 
l  liter 
LB  Lysogeny broth (incorrect Luria Bertani) 
LDH  lactate dehydrogenase 
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M  molar 
mA  milliampere 
mant-  N-methylanthraniloyl- 
mant-dADP 2’-deoxy-3’-O-(N’-methylanthraniloyl)adenosine 5’-O-diphosphate 
mant-dATP 2’-deoxy-3’-O-(N’-methylanthraniloyl)adenosine 5’-O-triphosphate 
min  minute 
MWCO  molecular weight cut off 
mdeg  millidegree 
NADH  Nicotinamide adenine dinucleotide, reduced form 
n.a. not available 
N-terminus amino terminus 
n.d.  not determined 
nm  nanometer 
OD  optical density 
o/n  over night 
ORF open reading frame 
PCR  polymerase chain reaction 
PDB  protein data bank (www.rcsb.org) 
PEP  phosphoenol pyruvate 
PK  pyruvate kinase 
PMSF  phenylmethylsulphonyl fluoride pyrene N-(1-pyrene)-maleimide 
rcf  relative centrifugal force 
rpm  rounds per minute 
RNA ribonucleic acid 
rRNA ribosomal RNA 
RT  room temperature 
s  seconds 
SDM  site-directed mutagenesis 
SDS  sodium dodecyl sulfate 
t  time 
T  temperature 
TEMED  N,N,N’,N’-tetramethyethylenediamine 
Tris  tris(hydroxymethyl)-amino-methane 
tRNA transfer RNA 
U  unit 
UV  ultraviolet 
(v/v) (volume/volume) 
w/o without 
WT wildtype 
(w/v)  (weight/volume) 
Yeast  saccharomyces cerevisiae 
